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ABSTRACT 
 
MODIFICATION OF NATURAL HYDROPHILIC POLYMERS FOR USE IN PHARMACEUTICAL 
FORMULATIONS 
 
The introductory chapter of this doctoral thesis provides an overview of the salient properties of 
pharmaceutical excipients, chitin, metal silicates and sugar alcohols in order to give a scientific 
background/context to the research subject matter reported in subsequent chapter of the thesis. 
When chitin is used in pharmaceutical formulations processing of chitin with metal silicates is 
advantageous, from both an industrial and pharmaceutical perspective, compared to processing 
using silicon dioxide. Unlike the use of acidic and basic reagents for the industrial preparation of 
chitin-silica particles, co-precipitation of metal silicates is dependent upon a simple replacement 
reaction between sodium silicate and metal chlorides. When co-precipitated onto chitin particles, 
aluminum, magnesium, or calcium silicates result in non-hygroscopic, highly compactable, and 
disintegrable compacts. Disintegration and hardness parameters for co-processed chitin compacts 
were investigated and found to be independent of the particle size. Capillary action appears to be 
the major contributor to both water uptake and the driving force for disintegration of compacts. The 
good compaction and compression properties exhibited by the chitin±metal silicates were found to 
be strongly dependent upon the type of metal silicate co-precipitated onto chitin. In addition, the 
inherent binding and disintegration abilities of chitin±metal silicates are useful in pharmaceutical 
applications when poorly compressible and/or highly non-polar drugs need to be formulated.  
The influence of the lubricant magnesium stearate (MgSt) on the powder and tablet properties of 
chitin-Mg silicate co-precipitate was examined and compared with lubricated Avicel® 200 and 
Avicel-Mg silicate co-precipitate. Crushing strength and disintegration-time studies were 
conducted in order to evaluate tablet properties at different compression pressures. Lubrication of 
chitin-Mg silicate powder with MgSt was evaluated using a high speed rotary tablet press. The 
compactability and disintegration time of chitin-Mg silicate are unaffected by the possible 
deleterious action of up to 2% (w/w) MgSt. The deleterious effect of MgSt on Avicel® 200 
compaction was found to be minimized when magnesium silicate was co-precipitated onto Avicel® 
200. Lubrication of chitin-Mg silicate with MgSt does not enhance particle agglomeration, whereas 
the opposite is the case for Avicel® 200; the foregoing was ascertained by measurements of the 
fixed measured bulk density, constant powder porosity using Kawakita analysis and by the absence 
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of variation in particle size distribution in the presence of up to 5% (w/w) MgSt. In the case of 
chitin-Mg silicate tablets the ejection force was greatly reduced at a compression speed of    
150,000 tablet/h at a MgSt concentration of 0.5% (w/w) when compared with the unlubricated 
powder. The physical properties and drug dissolution profile of ibuprofen tablets were found to be 
unaffected when chitin-Mg silicate was lubricated up to 5% (w/w) with MgSt. Optimal drug 
dissolution was attained for gemfibrozil tablets using 3% (w/w) MgSt when compared to a 
reference (LOPID® tablets). 
A co-processed excipient was prepared from commercially available crystalline mannitol and        
D-chitin using direct compression as well as spray, wet and dry granulation. The effect of the ratio 
of the two components, percentage of lubricant and particle size on the properties of the prepared 
co-processed excipient has been investigated. D-Chitin forms non-hygroscopic, highly 
compactable, disintegrable compacts when co-processed with crystalline mannitol. The compaction 
properties of the co-processed mannitol-chitin mixture were found to be dependent upon the 
quantity of mannitol added to chitin, in addition to the granulation procedure used. Optimal 
physicochemical properties of the excipient, from a manufacturing perspective, were obtained 
using a co-processed mannitol-chitin (2:8 w/w) mixture prepared by wet granulation (Cop-MC). 
Disintegration time, crushing strength and friability of tablets produced by Cop-MC, using 
magnesium stearate as a lubricant, were found to be independent of the particle size of the prepared 
granules. The inherent binding and disintegration properties of the compressed Cop-MC are useful 
for the formulation of poorly compressible, low and high strength active pharmaceutical 
ingredients. The ability to co-SURFHVVĮ-chitin with crystalline mannitol allows chitin to be used as 
a valuable industrial pharmaceutical excipient. 
The preparation and characterization of the performance of a novel excipient for use in the 
development of oro-dispersible tablets (ODT) has also been undertaken. The excipient consists of 
Į-chitin and crystalline mannitol. The physical properties (disintegration and wetting times, 
crushing force and friability) of the ODTs produced depend on the ratio of chitin and mannitol, in 
addition to the processing techniques used for excipient preparation. The excipient with optimal 
physicochemical properties was obtained at a chitin: mannitol ratio of 2:8 (w/w) produced by roll 
compaction (Cop-CM). Differential scanning calorimetry (DSC), Fourier-transform infrared       
(FT-IR), X-ray powder diffraction (XRPD) and scanning electron microscope (SEM) techniques 
were used to characterize the Cop-CM, in addition to characterization of its powder and ODT 
dosage forms. The effect of particle size distribution of the Cop-CM was investigated and found to
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have no significant influence on the overall tablet physical properties. The compressibility 
parameter (a) for Cop-CM was calculated from a Kawakita plot and found to be significantly 
higher (0.661) than that of mannitol (0.576) due to the presence of the highly compressible chitin 
(0.818). Montelukast sodium and domperidone ODTs, produced using Cop-CM, displayed the 
required physicochemical properties. The exceptional binding, fast wetting and super-
disintegration properties of Cop-CM, in comparison with commercially available co-processed 
ODT excipients, results in a unique multi-functional base which can successfully be used in the 
formulation of oro-dispersible and fast immediate release tablets. 
 
N. H. M. Daraghmeh [B.Sc.; M.Sc.] 
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ABBREVIATIONS 
Symbol Description 
NHCOCH3 Acetamide 
HCOOH Acetic acid 
API Active pharmaceutical ingredient
 
ATP Adenosine triphosphate 
Į- Alpha- 
UTP D-D-hexose-1- phosphate uridylyltransferase 
AlCl3 Aluminium chloride 
Al2(SiO3)3 Aluminum silicate 
NH2 Amine 
NH4NO3 Ammonium nitrate 
Å Angstrom 
BD Bulk density 
ȕ- Beta- 
Cop-MC Co-processed mannitol-chitin (2:8 w/w) mixture prepared by wet 
granulation 
Cop-CM Co-processed chitin-mannitol (2:8 w/w) mixture produced by roll 
compaction 
CaCO3 Calcium carbonate 
CaCl2 Calcium chloride 
CaCl22H2O Calcium chloride dihydrate 
Ca(SCN)2.4H2O Calcium cyanate tetrahydrate 
Ca(NO3)2.4H2O Calcium nitrate tetrahydrate 
CaSiO3 Calcium silicate 
CO2 Carbon dioxide 
C=O  Carbonyl 
(CHNO5)n Chitin  
CSD Colloidal silicon dioxide 
Crospovidone Cross-linked polymer of N-vinyl-2-pyrrolidinone 
Da Dalton 
DBCP Dibasic calcium phosphate 
DBCH Dibutyrylchitin 
DSC Differential scanning calorimetry 
DMAc/LiCl N,N-Dimethylacetamide/Lithium chloride 
DMF N,N-Dimethylformamide 
DC Direct compression 
Domp Domperidone 
EP European patent  
EDTA Ethylene di-amine tetra-acetic acid 
FDA Food and Drug Administration  
FCC Food Chemical Codex 
FTIR Fourier- transform infra-red 
J- Gamma- 
GRAS Generally recognized as safe 
HPLC High performance liquid chromatography 
HCl Hydrochloric acid 
HF Hydrofluoric acid 
H2O2 Hydrogen peroxide 
OH- Hydroxyl  
HPC Hydroxypropylcellulose 
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Symbol Description 
HPMC Hydroxypropylmethylcellulose  
ICH International conference of harmonization 
IPEC International Pharmaceutical Excipients Council 
JECFA The Joint Food and Agriculture Organization/World Health Organization 
Expert Committee on Food Additives 
LOQ Limit of quantitation 
MgCl2 Magnesium chloride 
MgCl2.6H2O Magnesium chloride hexahydrate 
Mg(NO3)2.6H2O Magnesium nitrate hexahydrate 
MgO  Magnesium oxide 
MgSiO3 Magnesium silicate 
MgSt Magnesium stearate  
LD50 Median toxic GRVH³/HWKDO'RVH´ 
MCC Microcrystalline cellulose 
Monte Montelukast sodium 
NF National Formulary 
NMR Nuclear magnetic resonance 
ODT Oro-dissolving tablets/Oro-disintegrating tablets 
O-3 MD O-3-Methylmethyldopa impurity 
KCl Potassium chloride 
KOH Potassium hydroxide 
PGS Pregelatinized starch 
RH Relative impurity 
RSD Relative standard deviation 
RC Roll compaction 
RSC Rosuvastatin calcium 
SEM Scanning electron microscope  
SMCC Silicified microcrystalline cellulose 
SiO2 Silicon dioxide 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
Na2HPO4.12H2O Sodium hydrogen phosphate dodecahydrate 
Na2SiO3 Sodium metasilicate 
H2SO4 /H3PO4 Sulphuric acid/Phosphoric acid 
TD Tapped density 
3D Three dimensional 
UV Ultra-violet 
USP United States Pharmacopiea 
UTM Universal testing machine 
UDP-N-acetylglucosamine Uridinediphosphate-N-acetyl-glucosamine  
V Voltage 
WG Wet granulation 
WHO/FAO World Health Organization/Food and Agriculture Organization of the 
United Nations 
XRPD X-Ray Powder Diffraction Spectroscopy 
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Introduction 
1.1 Pharmaceutical Excipients 
The International Pharmaceutical Excipients Council (IPEC) defines excipients as: 
³Substances, other than the active pharmaceutical ingredient (API) in finished dosage 
form, which have been appropriately evaluated for safety and are included in a drug 
delivery system to either aid the processing or to aid manufacture, protect, support, 
enhance stability, bioavailability or patient acceptability, assist in product 
identification, or enhance any other attributes of the overall safety and effectiveness 
of the drug delivery system during storage or use´ [1].  Ideally, excipients should not 
produce any pharmacological action, or adversely impact drug product quality, safety, 
or efficacy [2]. Recently, researchers have reached the conclusion that excipients are 
not inactive and have a substantial impact on the manufacture, quality, safety, and 
efficacy of the API in a dosage form [3]. Furthermore, variability in the performance 
of an excipient (both batch to batch within a single manufacturer as well as between 
batches from different manufacturers) is a key determinant of dosage form 
performance and consistency. Excipients are now known to have numerous, defined 
functional roles in pharmaceutical dosage forms [3]. These include:  
x   modulating the solubility and bioavailability of the API,  
x   enhancing the stability of the API  in the dosage form,  
x  contributing to the maintenance of a preferred polymorphic form or 
conformation of the API(s),  
x  pH and osmotic pressure modifiers,  
x  acting as antioxidants, emulsifying agents, aerosol propellants, tablet 
binders and tablet disintegrants, and 
x   preventing aggregation or dissociation.  
Excipients can be obtained from different sources (natural, animal, vegetable, semi-
synthetic, or synthetic) using different production technologies to be used for different 
functions and applications [3, 4]. Excipients are classified into different categories 
based on their function (e.g., diluent/filler, binder, disintegrant, glidant, lubricant, etc.) 
and they normally fulfill various performance characteristics and specifications (e.g., bulk 
density, particle size distribution, surface area, polymorphic form, water content etc.) 
depending on their uses in formulations, manufacturing processes, and the intended 
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dosage form [4, 5, 6]. The definitions of different excipient categories used in solid 
dosage form formulations are illustrated in Table 1.1.  
Table 1.1 Classification of excipients according to their functions. 
Excipient Function Definition 
Fillers/Diluents 
 
Fillers are added to increase the bulk of the formulation i.e. fillers fill out the size 
of a tablet or capsule, making it practical to produce and convenient for the 
consumer to use. Fillers make it possible for the final product to possess the 
proper volume for patient handling.  
Binders 
 
Some pharmaceutical ingredients require a binder for tabletting. This provides the 
cohesiveness necessary for bonding during tablet compression. Binders are usually 
starches, sugars, cellulose or a modified cellulose (such as microcrystalline cellulose, 
hydroxypropyl cellulose), lactose, or sugar alcohols like xylitol, sorbitol or maltitol. 
Binders can be used in dry (solid state) form or dissolved in solution. 
Disintegrants 
 
Usually added for the purpose of ensuring that compressed tablets break apart when 
placed in an aqueous medium. 
Lubricants 
 
Prevent ingredients from clumping together and from sticking to the tablet punches or 
capsule filling machine. Lubricants also ensure that tablet formation and ejection can 
occur with low friction between the solid and die wall. Common minerals like talc or 
silica, and fats, metal stearate like magnesium stearate or stearic acid are the most 
frequently used lubricants in tablets or hard gelatine capsules. 
Glidants 
 
Glidants are used to promote powder flow by reducing inter-particle friction and 
cohesion. Glidants, in some cases, occur in solution form due to the weight variation 
problems during tablet compression and capsule filling as a result of improving the 
powder flowability. Generally, materials that are good glidants are poor lubricants. 
 
Excipients play a pivotal role in the processing, stability, safety, and performance of 
solid dosage forms. Therefore, the critical excipient properties that can influence 
product performance need to be evaluated and controlled to ensure that consistent 
product performance is achieved throXJKRXW WKH SURGXFW¶V OLIH F\FOH [7, 8]. An 
overview of some dosage form parameters affected by excipients is given in         
Table 1.2. 
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Table 1.2 Dosage form parameters affected by excipients. 
Dosage form parameter Effect of excipients 
Stability  Residual moisture content/adsorbed moisture on excipient surface 
protects API from hydrolytic degradation. 
Processability x Surface area, surface free energy, crystal defects, and deformation 
potential affect compressibility and machine ability for high speed 
tabletting machines with reduced compression dwell times.  
x Particle size distribution and shape affect flow properties, efficiency 
of dry mixing processes, and segregation potential. 
x Compressibility, flowability, and dilution potential affect the choice 
of direct compression as a manufacturing process. 
Performance Cohesive and adhesive properties, surface free energy, and water 
uptake behavior affect disintegration and dissolution behavior. 
 
Generally, pharmaceutical excipients have to meet special requirements including [4]: 
x physiological inertness, 
x acceptance  by regulatory authorities, 
x physical and chemical stability, 
x commercial availability at pharmaceutical grade and standards, 
x being relatively inexpensive, and 
x their approval as a food additive if it is intended for use in dietary supplements 
and vitamin products. 
Table 1.3 lists some of the commercially available excipients, exploited for their 
different functionalities, commonly used in solid dosage formulations [9].  
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Table 1.3 Commonly used excipients in solid dosage formulations. 
Material Trade name Company Function 
Mannitol Pearlitol Roquette/ USA Filler 
Lactose monohydrate Pharmatose  DMV Pharma / Netherlands Filler 
Microcrystalline cellulose Avicel PH FMC Biopolymer / USA Filler 
Starch C*PharmGel Cerestar / France Filler/Disintegrant 
Croscarmelose sodium Ac-Di-Sol FMC Biopolymer / USA Disintegrant 
Sodium starch glycolate Explotab JRS Pharma LP / USA Disintegrant 
Cross-linked polyvinylpyrollidone  Polyplasdone XL ISP / USA Disintegrant 
Pregelatinized starch Starch 1500 Colorcon / UK Disintegrant/Binder 
Low substituted  
hydroxypropylcellulose 
L-HPC Shin-Etsu Chemical / Japan Disintegrant/Binder/
Filler 
Hydroxypropylcellulose Klucel Aqualon /USA Binder 
Poly(vinylpyrollidone) Kollidon PASF corp./USA Binder 
Sodium stearyl fumarate Pruv JRS Pharma LP/USA Lubricant 
Magnesium stearate Magnesium Stearate Mallinckrodt Baker/ USA Lubricant 
Purified talc Altalc Luzenac America/USA Lubricant/Glidant 
Colloidal silicon dioxide Aerosil Degussa Ltd / UK Glidant 
 
1.2 Preparation Techniques for Solid Dosage Forms 
Development of solid dosage forms, more specifically tablets, involves major 
alternative processing methodologies including wet granulation (low shear wet 
granulation, high shear wet granulation or fluid-bed granulation), dry granulation 
(slugging or roller compaction) or direct compression (DC) [8, 10]. The detailed 
processing steps involved in each of the three processing methods are explained in 
Figure 1.1 [4]. These processing methods share the following common problems [8]:  
x product weight variation due to poor flow properties, 
x problems in content uniformity during mixing, due to wide differences in 
density and particle size distribution, 
x loss of excipient compressibility due to wet granulation and repeated 
compaction cycles in dry granulation, or excessive usage of lubricants and 
poorly compressible ingredients in the formulation, and 
x poor disintegration of product due to excessive addition of binders. 
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The use of high speed tabletting machines and the increasing shift in the processing of 
tablets towards direct compression have, together, led to aggravating these problems.  
1.2.1 Wet Granulation [4, 11] 
Granulation is the process of collecting particles together by creating bonds between them. 
When the required homogeneity, compactibility or flowability of powder cannot be 
obtained by simple mixing, the ingredients must be granulated prior to compression. There 
are several reasons for using granulation processes (wet / dry) including the following: 
x improving powder flowability, 
x improving content uniformity of APIs in dosage form to assure consistency of dosing, 
x improving the bioavailability of  some APIs, 
x taste masking of poor taste APIs / improvement in palatability, 
x materials densification, 
x compactability and compressibility enhancement of the APIs, 
x drug release control, 
x reduction of dust, and 
x improvement in tablet physical properties 
Wet granulation is a process in which a liquid binder is added to the powder mixture and 
agitation is used to form granules. 
1.2.1.1 Advantages  
x Improvement of cohesiveness and compressibility of powders; hence the tablet 
compressibility is improved. 
x Drugs exhibiting a high dose and poor flowability and/or compressibility; their 
flowability and cohesion for compression will be improved by wet granulation. 
x The uniformity and distribution of soluble, low dosage drugs and colour additives can be 
obtained, especially if these materials are distributed in the granulation solution. Also it 
prevents segregation of components of a homogeneous powder during processing and 
transfer. 
x The dissolution rate of insoluble drugs can sometimes be improved by wet granulation. 
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Dry GranulationWet GranulationDirect Compression
Mixing/ blending of API 
and excipients
Tablet compression /
Capsules filling
Preparation of blinder 
solution  
Preparation of slugs/ 
compacts (by compression 
or roll compaction)
Wet granulation process 
using binder solution 
Drying of wet granules 
Screening of wet mass 
Milling/sieving of dried 
granules/ slugs 
Dry mixing of sieved granules with final 
mixing excipients (e.g., Lubricant, 
disintegrant, filler, etc.)
 
Figure 1.1 Comparison of steps involved in the different processing techniques for 
solid dosage form preparations. 
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1.2.1.2 Limitations  
The main disadvantage of wet granulation is its cost because of the space, time and 
equipment involved. For the following reasons, the process is labour intensive. 
x Long processing steps are involved and a relatively large space is needed for the 
preparation area. 
x Different types of expensive equipment are required. 
x It is time consuming, especially for the granulation and drying steps. 
x The manufacturing yield is much lower when compared with direct compression 
processing techniques because of the material losses in multi-step processes. 
x There is a greater possibility of cross-contamination, as there are many steps involved 
compared to direct compression. 
x Drug release is slower, sometimes due to stronger binding. 
x Many process variables including mixing, granulation, drying, granule sizing and final 
mixing are involved in the validation of the manufacturing process which is required to 
insure the consistency of the process. 
x Additional testing (e.g, gas chromatography) is required for residual solvents when non-
aqueous granulation is performed. 
1.2.2 Dry Granulation [12, 13] 
Dry granulation is used to form granules without using a liquid solution or it refers to 
the process of densification via roller compaction, followed by gravity 
milling/screening to give the required particle size distribution. This process is used 
when the product is sensitive to moisture and heat. Commonly, dry granulation 
processes can be conducted using slugging tooling via tablet compression machinery 
or by using other specialized machines such as a roller compactor. 
1.2.2.1 Advantages  
x Overcomes poor physical properties of API (particle size, shape). 
x Improves the flowability, content uniformity, and compaction properties of powders. 
x Dry granulation equipment offers a wide range of pressure and roll types to attain proper 
densification.  
x The process cycle is often reduced and equipment requirements are minimized; thus the 
cost is reduced.  
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1.2.2.2 Limitations  
x Dry granulation often produces a higher percentage of fines or non-compacted products, 
which can affect the quality or create yield problems in the tablet produced. 
x  Requires drugs or excipients with cohesive properties. 
x Longer processing time when compared to direct compression process which may 
compromise compactibility. 
1.2.3 Direct compression [11, 14] 
This method is used when a group of ingredients can be blended and compressed into 
tablets without any of the ingredients having to be changed. Powders that can be 
blended and compressed are commonly referred to as direct compression excipients. 
1.2.3.1 Preparation methods of direct compression excipients 
Direct compression excipients can be produced by different technelogies. The 
advantages, limitations and main features of the methods are listed in Table 1.4. 
Table 1.4 Methods used to prepare direct compression excipients. 
Method Advantages and limitation Examples 
Chemical 
modification  
- Relatively expensive  
- Toxicological data required 
- Time consuming  
Ethyl cellulose, methylcellulose, and 
sodium carboxymethyl cellulose from 
cellulose, lactitol  
Physical 
modification  
Relatively simple and economical  Dextrates of compressible sugar, 
sorbitol  
Grinding and/or 
sieving  
Compressibility may alter because of changes 
in particle properties such as surface area and 
surface activation 
Pharmatose® 150M, Pharmatose® 
100M, Pharmatose® 50M, Capsulac® 
60, PrismaLac® 40 
Crystallization  Import flowability to excipient but not 
necessarily self-binding properties, require 
stringent control on possible polymorphic 
conversions and processing conditions 
E-lactose, dipac  
Spray drying  Spherical shape and uniform size gives spray-
dried materials good flowability- poor  
re- workability  
Spray dried lactose, Avicel PH, TRI-
CAFOS S, Advantose 100 maltose 
powder. FlowLac® 100, Pharmatose® 
DCL 11 
Granulation/ 
agglomeration  
Transformation of small particle, cohesive, 
poorly flowable powders into  flowable and 
directly compressible powders 
Granulated Lactitol, Tablettose® 70, 
Tablettose® 80 
Dehydration Increased binding properties by thermal and 
chemical dehydration  
Anhydrous D-lactose  
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1.2.3.2  Advantages and limitations of direct compression processes 
In direct compression the manufacturing cycle is much shorter and the product yield 
is much higher than wet or dry granulation techniques. Less manufacturing steps and 
machines are involved in direct compression, resulting in a reduction in the 
processing costs. Regarding the product quality, the most significant advantage is that 
processing is performed in the absence of moisture and heat. The critical issue in 
direct compression formulations is the choice of excipients involved (e.g. the 
compressibility and flowability of the fillers/binders). The particle size distribution, 
strength, compactability and the physical properties of the API also play an important 
role in using this process. The critical issues, advantages and limitations which may 
occur in direct compression processes are outlined in Table 1.5.  
Table 1.5 Critical issues, advantages and limitations of direct compression. 
Critical Issues Advantages Limitations 
Flowability Cost effective production Segregation, problems in the 
content uniformity of the API 
Compressibility and 
compactibility 
- Better stability of API 
- Retains compactibility of materials 
Tablet weight variation due to 
poor flow properties 
Dilution potential Faster dissolution rate Low dilution potential 
Reworkability (reprocessing) Less wear and tear of punches Re-workability 
Stability Simple process validation High content of poorly 
compressible APIs  
Controlled particle size Lower microbial contamination Lubricant sensitivity 
 
Direct compression excipients, especially fillers and binders, are mostly common 
excipients modified using special procedures to improve their flow properties and 
compressibility. The physical and chemical properties of this special type of excipient 
are of significant importance when they are manufactured or involved in formulation 
design. Many factors are involved in the selection of a suitable, direct compression 
excipient which is to be used in tablet formulation including powder characteristics, 
solubility, stability, compatibility, flowability, compressibility and cost. Examples of 
some commercially available direct compression excipients are listed in Table 1.6 [9, 
15]. 
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Table 1.6 Examples of commercially available direct compression excipients. 
Excipient Brand Name (Manufacturer, country) 
Lactose  Tablettose (Meggle, Germany), pharmatose (DMV, the Netherland), fast-flo 
lactose (Foremost) 
Microcrystalline cellulose/cellulose  Avicel PH (FMC, USA), Emcocel (Edward mendell, USA, Vivacel (JRS, USA) 
Mannitol Mannogem  2080 (SPI Polyols, France), Sorbidex P (Cerestar, USA)  
Starch  Starch 1500 (Colorcon, USA Spress B820 (GPC, USA) Era Tab (Erawan, 
Thialand), Purity (National starch, USA), pharm DC 93000 (Cerestar, USA) 
Di-calcium phosphate Emcompress (JRS, GmbH), A-Tab and  Di-Tab (Rhodia, USA) 
Tri-calcium phosphate  Tri-Tab (Rohodia, USA)  
Sorbitol Neosorb 60 (Roquette, France) sorbogem (SPI polyols, France), sorbidex P 
(Cerestar, USA) 
Sucrose  Di-pac (American sugar company, USA), NuTab (ingredient technology Inc., 
USA) 
Dextrose  Emdex (Edward mendell, USA)  
Lactitol Finlac DC (Danisco, USA ), Lacty-TAB (Purac, USA)  
Xylitol Xylitab (Danisco, USA) 
Maltodextrin Maltrin (Grain Processing Corp, USA) 
Powdered Cellulose/Cellulose   Elcema (Allchem Pharma, UK)  
Calcium sulphate  Destab (Particle Dynamics, USA) 
Calcium lactate penta-hydrate  Puracal DC (Purac, USA)  
Calcium lactate tri-hydrate  Puracal TP (Purac, USA) 
Aluminium hydroxide   Barcroft (SPI Polyols, France) 
1.3 Co-Processed Excipients [8, 16] 
There are three possible procedures by which a new excipient can be developed: 
x new chemical entities as excipients, 
x new grades of already existing excipients, and 
x new combinations of existing excipients. 
Additionally, regulatory expectations of safety and toxicity properties ensure that new 
chemical entities being developed as excipients undergo various stages of scrutiny, 
which is a lengthy and costly process. Furthermore, the excipient is required to 
undergo a phase of generic development which shortens the market exclusivity 
period. Accordingly, modification of the physicochemical properties of existing 
excipients has been the most successful strategy to produce new functional excipients. 
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The introduction of high-speed tablet compression machines and the shift in tablet 
manufacturing toward direct compression process have encouraged the search for new 
excipients meeting special requirements. Tablet formulators have recognized that 
single component excipients do not always provide the requisite performance to allow 
certain active pharmaceutical ingredients to be formulated or manufactured 
adequately. In response to these deficiencies, they have relied on increasing numbers 
of combination excipients introduced by excipient manufacturers into the commercial 
market (Table 1.7). Combination excipients fall into two broad categories. 
1.3.1 Physical mixtures 
Physical mixtures are simple admixtures of two or more excipients typically produced 
by short duration low shear processing. They may be either liquids or solids and are 
generally used for convenience rather than for facilitating the manufacturing process 
or improving the resultant pharmaceutical product. Examples of such physical 
mixtures include immediate release film coating powders for dispersion that reduce 
the time required to prepare film coating suspensions and to minimize colour variation 
of the final product. Such physical mixtures are not appropriate for consideration for 
National Formulary (NF) monographs because the individual components are isolated 
(distinct and intact) before mixing; i.e., the manufacturing process for each of the 
individual components has been taken to completion, and consequently these 
components can be adequately controlled before mixing.  
1.3.2 Co-processed excipients  
Co-processed excipients can be defined as a combination of two or more excipients 
that possess performance advantages that cannot be achieved using a physical 
admixture of the same combination of excipients. Co-processing of excipients was 
introduced in the pharmaceutical industry in the late 1980s, by e.g. co-processing 
MCC and calcium carbonate followed by ³Cellactose´ (Meggle, Germany) in 1990, a 
co-processed combination of cellulose and lactose, and silicified microcrystalline 
cellulose (SMCC) in 1996, a co-processed product of MCC and colloidal silicon 
dioxide (CSD). 
CHAPTER ONE  INTRODUCTION 
 12  N.H.M.Daraghmeh±PhD Thesis 
 
Table 1.7 Commercially marketed co-processed direct compression excipients. 
CO-PROCESSED EXCIPIENTS TRADE NAME MANUFACTURER ADVANTAGES/FUNCTION 
Lactose monohydrate (93%), Kollidon 30 
(3.5%), and Kollidon CL (3.5%) Ludipress

  
BASF AG. Ldwigshafen, 
Germany  
Lower hygroscopicity, good flow ability, tablet hardness independent 
of machine speed 
Lactose monohydrate (96.5%) and 
Kollidon 30 (3.5%) Ludipress LCE 
BASF AG, Ludwigshafen, 
Germany Lower hygroscopicity, higher tablets hardness 
Į-Lactose monohydrate (75%) and 
cellulose powder (25%) Cellactose

 80  Meggle GmbH &, Co. KG, Germany Highly compressible, good mouth feel, better tabletting at low cost  
Į-Lactose monohydrate (75%) and MCC 
(25%) MicroceLac 
100 Meggle GmbH &, Co. KG, Germany Capable of formulating high-dose small tablets with poor flowability   
Į-Lactose monohydrate(85%) and maize 
starch (15%)  starLac
TM
 Roquette, Lestrem, France Good flow, optimized disintegration, excellent tablet hardness   
$QK\GURXVȕ-lactose (95%) and lactitol 
(5%) Pharmatose

 DCL-40 j. Rettenmaier & Sohne GmbH & Co. KG, Germany High compatibility, superior flow properties, low lubricant sensitivity    
Silicified microcrystalline cellulose 
(SMCC)  [microcrystalline cellulose 
(MCC) 98% and colloidal silicon dioxide 
(CSD) (2%)] 
ProSolv HD 90, ProSolv SMCC 
50, ProSolv SMCC 90 
FMC Biopolymer, Newark, 
Delaware, U.S.A. 
High compatibility, high intrinsic flow, good blending properties, 
reduced sensitivity to wet granulation, better tablet hardness 
MCC and guar gum  Avicel CE-15 FMC BioPolymer, Netwark, Delaware, U.S.A. 
Less grittiness, reduced tooth packing, minimal chalkiness, creamier 
mouth feel, improved overall palatability  
MCC and carboxymethylcllulose sodium  Avicel RC-581, RC-591, CL-661 FMC BioPolymer, Netwark, Delaware, U.S.A. 
Viscosity regulator and modifier , thixotropic characteristics, heat and 
freeze-thaw stable, long shelf-life stability, lengthy hydration times 
eliminated, stable in the  4-11 pH range 
MCC and calcium phosphate  Celocal  FMC BioPolymer, Netwark, Delaware, U.S.A. Direct compression excipient 
MCC (65%) and calcium carbonate (35%)  Vitacel VE-650 FMC BioPolymer, Netwark, Delaware, U.S.A. Direct compression, encapsulation  
MCC and carrageenan  LustreClear TM FMC BioPolymer, Netwark, Delaware, U.S.A. 
Efficient tablet-coating with short hydration time prior to coating and 
fast drying time  
Mannitol 85%, crospovidone 10%, sorbitol 
5%, silicon dioxide <1%.  Pharmaburst 
TM
 B2 
SPI Pharma TM, Inc., New 
Castel , U.S.A/ 
High compactibility, high loading in small diameter tablets, smooth 
mouth feel, rapid disintegration  Mannitol 84%, crospovidone 16%, silicon 
dioxide <1% Pharmaburst 
TM
 C1 
Fructose (95%) and starch (55) AdvantoseTM FS Fructose SPI Pharma TM, Inc., New Castel , U.S.A/ 
Excellent flow, good compressibility, tablets hold shape well, but are 
very chewable  
CHAPTER ONE  INTRODUCTION 
 13  N.H.M.Daraghmeh±PhD Thesis 
 
 
Table 1.7. (continued) 
CO-PROCESSED EXCIPIENTS TRADE NAME MANUFACTURER ADVANTAGES / FUNCTION 
MCC, mannitol Avicel HFE102 FMC, USA High compatibility, superior flow properties, low lubricant sensitivity    
Xylitol, carboxymethyl cellulose sodium XyliTab  Danisco Sweeteners, Finland Artificial sweeteners  for medical purposes 
Vinylacetate, vinylpyrollidone  Plasdon S-630  (Copovidone) ISP, USA  
Excellent tablet binder, matrix polymer 
for solid dispersions and film former for topical applications 
Sucrose (97%) and dextrin (3%) Di-Pac  American Sugar Co, New York, U.S.A. Direct compression excipient  
Calcium carbonate, starch Barcroft CS 90 
SPI Pharma, France 
Directly compressible calcium carbonate 
Aluminium hydroxide, magnesium hydroxide, sorbitol  
and mannitol Barcroft AHMN  
A free flowing, highly reactive, and directly compressible antacid 
powder 
Calcium carbonate (70%) and sorbitol (30%)  Formaxx CaCO3 70 Merck KGaA, Darmstadt, Germany. 
High compressibility, excellent  taste masking, free flow, superior 
content uniformity, controlled particle size distribution 
Calcium carbonate, acacia Carbofarma GA10 Resinas industrials, 
S.A., Argentina Directly compressible calcium carbonate Calcium carbonate, maltodextrin Carbofarma GM11 
Polyhydric sugar alcohol (75%), proprietary silicate salt 
(25%) PanExcea MC200G Malinkrodt Baker/USA 
High performance rapid disintegrating direct compression excipient for 
oro-dissolving tablets formulation. 
MCC (89%), hydroxypropylmethyl cellulose (HPMC) 2% 
and crospovidone (9%) PanExcea MHC300G High performance excipient for immediate release formulation 
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Co-processing is typically performed using some form of specialized manufacturing 
process such as high shear dispersion, granulation, spray drying, or melt extrusion. It 
is the one of the most widely explored and commercially utilized method for the 
preparation of direct compression excipients. Co-processing offers the following main 
advantages. 
x Provides a single excipient with multiple functionalities. 
x Produces a product with added value related to the ratio of its functionality 
against price. 
x Improved compressibility and flow properties. Better dilution potential can be 
obtained where co-processed excipient possess a higher dilution potential than 
a physical mixture of its constituent excipients (dilution potential is defined as 
the amount of an active ingredient that can be satisfactorily compressed into 
tablets along with the direct compression excipient at a minimum possible 
weight). 
x Allows the development of superior excipients by keeping functionality and 
removing undesirable properties, which helps in faster product development. 
x Improvement in organoleptic properties (e.g., a co-processed excipient of MCC 
and guar gum, designed for providing chewable tablets with reduced grittiness 
and tooth packing, minimal chalkiness, better mouth feel, and improved 
overall palatability). 
x Provides more robust tablets at low compression force. Co-processing of 
mannitol with sorbitol results in excipients with stronger binding capacity. 
This permits the packaging of orally dissolving tablets (ODTs) in conventional 
HDPE bottles, eliminating the need for specialized packaging where 
significant cost reduction can be achieved. 
x Reduces product cost due to improved functionality and fewer test requirements 
compared to individual excipients. 
x Provides intellectual benefits in terms of proprietary combinations, specific for 
in-house use. 
x Co-processing is another way that new excipients are coming to market without 
undergoing the rigorous safety testing of a completely new chemical entity. 
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Co-processed excipients development generally starts by designing the following 
factors. 
x The selection of the excipients to be combined and their targeted proportion. 
x The selection of the preparation method to obtain an optimized product with the 
desired physicochemical parameters.  
x Optimization of the preparation method to assure process reproducibility and 
product quality and functionality.  
An overview of the co-processing methodology is shown in Figure 1.2. 
 
 
Figure 1.2 Co-processing methodology. 
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1.3.3 Role of Material Characteristics in Co-Processing [8, 17] 
Material science plays a significant role in altering the physico-mechanical 
characteristics of excipients, especially with regard to their compression and flow 
properties. The solid materials can be classified according to their response towards 
applied mechanical force into three categories (Table 1.8): elastic, plastic and brittle 
(Figure 1.3.A).  
Table 1.8 Material classification according to their response to applied mechanical force. 
Material classification Description 
Elastic 
Any change in shape is completely reversible, and the material returns to 
its original shape upon release of applied stress. 
Plastic 
Permanent change in the shape of a material due to applied stress, e.g., 
MCC, corn starch, and sodium chloride. 
Brittle 
Rapid propagation of a crack throughout the material on application of 
stress, e.g., sucrose, mannitol, sodium citrate, lactose, and di-calcium 
phosphate. 
 
The predisposition of a material to deform in a particular manner depends on its 
lattice structure; in particular whether weakly bonded lattice planes are inherently 
present. In definitive terms, most of the materials cannot be classified distinctly into 
individual categories. Pharmaceuticals exhibit all three characteristics, with one of 
them being the predominant response, thus making it difficult to clearly demarcate the 
property favorable for compressibility. Compression refers ³to a reduction in the bulk 
YROXPH RI PDWHULDOV DV D UHVXOW RI GLVSODFHPHQW RI WKH JDVHRXV SKDVH´ Stages 
involved in the bulk reduction of powdered solids are shown in Figure 1.3.B. There 
are four stages encountered during compression:  
 (I)   initial repacking of particles,  
 (II) elastic deformation of the particles until the elastic limit (yield point) is 
reached,  
(III) plastic deformation and/or brittle fracture then predominate until all the 
voids are virtually eliminated, and  
(IV)  compression of the solid crystal lattice then occurs. 
At the onset of the compression process, when the powder is filled into the die cavity, 
and prior to the entrance of the upper punch into the die cavity, the only forces that 
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exist between the particles are those that are related to the packing characteristics of 
the particles, the density of the particles and the total mass of the material that is filled 
into the die (Figure 1.3.B.I).  
 
 
 
 
Figure 1.3 (A) Material classification on the basis of deformation behavior in the 
presence of an applied mechanical force, (B) stages involved in compression (I-III) 
and decompression. 
Packing characteristics of a mass of dry powder are determined, in large part, by the 
characteristics of the individual particles. When external mechanical forces are 
applied to a powder mass, there is usually a reduction in volume due to closer packing 
(A)  
(B)  
CHAPTER ONE  INTRODUCTION 
 18  N.H.M.Daraghmeh±PhD Thesis 
  
of the powder particles and, in most cases, this is the main mechanism of initial 
volume reduction (Figure 1.3.B.II). However, as the load increases, rearrangement of 
particles becomes more difficult and further compression leads to some type of 
particle deformation (Figure 1.3.B.III). If on removal of the load (decompression), the 
deformation is, to a large extent, reversible (behaves like rubber) then the deformation 
is said to be ³elastic´. All solids undergo elastic deformation, to some extent, when 
subjected to external forces. In some groups of powdered solids, an elastic limit is 
reached, and loads above this level result in deformation not immediately reversible 
on the removal of the applied force. Bulk volume reduction, in such cases, results 
from plastic deformation and/or viscous flow of particles, which are squeezed into the 
remaining void spaces. This mechanism predominates in materials in which the shear 
strength is less than the tensile or breaking strength. Plastic deformation is believed to 
create the greatest number of clean surfaces. Because plastic deformation is a time 
dependent process a higher rate of force application leads to the formation of less new 
clean surfaces and thus results in weaker tablets. Furthermore, since tablet formation 
is dependent on the formation of new clean surfaces, high concentrations or over 
mixing of materials that form weak bonds result in weak tablets (e.g, over mixing the 
granules with magnesium stearate may produce weak tablets due to the formation of 
weak bonds and easily wet surfaces). Conversely, in materials in which the shear 
strength is greater than the tensile strength, some particles may be preferentially 
fractured, and the smaller fragments then help to fill up the adjacent air spaces. This is 
PRVW OLNHO\ WR RFFXU ZLWK KDUG EULWWOH SDUWLFOHV DQG LV NQRZQ DV ³brittle fracture´; 
sucrose behaves in this manner. The ability of a material to deform in a particular 
manner depends on the lattice structure; in particular whether weakly bonded lattice 
planes are inherently present. Brittle fracture creates clean surfaces that are brought 
into intimate contact by an applied load. Irrespective of the behavior of large particles, 
small particles may deform plastically via a process known as ³microsquashing´, and 
the proportion of fine powders in a sample may therefore be significant.  
Co-processing offers an interesting tool for altering these physico-mechanical 
properties of excipients. It is generally conducted using plastic and brittle excipients. 
In this regard cellactose is an appropriate example which involves co-processing of 
75% lactose (a brittle material) with 25% cellulose (a plastic material). Use of this 
particular combination prevents the storage of excessive elastic energy during 
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compression, resulting in a small amount of stress relaxation and a reduced tendency 
for capping and lamination. However, examples at the other extreme also exist, e.g., 
silicified microcrystalline cellulose (SMCC) which contains a large amount of 
microcrystalline cellulose (MCC) (a plastic material) and a small amount of colloidal 
silicon dioxide (CSD) (a brittle material). These two cases exemplify the fact that co-
processing is generally performed by using a combination of materials possessing 
plastic deformation and brittle fragmentation characteristics.  
Particle properties have a direct influence on excipient functionalities such as the 
potential for dilution, disintegration, and lubrication. Therefore, when developing a 
new excipient particle design must be taken into consideration. The role of particle 
engineering, by varying various particle properties, in achieving the desired excipient 
functionalities is shown in Table 1.9. 
Table 1.9 Particle properties influencing excipient functionality. 
Particle property  Affected excipient functionality 
Particle size Flowability, content uniformity, compressibility, 
disintegration, dissolution  rate 
Particle size 
distribution 
Segregation potential 
Particle shape Flowability, content uniformity, compressibility 
Particle porosity Compressibility, disintegration, dissolution  rate 
Surface roughness Flowability, segregation potential, dilution 
potential, lubricant sensitivity 
 
1.3.4  Characterization of Co-Processed Excipients [8, 14, 18] 
Formulations are developed by characterizing particles, powders, and compacts of 
API and excipients. Such characterization is associated with some predictive tools and 
allows formulators to understand the important physical, chemical, and mechanical 
properties of materials and thus design robust formulations at a relatively low cost and 
to achieve acceptable exposure in clinical studies. 
The improvement in performance due to co-processing is the driving force for the 
introduction of excipients into the market. The absence of any chemical reaction 
between individual ingredients in the co-processed excipient must initially be 
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analytically demonstrated and over the proposed storage period of the co-processed 
excipient using different analytical techniques (e.g. X-ray powder diffraction 
spectroscopy (XRPD), Fourier-transform infra-red (FTIR) spectroscopy, differential 
scanning calorimetry (DSC), scanning electron microscope (SEM), etc.). The 
performance and functionality of the developed co-processed excipient should be 
evaluated using different testing procedures to prove the added value over the 
individual components properties. Table 1.10 presents the important parameters 
involved in the evaluation of co-processed and direct compression excipients. 
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Table 1.10 Parameters involved in the evaluation of co-processed and direct compression excipients. 
Property Related parameters Comments 
Ta
bl
et
 c
ha
ra
ct
er
ist
ic
s 
Lubricant sensitivity  
Lubricant, especially metal stearates, reduce the tensile strength (due to 
reduction of inter-particle bonding) and/or make the API hydrophobic 
and thereby prolong the disintegration time or decreases it on long, 
intensive mixing. The material undergoing plastic deformation is more 
susceptible to the negative effect of lubricant. 
Re-workability (re-
processing) 
This is the ability to reprocess a defective batch. Re-workability is 
influenced by the deformability of the directly compressible adjuvant on 
initial compression. 
Tensile strength, friability, 
and disintegration time  
These are important parameters for the quality control of tablets. The 
mechanical properties of a tablet are the consequence of consolidation 
and expansion phenomenon. The increase in particle surface contact 
promotes a greater propensity for increased bonding. Tablets should have 
sufficient tensile strength to hold the API intact at the lowest 
compression force. Simultaneously it should give low friability and 
desired disintegration time.  
 
Dilution potential and 
loading capacity 
High dilution potential is desirable to produce tablets with less weight. 
Compressibility and flowability of the drug has a strong influence on it. 
Others parameters such as moisture absorption or stability upon storage can be used to compare the performance of directly 
compressible excipients. 
Po
w
de
r 
Ch
ar
ac
te
ris
tic
s (
Fl
ow
-
ab
ili
ty
) Angle of repose, &DUU¶V 
index (Compressibility 
index) DQG+DXVQHU¶VUDWLR 
x Carr¶V index (C) is an indication of the compressibility of a powder. It 
is calculated by the formula: C = 100 VT - VB / VT , where VB is the bulk 
volume of a given mass of powder, and VT is the tapped volume of the 
same mass of powder. 
x +DXVQHU¶V UDWLR (H) is an indication of powder flowability and it is 
measured by the ratio: tapped density / bulk density. 
x Angle of repose (ș is defined as the maximum angle possible between 
the surface of a pile of powder and the horizontal plane. 
(ș Wan-1 h/r ) where, h = height of the cone,  r = radius of the cone base  
According to US pharmacopeia 31, General chapter <1174 >, angle of 
repose (25-30q) indicates excellent flow, and 31-35q indicate good flow. 
&DUU¶V LQGH[10 indicates excellent flow whereas 11-15 indicates good 
flow. +DXVQHU¶VUDWLROHVVWKDQ0-1.11 indicates excellent flow, whereas 
1.12±1.18 indicates good flow. Good flowability of powder is needed for 
content uniformity and less weight variation in final tablets.   
Bulk density/Tapped density 
x Bulk density is defined as the mass of a powder divided by the bulk 
volume and has units of gm/cm 3
.
 
x Tapped density is the ratio of the mass of the powder to the volume 
occupied by the powder after it has been tapped for a defined period of 
time. 
The bulk density of a powder mainly depends on particle size 
distribution, particle shape and the tendency of particles to adhere 
together. The bulk and tapped density values influence the ability of the 
material to undergo compression and the final volume of the tablets.  
Particle size distribution  
- Mean particle size  
- Percentage fines 
The angle of repose DQG +DXVQHU¶V UDWLR DUH EDVHG Rn the ability of a 
mass of powder to flow. The flowability of the direct compression 
excipient is influenced by particle size and shape. Fine powder retards 
the flow, whilst particles with uniform size and shape exhibit better flow 
than irregular particles of the same size and shape.  
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Property Related parameters Comments 
Po
w
de
r 
Ch
ar
ac
te
ris
tic
s (
Co
m
pr
es
sib
ili
ty
) 
Heckle and Kawakita 
equations  
A direct compression excipient should exhibit an acceptable pressure-
volume profile (compressibility). Heckle and Kawakita equations are 
most widely used to assess material compressibility. The slope, k, of the 
Heckle plot gives a measure of the plasticity of a compressed material 
and the reciprocal of k is known as the yield value (Py). The yield value 
reflects the deformability of the material; soft, ductile powders have a 
lower yield value, the agglomerates with low yield value can be 
plastically deformed as a result of the rebinding of smaller primary 
crystals. Low values of Py (steep slope) reflect low resistance to pressure, 
good densification and ease of compression. A large slope value indicates 
the onset of plastic deformation at relatively low pressure.  
In »¼
º«¬
ª
 D1
1
=kP+A  (Heckel Equation)  
where, D is the relative density of a powder compact at pressure P . The 
constant k is a measure of the plasticity of a compressed material. The 
constant A is related to the die filling and particle rearrangement before 
deformation and bonding of the discrete particles. 
The Kawakita equation is used to study powder compression using the 
degree of volume reduction, C. The basis for the Kawakita equation for 
powder compression is that particles subjected to a compressive load in a 
confined space are viewed as a system in equilibrium at all stages of 
compression, so that the product of the pressure term and the volume 
term is a constant:  
C = [V0 ± V/V0] = [abP/1 + bP]   (Kawakita Equation) 
where, C is degree of volume reduction, V0 is the initial volume; V is the 
volume of powder column under the applied pressure P. The a value is 
WKH PDWHULDO¶V PLQLPXP porosity before compression while b relates to 
plasticity of the material. The smaller a value for the granules indicates 
good packing even without tapping. The large value of b indicates rapid 
packing velocity of the powder or agglomerates. The reciprocal of b 
defines the pressure required to reduce the powder bed by 50%.  The 
equation above can be rearranged in linear form as: 
 P/C = P/a + 1/ab   
The expression of particle rearrangement could be affected 
simultaneously by the two Kawakita parameters a and b. The 
combination of these into a single value, i.e. the product of the Kawakita 
parameters a and b, may hence be used as an indicator of the expression 
of particle rearrangement during compression. 
Functionality 
Co-processed excipient can involve APIs using different processing 
techniques including direct compression, wet or dry granulation to assess 
the capability of the co-processed excipient to maintain and preserve its 
superior properties and functionality.  
 
Moisture Uptake 
(Hygroscopicity) 
Moisture uptake is an important characteristic of pharmaceutical 
powders. Many pharmaceutical excipients can sorb atmospheric 
moisture. Moisture has a significant impact on the physical stability, 
chemical stability, flowability, and compactibility of powder excipients 
and formulations (e.g., moisture-sensitive APIs formulation). Water 
sorption and equilibrium moisture content depend upon the atmospheric 
humidity, temperature, surface area, and exposure, as well as the 
mechanism for moisture uptake [17]. 
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1.4 Special Types of Excipients (Oro-Dissolving Tablets) [19, 20] 
Oro-dissolving tablets (ODTs) are solid dosage forms containing medicinal 
substances that disintegrate rapidly in the oral cavity and disperse in the saliva 
without the need for water. In April 2007, the Food and Drug Administration (FDA) 
issued draft guidance, Guidance for Industry: Orally Disintegrating Tablets [21]. The 
definition considers ODTs to be solid oral preparations that disintegrate rapidly in the 
oral cavity with an in vivo disintegration time of approximately 30 seconds or less, 
when based upon the USP disintegration test method. Besides convenience of intake 
the advantage of this dosage form is fast bioavailability of the active ingredient. The 
mechanism behind the disintegration of ODTs is illustrated in Figure 1.4.  
 
Figure 1.4 Mechanism of disintegration of ODTs. 
Orally disintegrating tablets offer all the advantages of solid dosage forms and liquid 
dosage forms together with special advantages, including the following. 
x ODTs are solid dosage forms which provide good stability, accurate dosing, 
easy manufacturing, small packaging size and easy to handle by patients. 
x No risk of obstruction of dosage form, which is beneficial for traveling patients 
who do not have access to water.  
x Easy to administer for pediatric, geriatric, mentally retarded and psychiatric 
patients.  
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x Rapid disintegration of tablet results in quick dissolution and rapid absorption 
which provide rapid onset of action. 
x Medication as a "bitter pill" has changed because of acceptable mouth feel 
properties produced by the use of flavors and sweeteners in ODTs.  
x Bioavailability of drugs that are absorbed from the mouth, pharynx, and 
oesophagus is increased. 
x Pre-gastric absorption of drugs avoids hepatic metabolism, which reduces the 
dose and increase the bioavailability.  
Some challenges may be faced when developing and designing ODT solid dosage 
forms including the following.  
x Achieving rapid disintegration of tablets.  
x Avoiding an increase in tablet size.  
x Obtaining sufficient mechanical strength for tablets.  
x Minimizing or avoiding residue in mouth.  
x Protecting tablets from moisture.  
x Good package design (necessary because of low tablet hardness).  
x Compatibility of API with taste masking technology.  
x Overcoming undesirable API properties. 
Several technologies are commonly used by the manufacture of ODTs (Table 1.11). 
These technologies differ in their methodologies and the ODTs produced vary in their 
properties such as: 
x mechanical strength, wetting and disintegration time of tablets  
x taste and mouth feel  
x swallow-ability  
x drug dissolution in saliva  
x bioavailability  
x stability 
The most common procedures are lyopholization (freeze drying) and direct 
compression. 
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Table 1.11 Technologies used in ODT preparations. 
Innovator/ Dosage form Technology Technology Basic Drug marker Marketed product/Indication 
(CIMA Labs) 
Direct compression tablet 
Durasolv 
 
Conventional direct compression tablets 
containing API, filler, disintegrant, 
flavourings, sweeteners, colorants and 
lubricant. 
Conventional direct compression tablets 
containing API, filler, disintegrant, 
flavourings, sweeteners, colorants and 
lubricant. 
Alamo Fazaclo (clozapine) / Antipsychotic 
AstraZeneca Zomig-ZMT (zolmitriptan) / Migraine 
Organon Remeron, SolTabs (mirtazapine)/ Depression 
Schwarz Pharma 
Fluxid (famotidine) / Duodenal ulcers 
Orasolv 
Conventional direct compression tablets 
containing API, filler, disintegrant, flavourings, 
sweeteners, colorants and lubricant. 
NuLev (hyoscyamine sulfate) /  Irritable bowel 
3DUFRSDFDUELGRSDOHYRGRSD3DUNLQVRQ¶V
disease 
Wyeth Alvert  (loratadine) /Allergy 
(Ethypharm/BMS) 
Compressed tablet Flash Tab 
A direct compression tablets consist of Eudragit-
microencapsulated API and effervescent couple 
Bristol-Myers 
Squibb 
Excedrin, QuickTabs (acetaminophen, caffeine) / 
Headache 
(Yamanouchi) 
Compressed molded tablet 
WOWTAB 
(Without 
water) 
API is mixed with a low mouldability saccharide 
(lactose, mannitol, maltose and maltilol)  and 
granulated with a high mouldability saccharide 
and compressed into tablet 
Pfizer Benadryl, Fastmelt (diphenhydramine citrate, pseudoephedrine HCL / Allergy and sinus 
(Cardinal Health) 
Lyophilized (Freeze-
dried) wafer 
Zydis 
A Zydis tablet is produced by lyophilizing 
(freeze-drying) the API in a matrix usually 
consisting of gelatin. Amorphous porous 
structure is formed that can dissolve rapidly. 
Freeze drying technique has demonstrated 
improved absorption and increase in 
bioavailability of APIs. 
Eli Lilly Zyprexa, Zydis (olanzapine) / Schizophrenia 
GlaxoSmithKline Zofran ODT (ondansetron) / Nausea and vomiting 
Janssen Risperdal, M-Tab (risperidone)/Schizophrenia 
Merck Maxalt-MLT (rizatriptan benzoate) / Migraine 
Schering-Plough 
Claritin, Resitags (loratadine) / Allergy 
Clarinex. Reditabs (desloratadine) / Allergy 
(Biovail) 
 Floss-based tablet 
technology 
Flash Dose 
A sugar-based tablet matrix prpared in a 
procedure similar to that used in the preparation 
of cotton candy usind high temperature called 
µ)ORVV¶LVXVHGWRPDVk the bitter taste of API. 
Reckitt Benckiser 
Healthcare (UK) 
Ltd 
 
Nurofen meltlet/ NSAIDs 
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However, the number of fillers/binders that can be used for ODT formulations is 
limited because these bulk excipients have to fulfil special requirements, such as 
being soluble in water, having a pleasant sweet taste and mouth feel, as well as being 
rapidly dispersible.  
Direct compression ODT formulations usually contain the API, diluents/fillers, 
disintegrants, lubricants, flavourings, sweeteners and colorants. The most commonly 
used bulk excipients for the development of this kind of formulations are sugar based 
excipients such as dextrose, fructose, isomalt, lactilol, maltilol, maltose, mannitol, 
sorbitol, starch hydrolysate, polydextrose and xylitol, which display high aqueous 
solubility and sweetness in addition to other favourable characteristics which improve 
the performance and impart taste masking property of ODTs [22].  
No single excipient can fulfil the requirements of all ODT formulations. A popular 
way to enhance disintegration properties is the addition of a super-disintegrant, such 
as croscarmelose sodium, sodium starch glycollate and crospovidone. Table 1.12 
shows the most commonly used excipients/fillers for the preparation of ODTs. 
Table 1.12 Commonly used excipients in ODT preparations. 
Excipient Manufacturer Manufacturer Website 
PanExcea MC200G Mallinckrodt Baker / USA http://www.mallbaker.com/panexcea/ 
Isomalt galenIQ-720 
BENEO-Palatinit GmbH 
(Germany) 
http://www.beneo-
palatinit.com/en/Pharma_Excipients/galenIQ/galenIQ_Grades/ 
 
Isomalt galenIQ- 721 
Ludiflash BASF / Switzerland http://www.pharma-ingredients.basf.com/Ludiflash/Home.aspx 
Pharmaburst TM 
SPI / FRANCE 
http://www.spipharma.com/default.asp?contentID=588 
 
3KDUPDIUHH]H 
Mannitol  (Mannogem) 
Lactose Spry Dried (Fast-
Flu) Foremost / USA 
http://www.foremostfarms.com/Commercial/Dairy-
Ingredients/Pharmaceutical-Grade-Lactose.php 
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1.5 Chitin: A Solid Dosage Form Excipient [23] 
LDFNRIWKHDPLQHJURXS³1+2´ makes chitin almost chemically inactive. In addition, 
the availability of chitin as the second most naturally abundant material, after 
cellulose, allows its use as an excipient in processing solid drug dosage forms. This 
facilitates its use with other common excipients, namely microcrystalline cellulose 
(MCC), lactose, starch, and calcium hydrogen phosphate. Consequently, chitin is a 
natural hydrophilic polymer wherein chemical modification and co-processing can be 
carried out to prepare multi-functional excipients. 
1.5.1 Chemical names and structural formula of chitin (CAS No.:  -61-4) 
³Chitin´ and ³chiton´ (a marine animal) both derive from the same Greek word 
meaning ³tunic´, referring to the protective shell. Chitin is a white, hard, inelastic, 
nitrogenous polysaccharide found in the outer skeletons of crabs and lobsters as well 
as in the internal structures of other invertebrates. Chitin (CHNO5)n LVȕ-(1,4)-2-
acetamido-2-deoxy-D-glucopyranose, poly-N-acetyl-D-glucosamine [poly (D-
*OF1$F@ ȕ-1, 4-poly-N-acetyl-D-glucosamine, poly-ȕ-4)-N-acetyl-glucosamine, 
poly-DFHW\O DPLQR JOXFRVH ȕ- (1,4)-2-acetamido-2-deoxy-D-glucose, 2-acetamido-
2-deoxy-D-JOXFRVH ȕ-(1,4)-2-amino-2-deoxy-D-glucose, poly-(N-acetyl-1,4-E-D 
glucopyranosamine), fully acetylated chitosan. Chitin has a monomer molecular 
weight of 203.19 and average molecular weight ranging from 1.0 to 2.5 million Da. 
The variation in the molecular weight is a function of the extent of  
N-acetylation. The chemical structure of the monomeric unit of chitin is shown in 
Figure 1.5. The elemental composition of fully acetylated chitin is: carbon: 47.29%, 
hydrogen: 6.45%, nitrogen: 6.89% and oxygen: 39.37% 
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Figure 1.5 Chemical structure of chitin showing its monomer: N-acetyl-D-
glucosamine [24]. 
1.5.2 Preparation of chitin 
Crude chitin is isolated from the outer skeletons of crustaceans, molluscs or 
invertebrate animals, insects and certain fungi. Commercially, crab and shrimp shells 
are the major sources of chitin. Crustacean shells consist of 30-40% protein, 30-50% 
calcium carbonate and 20-30% chitin, but also contain pigments of a lipidic nature 
such as carotenoids. These components have to be quantitatively removed to obtain 
pure chitin necessary for biological applications. Several published methods for the 
extraction of chitin from crustacean shells in addition to enzymatic preparation are 
summarized in Table 1.13. 
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Table 1.13 Methods for the preparation of chitin [25-28]. 
Method Procedure 
Method 1 
Crude chitin is washed with water, dried at room temperature and cut into small pieces, then treated 
with acid (HCl, HNO3, H2SO4, CH3COOH, or HCOOH) (demineralization), followed by alkali using 
NaOH at 105-110oC (deproteinization). The decolouration is performed by refluxing in ethanol or by 
using oxidizing or bleaching agents (e.g. KMnO4, NaOCl and H2SO4). 
Method 2 
Crude chitin is washed with water, dried at room temperature and cut into small pieces, then soaked 
for 3 days in 10% NaOH solution (freshly prepared and degassed every day at room temperature). The 
obtained solid is then treated with 95% ethanol to clean the pigment products. The white protein free-
residue is then suspended in 37% HCl at 20°C for 4 hours. The solid is filtered and washed with water, 
ethanol and ether. 
Method 3 
The shells are partially digested with an organic acid, followed by 2N HCl for 5 hours at room 
temperature. The decalcified shells are shaken for 18 hours with 90% formic acid at room temperature 
and then filtered. The solid is washed with water and treated for 2.5 hours with 10% NaOH solution on 
a steam bath. The suspension is then filtered, washed with water, ethanol and ether. 
Method 4 
Decalcification with EDTA at pH 10 at room temperature for 2 or 3 weeks. Large cuticle fragments of 
the crab Cancer parugus are reacted slowly (2 or 3 weeks) with EDTA at pH 9.0. The solid is then 
further treated with EDTA at pH 3, extracted with ethanol for pigment removal and with ether for the 
removal of lipids. The protein is removed with formic acid (98-100%) followed by treatment with hot 
alkali. 
Method 5 
Decalcification with EDTA at pH 10 at room temperature, followed by digestion with a proteolytic 
enzyme such as tuna proteinase at pH 8.6 and 37.5ºC, or papain at pH 5.5-6.0 and 37.5ºC or a bacterial 
proteinase at pH 7.0 and 60ºC for over 60 hours. The remaining protein (~5%) is removed by 
treatment with sodium dodecylbenzensulfonate or dimethylformamide. 
Method 6 
Decalcification is carried out by a simple treatment with 1.4N HCl at room temperature in a plastic or 
wooden container. After completion of the decalcification treatment, proteins are removed using 
papain, pepsin or trypsin. This method is simple and suitable for the mass production of chitin with 
little deacetylation. 
Method 7 
The shell wastes are treated with hot 1% Na2CO3 solution followed by dilute HCl (1-5%) at room 
temperature, and then 0.4% Na2CO3 solution 
Method 8 
Hydrolysis of protein present in the shell followed by digestion of CaCO3. The shells are treated with 
hot 5% NaOH, followed by cold NaOCl  and then with warm 5% HCl. 
Method 9 
Trehalose is hydrolyzed with the enzyme trehalase, followed by phosphorylation with ATP/enzyme 
hexokinase to form glucose-6-phosphate, which is transformed to fructose-6-phosphate in the presence 
of the enzyme glucose phosphate isomerase. Amination occurs in the presence of glutamine amino-
transferase and the amino acid glutamine to form D-D-glucosamine-6-phosphate. Acetylation by 
acetyl-CoA in the presence of the enzyme glucosamine-6- phosphate-N-acetyl transferase causes the 
formation of N-acetylglucosamine-6-phosphate. The latter rearranges via the enzyme 
phosphoacetylglucosamine mutase to form N-acetylglucosamine-1-phosphate, which is converted to 
uridinediphosphate-N-acetyl glucosamine (UDP-N-acetylglucosamine) via the enzyme 
uridinediphosphate-N-acetylglucosamine pyrophosporylase and UTP. The final product, chitin, is 
produced via the enzyme chitin synthesase by the loss of UDP (Figure 1.6). 
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Figure 1.6 Biosynthesis of chitin [26]. 
 
1.5.3 Deacetylation of chitin (chitosan preparation) 
The most important derivative of chitin is chitosan obtained by partial deacetylation 
of chitin in the solid state under alkaline conditions or by enzymatic hydrolysis in the 
CHAPTER ONE  INTRODUCTION  
 
 31  N.H.M.Daraghmeh±PhD Thesis 
  
presence of a chitin deacetylase. The ratio of 2-acetamido-2-deoxy-D-glucopyranose 
to 2-amino-2-deoxy-D-glucopyranose moieties determines the identity of the product 
i.e. chitin or chitosan. Published methods used for the production of chitosan from 
chitin are summarized in Table 1.14. 
Table 1.14 Methods used for the deacetylation of chitin to form chitosan [26, 27, 29, 
30]. 
 
Method Procedure 
Method 1  40% NaOH solution is added to chitin and refluxed under nitrogen at 
115°C for 6 hours. The cooled mixture is then filtered and washed 
with water until the washings are neutral to phenolphthalein. The 
crude chitosan is purified as follows. It is dispersed in 10% acetic 
acid and then centrifuged for 24 hours, to obtain a clear supernatant 
liquid. The latter is treated drop-wise with 40% NaOH solution and 
the white flocculent precipitate formed at pH 7. The precipitate is 
then recovered by centrifugation, washed repeatedly with water, 
ethanol and ether and the solid collected and air-dried (Figure 1-7). 
Method 2 Fusion with solid KOH at very high temperature in a nickel crucible 
under nitrogen atmosphere. The melt is poured carefully into ethanol 
and the precipitate washed with water to neutrality. 
Method 3  Heating in 40% NaOH solution at 115 ºC for 6 h under nitrogen. 
After cooling, the mixture is filtered and washed with water until 
neutral. This method does not include a purification step. 
Method 4  Kneading with NaOH and liquid paraffin in a 1:1:10 ratio, and stirred 
for 2 h at 120°C. The mixture is poured into cold water, filtered and 
thoroughly washed with water. 
Method 5 Steam heating with a solution containing 50% KOH, 25% EtOH 
(96%) and 25% mono-ethylene glycol. The temperature of the system 
is 120°C. The obtained chitosan is filtered, washed with water until 
neutral, and then dried at moderate temperatures. 
Method 6 Recovery of shell proteins, sodium acetate and calcium carbonate in 
addition to chitosan as commercial pure products. The extraction 
procedure includes different reaction and crystallization steps. 
Method 7 The fungal order mucorales contains chitosan as a cell wall 
component. Absidia coerula a member of this class is readily 
cultured on nutrients (e.g. glucose or molasses) and the cell wall 
material recovered by simple chemical procedures. 
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Figure 1.7 Scheme for the deacetylation of chitin [29]. 
 
1.5.4 Hydrolysis products of chitin (oligomers)  
Chitin is hydrolyzed to form smaller oligosacharides by different methods including 
acetolysis using acetic anhydride/H2SO4, hydrolysis with HCl/sonolysis under 
ultrasound irradiation or fluorohydrolysis using anhydrous HF (Figure 1.8). 
Enzymatic hydrolysis is a useful method for the preparation of monomers from chitin 
and chitosan because the yield of monomers is greater by enzymatic hydrolysis than 
by acid hydrolysis. The enzyme chitin deacetylase hydrolyzes the acetamido group in 
the N-acetylglucosamine units of chitin and chitosan, thus generating glucosamine 
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units and acetic acid (Figure 1.9).  
 
 
Figure 1.8 Mechanisms for the acid hydrolysis of chitin [31]. 
 
Figure 1.9 Enzymatic hydrolysis of chitin and chitosan into their monomers [31]. 
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1.5.5 Other derivatives  
Carboxymethyl chitin (CM-chitin), as a water-soluble anionic polymer, is the second 
most studied derivative of chitin after chitosan. The carboxymethylation of chitin is 
undertaken in a similar manner to that of cellulose. Chitin is treated with 
monochloracetic acid in the presence of concentrated NaOH. The same cellulose 
derivatization procedure can be used to prepare hydroxypropylchitin, which is a 
water-soluble derivativHXVHGIRUDUWL¿FLDOODFKU\PDOGURSV Fluorinated chitin, N- and 
O-sulfated chitin, (diethylamino) ethylchitin, phosphoryl chitin, mercaptochitin and 
chitin carbamates have also been reported and described in the literature. Similar 
FKHPLFDOPRGL¿FDWLRQVHJHWKHUL¿FDWLRQDQGHVWHUL¿FDWLRQDVIRUFHOOXORVHFDQEH
performed for chitin. Chitin can be used in blends with natural or synthetic polymers; 
it can be cross-linked by the reagents used for cellulose (e.g, epichlorhydrin and 
glutaraldehyde) or grDIWHGLQWKHSUHVHQFHRIFHULFVDOWRUDIWHUVHOHFWLYHPRGL¿FDWLRQ 
Another chitin derivative dibutyrylchitin (DBCH) is prepared from krill chitin by 
esterification with butyric anhydride in the presence of perchloric acid. DBCH can be 
used in fibre spinning. DBCH fibres have been manufactured from a polymer solution 
in ethyl alcohol by extrusion. 
1.5.6 Physical characteristics of chitin 
1.5.6.1 Solubility  
Table 1.15 Solubility of D-chitin in different solvents and solvent mixtures at room 
temperature [32-34]. 
Solvent/Solvent mixture Solubility 
Water i 
Dilute acids i 
Dilute and concentrated alkalies i 
Alcohol i 
Organic solvents i 
Concentrated HCl, H2SO4 or H3PO4, anhydrous HCOOH s (with depolymerization) 
N,N-dimethylacetamide (DMAc)/5% LiCl s 
Dinitrogen tetroxide/N,N-dimethylformamide (DMF) s 
Fluoroisopropanol/hexafluoroacetone s 
N,N-dimethylacetamide/N-methyl-2-pyrrolidone/LiCl s 
N-methyl-2-pyrrolidone/5% LiCl s 
i and s represent insoluble and soluble, respectively 
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The dissolution mechanism of D-chitin in DMAc/5% LiCl (Table 1.15) can be 
attributed to the formation of a weak complex between Li ions and the carbonyl 
oxygens of the DMAc, which solvates the polyelectrolyte formed between the Cl 
ions and labile proton groups (OH and NHCOCH3) of the chitin chain, disrupting the 
extensive intra- and inter-molecular hydrogen bonds of the crystalline sheet structure 
of D-chitin.  
Table 1.16 shows the effect of different solvent mixtures containing methanol, ethanol 
and anhydrous and hydrate forms of calcium and magnesium salts.  
Table 1.16 Solubility of D-chitin in various calcium and magnesium salt-alcohol 
solutions [32-34]. 
Solvent System Solubility* 
Saturated anhydrous CaCl2-methanol p.s. 
Saturated CaCl2.2H2O-methanol s 
Saturated CaCl2.2H2O-ethanol p.s. 
Saturated MgCl2.6H2O-methanol i 
100%(w/v) Ca(NO3)2.4H2O-methanol i 
100%(w/v) Mg(NO3)2.6H2O-methanol i 
200%(w/v) Ca(SCN)2.4H2O-methanol p.s 
*0.5g chitin was stirred in 50 mL of each solution at room temperature; s, p.s. and i represent soluble, 
partially soluble and insoluble, respectively. 
By comparing the solubility of D- DQG ȕ-chitins (although the later exists in a 
FU\VWDOOLQHK\GUDWHGVWUXFWXUHZKLFKLVPXFKORRVHUWKDQWKDWRIWKHĮ-FKLWLQȕ-chitin 
shows lower solubility due to the penetration of water between the chains of the 
lattice. Based upon data for chitin-solvent interactions and solubility mechanisms,    
ȕ-FKLWLQ VWDUWV JHOOLQJ DW D ORZHU FRQFHQWUDWLRQ WKDQ Į-chitin. Table 1.17 shows the 
solubility of chitin and structurally related compounds in a saturated CaCl2.2H2O-
methanol solvent system. 
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Table 1.17 The solubility of D-/E-chitins and structurally related compounds in a 
saturated CaCl2.2H2O-methanol solvent system [32-34]. 
Material Solution (g/100 mL) Solubility* 
Į-Chitin 2.00 s 
ȕ-Chitin 1.25 t 
Chitosan 5.00 i 
Bacterial cellulose 0.15 g 
O-Acetylated chitin 1.25 t 
Nylon-6 5.00 s 
*s, t, g, and i represent soluble, turbid or gelation, gelation and insoluble, respectively. 
 
1.5.6.2 Chitin Morphology 
The morphology of D-chitin was determined using a Quanta-200 3D scanning 
electron microscope (SEM) operated at an accelerating voltage of 1200 V. The 
sample (0.5 mg) was mounted onto a 5×5 mm silicon wafer affixed via graphite tape 
to an aluminium stub. The powder was then sputter-coated for 105 s at a beam current 
of 20 mA/dm3 with a 100 Å layer of gold/palladium alloy. The SEM images in   
Figure 1.10 show the highly porous structure of D-chitin in addition to the high 
particulate surface area. 
A 
 
B 
 
Figure 1.10 SEM images of D-chitin, at magnifications of (A) x160 and (B) x1600 [35]. 
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1.5.6.3 Chitin polymorphs and their sources  
Chitin is isolated from the exoskeletons of crustaceans (e.g, crabs, lobsters, crayfish, 
shrimp, krill, barnacles), molluscs or invertebrate animals (e.g, squid, octopus, 
cuttlefish, nautilus, chitons, clams, oysters, scallops, geoducks, mussels, fossils, 
snails), insects (e.g. ants, scorpions, cockroaches, beetles, spiders, brachiopods) and 
certain fungi. Commercially, crab and shrimp shells are the major sources of Į-chitin 
whereas squid is the source of ȕ-chitin. There are three polymorphic forms of chitin: 
ĮȕDQGȖ7KH\GLIIHULQWKHDUUDQJHPHQWRIFKDLQVLQWKHFU\VWDOOLQHSKDVH7KHPRVW
abundant and stable form is Į-chitin, which displays orthorhombic crystals. The 
FU\VWDOORJUDSKLF SDUDPHWHUV IRU Į- DQG ȕ-chitin are shown in Table 1.18. The 
neighboring sheets in D- and E-chitin are connected by hydrogen bonds via C=O and 
N-H groups. In addition, each chain has intra-molecular hydrogen bonds between the 
neighboring sugar rings (C=O and OH groups on C-6 and a second hydrogen bond 
between the OH- group on C-3 and the ring oxygen) (Figure 1.11). The differences 
among chitin polymorphs are due to the arrangement of the chains in the crystalline 
regions. Į-Chitin has a structure of anti-SDUDOOHO FKDLQV ȕ-chitin has intra-sheet 
hydrogen-ERQGLQJ UHVXOWLQJ LQ SDUDOOHO FKDLQV DQG Ȗ-chitin, being a combination of  
Į- DQG ȕ-chitin, has both parallel and anti-parallel structures. Because of these 
differences each chitin polymorph differs in specific properties. The poor solubility of 
chitin is a result of the close packing of chains and its strong inter- and intra-
molecular bonds between the hydroxyl and acetamide groups. On the other hand,  
ȕ-chitin lacks these inter-chain hydrogen bonds; therefore it swells readily in water 
and it is more prone to N-GHDFHW\ODWLRQWKDQĮ-chitin. 
Table 1.18 &U\VWDOORJUDSKLFSDUDPHWHUVIRUĮ-DQGȕ-chitin [36, 37]. 
Compound a (nm)  b (nm)  c (nm)  Ȗq)  Space group  
Į-Chitin  0.474 1.886 1.032 90.0 P212121 
ȕ-Chitin  0.485 0.926 1.038 97.5 P21 
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A 
 
B 
 
Figure 1.11 Modes of hydrogen bonding in (A Į-chitin: (a) intra-chain C(3c) 
OH···OC(5) bond; (b) intra-chain C(6c1)OH···O=C(71) bond; (c) inter-chain 
C(6c1)O···HOC(62) bond; (d) inter-chain C(21)NH···O=C(73) and (B) E-chitin: 
(a) intra-chain C(3c)OH···OC(5) bond; (b) inter-chain C(21)NH···O=C(73) bond 
DQG &¶1)OH···O=C(73) bond (ac plane projection); (c) inter-chain 
C(21)NH···O=C(73) bond (ab plane projection) [36,37]. 
 
The seafood industry produces in excess of 3.5 million tonnes of solid waste each 
year and with this figure rising, there is a subsequent waste disposal issue. Chitin is 
mainly used as a raw material to produce chitin-derived products such as chitosans, 
chitin/chitosan derivatives, oligosaccharides and glucosamine. An increasing number 
of useful products derived from chitin continue to attract commercial development. 
The large number of patents filed involving chitin-derived products reflects the 
commercial expectations for these products. An estimated 75 % of chitin produced is 
used to manufacture products for the nutraceutical market. Currently the major 
CHAPTER ONE  INTRODUCTION  
 
 39  N.H.M.Daraghmeh±PhD Thesis 
  
driving force in the market is the increasing sales of glucosamine as a dietary 
supplement. Approximately 65% of the chitin produced is converted into 
glucosamine, nearly 25% is converted into chitosans, about 9% is used to produce 
oligosaccharides and approximately 1% is used in the production of  
N-acetylglucosamine. Table 1.19 shows the estimated global price of high purity 
chitin, mannitol and different pharmaceutical grades of microcrystalline cellulose and 
microcrystalline cellulose related products.  
 
Table 1.19 Estimated global market prices of some pharmaceutical excipients [35]. 
Item Pharmaceutical Application Price* in USD/Kg 
Chitin (high purity powder 
grade) 
Tablet/ capsule filler and 
disintegrant 8-15 
D-Mannitol (Crystalline) Tablet/ capsule filler 5-15 
Microcrystalline Cellulose PH 
200 
Direct compression excipient 
for tablet/ capsule formulation 6-10 
Silicified Microcrystalline 
Cellulose 
Direct compression excipient 
for tablet/ capsule formulation 21-27 
AVICEL HFE 102 NF  
(Mannitolized Microcrystalline 
Cellulose) 
Direct compression excipient 
for tablet/ capsule formulation 10-15 
    * The price range is dependent on the quantity supplied, grade and supplier. 
1.5.6.4 Chitin stability 
Chitin is a stable compound, incompatible with oxidizing agents. In the solid state 
under alkaline condition (e.g, NaOH, KOH, heat at about 120oC) or by enzymatic 
hydrolysis in the presence of a chitin deacetylase, it hydrolyses to form the 
deacetylated degradation product chitosan. It was found that the presence of urea in 
basic media and at low temperature (-20oC) had little effect on chitin structure and 
WKDW XUHD LV RI EHQH¿W WR WKH VWDbility of chitin solution. Under acidic conditions 
including acetolysis with acetic anhydride/H2SO4, hydrolysis with HCl/sonolyses 
under ultrasound irradiation and fluorohydrolysis with anhydrous HF or by using the 
enzyme chitin deacetylase, it forms smaller oligosaccharides. The effect of hydrogen 
peroxide on the stability of chitin by microwave radiation was investigated, it was 
suspended in water, and 30% hydrogen peroxide was added in quantities to achieve 
H2O2 concentrations of 1%, 5%, 9% and then subjected to 600 W microwave 
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radiation for 10 to 30 min. The results indicated that chitin degradation with hydrogen 
peroxide in a microwave field caused significant changes in the molecular weight and 
the chemical structure of the polymer in a short period (up to 30 min). The limiting 
viscosity numbers of the degradation products were from 15 to 83% lower than those 
of the initial chitin. 
1.5.6.5 Biodegradability and toxicology  
Chitin is a biodegradable material and undergoes biodegradation by enzymes such as 
lysozyme and chitinase. In-vivo studies show that lysozyme plays an important role in 
the degradation of chitin to produce mostly soluble oligomers such as  
N-acetylglucosamine upon hydrolysis. Chitin is not believed to present a significant 
health risk. Also no risk to humans is expected when products containing chitin are 
used according to label directions. Chitin is structurally closely related to the active 
ingredient chitosan (poly-D-glucosamine), which shows no toxicity in mammals, and 
is approved by the FDA as a food additive. The LD50 for the intravenous 
administration of chitin is 50 mg/Kg in rats. 
1.5.6.6 Chitin/ chitin derivatives applications 
Chitin and its derivatives have been used in different applications including the food, 
medical, pharmaceutical, agriculture and biotechnology industries. Table 1.20 
illustrates some of these applications.  
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Table 1.20 Examples of applications of chitin and its derivatives [34, 38]. 
Fields Chitin and Chitosan Chitin and chitosan oligomers 
Food  Antimicrobial agent  
preservative agent 
Edible film 
Antimicrobial agent 
preservative agent 
 
Pharmaceutical  Protective effect on bacterial infection  
Antitumor agents  
Immunopotentiating agent  
Carrier for drug delivery system 
Protective effect on bacterial infection  
Antitumor agents  
Immunopotentiating agent  
 
Medical  Accelerator for wound healing  
Artificial skin 
Fiber for absorbable sutures 
  
Nutritional  Dietary fiber  
Hypocholesterolemic agent  
Antihypertensive agent 
Hypocholesterolemic agent  
Calcium absorption accelerator in vitro 
Biotechnological  Carrier for immobilized enzymes and cells  
Porous bead for bioreactors  
Resin for chromatography 
Membrane material  
 
Agricultural  Seed coating preparation 
Activator of plant cells 
Activator of plant cells 
Others  Coagulant for wastewater treatment processing 
plants 
Removal of heavy metal from wastewater 
Cosmetics material 
 
 
 
1.5.6.7 Chitin in the pharmaceutical industry 
Because chitin is a non-toxic material biodegradable material, it is attractive for use in 
a wide variety of applications. 
1.5.6.8 Chitin as a tablet/capsule disintegrant  
Chitin is well known as a disintegrant in pharmaceutical solid dosage formulations in 
tablets to facilitate their break up or disintegration after oral administration. Chitin, as 
a disintegrant, can be used at the 2 ± 20% (w/w) level. 
1.5.6.9 Chitin as a tablet diluent and disintegrant  
A study was undertaken of directly compressed tablet matrices containing chitin or 
chitosan in addition to lactose, microcrystalline cellulose (MCC) or starch 
formulation. Using lactose/chitin, lactose/chitosan, and lactose/MCC tablet hardness 
increases with the addition of chitin, chitosan and MCC as shown in Figure 1.12.A. 
Comparing the hardness of starch/MCC tablets with that of starch/chitin, there was no 
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statistical difference at 10 and 30% (w/w) addition. The hardness of the tablets 
containing chitin, chitosan and MCC is increased by increasing the compression force 
(Figure 1.12.B). This study also shows that the hardness of chitin tablets is greater 
than that of chitosan due to the structural rigidity of chitin, attributed to the 
acetylamino groups. Results suggest that chitin and chitosan can be used as direct 
compression diluents. Rapid disintegration time was obtained for tablets produced 
from lactose/chitin, lactose/chitosan, lactose/MCC, potato starch/chitosan and potato 
starch/ MCC below a certain concentration level of excipient (chitin, chitosan and 
MCC), as shown in Figure 1.12.C.  
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Figure 1.12 A) Relationship between tablet hardness and applied compression 
pressure, B) relationship between the tablet hardness and concentration of used 
excipient and C) relationship between tablet disintegration time and concentration of 
excipient (x: disintegration was not completed within 60 min) [39,40]. 
 
1.5.6.10 Directly compressed tablets containing chitin or chitosan in addition to 
mannitol  
Mannitol is not a compressible material. The addition of chitin, chitosan and MCC 
improves the compressibility of mannitol. The measured hardness for the tablets 
composed of mannitol/chitin, mannitol/chitosan and mannitol/MCC increased with 
increase in the concentration of chitin, chitosan or MCC (Figure 1.13). Chitin, 
chitosan and MCC should be added at a level >20% w/w in order to improve the 
compressibility of mannitol tablets. The relationship between the disintegration time 
of tablets and the concentration of chitin chitosan or MCC excipients added to 
mannitol were investigated. Results showed that all tablets obtained disintegrate 
within 1 minute except for those containing 80% w/w chitosan [23]. 
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Figure 1.13 The relationship between the tablet hardness and excipient concentration [40]. 
The compactibility of chitin and chitosan were evaluated by investigating the 
relationship between applied compression pressure and obtained tablet crushing 
strength (Figure 1.14). Chitin and chitosan exhibited almost identical compression 
pressure-crushing strength profiles, being clearly more compressible than DBCP and 
PGS. MCC showed the highest tablet crushing strength values (highest slope of the 
curve). Table 1.21, shows the compression and friction properties (tensile strength, 
net work, compactibility and R-value) of the chitin and chitosan in comparison with 
the commercially available reference excipients at an applied compression pressure of 
94 Mpa. The tensile strength and compactibility values for microcrystalline cellulose 
(MCC) were the highest among the others, while chitin and chitosan presented similar 
results of these parameters, and dibasic calcium phosphate (DBCP) the lowest values. 
The excipients exhibited the same order with the present parameters as was found 
with the compression profiles. MCC, chitin and chitosan presented the highest R-
values. The magnitude of this effect conformed to the following descending rank 
order: MCC, chitosan, chitin, pregelatinized starch (PGS) and DBCP. Chitin and 
chitosan were found to be potential co-excipients for direct compression applications. 
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Figure 1.14 Effect of compression pressure on the crushing strength of chitin, chitosan 
and direct compressed reference tablets [41]. 
 
Table 1.21 Compression and compaction properties of chitin, chitosan and direct 
compression reference excipients [41]. 
Material Tensile strength (Mpa) R-value 
(1)
 
Wnet  
(J) 
Compactibility (2) 
(Mpa/J) 
Chitin 64.91 0.919 4.31 15.06 
Chitosan 60.19 0.921 3.74 16.10 
 MCC (Avicel PH 102) 146.87 0.920 5.45 26.93 
 DBCP (Emcopress) 8.96 0.679 2.62 3.41 
 PGS (Starch 1500) 18.16 0.726 3.18 5.72 
(1) R-value
 
is the lubrication coefficient. 
(2) Compactibility is calculated from the ratio between tensile strength and netZRUN³:net´ 
1.4.6.11 Co-processed tablet excipient composed of chitin and silicon dioxide 
Chitin is a water-insoluble hydrophilic polymer that can absorb water and function as 
a disintegrant. Due to the unacceptable flow and compression properties of chitin,    
co-precipitation with silicon dioxide was used to provide a new excipient with 
excellent flow, compaction and disintegration properties when compared to the 
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individual components or commercially available direct compression fillers and 
disintegrants. The optimal composition of the co-processed excipient contains a 
silicon concentration of about 50 % w/w. 
1.6 Synthetic Metal Silicates [8, 42] 
Synthetic metal silicates are non toxic materials widely used in food and 
pharmaceutical industry. Synthetic metal silicates i.e. ³brittle materials´ are good 
candidates for preparing co-processed excipients when combined with chitin, a 
³SODVWLFPDWHULDO´ 
1.6.1 Synthetic Magnesium Silicate [43] 
Magnesium silicate (silicic acid, magnesium salt) is a compound of magnesium oxide 
and silicon dioxide. Magnesium silicate occurs as an odourless and tasteless, fine, 
white coloured slightly hygroscopic powder that is free from grittiness. Magnesium 
silicate is used in oral pharmaceutical formulations and is generally regarded as an 
essentially nontoxic and nonirritant material. Orally administered magnesium silicate 
is neutralized in the stomach to form magnesium chloride and silicon dioxide; some 
magnesium is absorbed. Magnesium silicate is listed in GRAS and accepted for use as 
a food additive in Europe. It is included in the FDA regulation SDUW³6XEVWDQFHV
JHQHUDOO\ UHFRJQL]HG DV VDIH´ sub-part C as anti-caking agents. Also, in part 169 
³)RRGGUHVVLQJVDQGIODYRXULQJV´6XESDUW%± requirements for specific standardized 
food dressings and flavourings. 
1.6.1.1  Structural formula and composition 
Magnesium silicate is a compound of magnesium oxide and silicon dioxide; it is the 
magnesium salt of silicic acid containing an unspecified amount of water. Many 
natural silicate minerals are formed under aqueous conditions by reactions which are 
hypothesized to proceed via "protosilicate" intermediates, gels of hydrated oxides 
which, in the absence of structural information, have been described as 
xMgO.ySiO2.zH2O. The molecular formula may be expressed as MgSiO3.xH2O, 
Figure 1.15. 
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xxH2O 
 
Figure 1.15 A schematic of the structure of magnesium silicate [44]. 
The USP/NF and JP state that the assay of magnesium silicate should be expressed as 
the percentages of magnesium oxide (MgO) and silicon dioxide (SiO2). Table 1.22 
shows the acceptance criteria for the content of magnesium silicate, as reported in the 
USP/NF and JP. 
 
Table 1.22 Acceptance criteria of content of magnesium oxide and silicon dioxide in 
magnesium silicate [45, 46]. 
Component 
Content 
USP/NF JP 
MgO (%) t 15.0* t 20.0 
SiO2 (%) t 67.0* t 45.0 
MgO (%)/SiO2 (%) 2.50 ± 4.50* 2.2 ± 2.5 
*Calculated on the basis of ignition. 
 
1.6.1.2 Methods of preparation of synthetic magnesium silicate 
I) Precipitation Method 
The most common route for the synthesis of magnesium silicate is via the 
precipitation reaction between a soluble metal silicate (e.g. sodium orthosilicate, 
sodium metasilicate or potassium silicate) and a soluble magnesium salt (magnesium 
sulphate, nitrate, or chloride). The aqueous suspension of the precipitate is filtered and 
the collected solid washed and dried. The physical properties and magnesium oxide 
(MgO) content of the precipitated magnesium silicate depend on the type of 
magnesium salt, sequence of addition of magnesium salt and metal silicate, type and 
concentration of dispersion modifiers (e.g. non-ionic surfactants, NaOH), and 
experimental conditions. Regardless of the type of soluble metal silicates used, they 
are subject to the same molecular speciation in aqueous solution resulting in a mixture 
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of monomeric tetrahedral ions, oligomeric linear or cyclic silicate ions and 
polysilicate ions. Sodium metasilicate, an example of a soluble metal silicate, can be 
prepared in anhydrous form, or with water of crystallisation as the penta- or 
nonahydrate. It is readily soluble in water. 
The dissolution process of sodium silicate consists of its hydration with the formation 
of NaOH. Sodium orthosilicate hydrolyzes according to equation 1: 
Na4SiO4 + H22ĺ1D2+1D2SiO3 (1) 
The hydrolytic dissociation is particularly strong with sodium metasilicate (equations 
2 and 3): 
2Na2SiO3 + H22ĺ1D2Si2O5 + 2NaOH (2) 
Na2SiO3 + H22ĺ1D+6L23 + NaOH (3) 
Sodium silicate reacts with ions in solution (e.g. magnesium) forming nearly insoluble 
magnesium silicates. The effectiveness of sodium silicate on precipitation of Mg2 
ions when a bulk solution with magnesium chloride added to deionized water is 
shown in Figure 1.16. It can be seen that the ion concentration of Mg2+ decreases 
rapidly with the addition of sodium silicate. 
 
[Sodium silicate] mM 
 
[M
g2
 io
n
] m
M
 
 
Figure 1.16 Concentration of Mg2 ions, in deionized water, as a function of sodium 
silicate concentration (pH 8.5) [47]. 
II) Hydrothermal Precipitation Method 
A hydrothermal solution is a multi-component system containing compounds of Na, 
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K, Si, Ca, Mg, Al, Fe, Cl, S, O, C, B, Li, As, Cu, Zn, Ag, Au, and other elements in 
ionic and molecular forms; Si is usually present at high concentrations. Silica, 
together with other compounds, passes into this hydrothermal solution due to the 
chemical interaction of water with aluminosilicate minerals of rocks of hydrothermal 
fields at a depth in regions of thermal anomalies at high temperatures and pressures. 
At temperatures of 250±300°C, silicon occurs in solution predominantly in the form 
of individual molecules of silicic acid, H4SiO4. As a consequence, such an aqueous 
solution becomes supersaturated with respect to solutions of amorphous silica in pure 
water. When metal cations (e.g. Ca2+, Mg2 and Co2+) are introduced into the solution, 
some of these ions are sorbed by the surface of colloidal particles resulting in 
neutralization of the negative surface charge. Bridging bonds, with the participation of 
coagulating ions, are formed between the surfaces of particles which results in 
coagulation and precipitation of colloidal silica. The material precipitated by metal 
ions has an amorphous structure of metal silicate. After high-temperature calcination 
at 900oC, the amorphous samples prepared upon addition of magnesium sulfate or 
cobalt sulfate (with simultaneous alkalization to pH 12.4) have a crystalline structure 
of forsterite (Mg2SiO4) or cobalt silicate (Co2SiO4), respectively. 
III) Mechano-chemical Dehydration Method 
An amorphous phase can be formed as a result of the reaction of amorphous SiO2 
with magnesium hydroxide. The solid-state reaction between Mg(OH)2 and SiO2 
begins at the contact points between these dissimilar particles. Mechano-chemical 
dehydration and amorphization of Mg(OH)2 are substantially enhanced by grinding 
with SiO2. In the mixture, enhanced mechano-chemical dehydration of Mg(OH)2 is 
explained by assuming the following complex processes take place: intimate mixing, 
agglutination at the contact points of dissimilar particles promoted by the higher 
affinity of silica over magnesia towards hydroxyl groups and initiation of 
simultaneous solid-state reactions. Since magnesium hydroxide is a strong base and 
silicic acid is a weak acid, acid-base neutralization ensues. A possible reaction 
mechanism involves the release of excess water from the silicic acid which makes the 
surface of the magnesium hydroxide more alkaline. This leads to the dissolution of 
silica at the contact points, resulting in precipitation of amorphous magnesium 
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silicate. Thus the reaction between the two ingredients and dehydration results in a 
precursor of magnesium silicate in an amorphous state. 
1.6.1.3 Solubility characteristics 
Magnesium silicate is practically insoluble in ethanol (95%), ether and water. It is 
readily decomposed by mineral acids. 
Table 1.23 shows the total amount of Mg and Si (mg/50 mL) dissolved in various 
aqueous solutions (H2O, HNO3, HCl, H3PO4, and NaOH), which reflects the solubility 
of magnesium silicate in these solvents. The experiment was performed by the 
addition of about 0.5 g of magnesium silicate to 50 mL of solution at room 
temperature (25°C) followed by incubation for 24 hours with intermittent shaking. 
The total amount of Mg and Si was measured using an ICPseq-7500 spectrometer. 
 
Table 1.23 The total amount of Mg and Si dissolved (mg/50 mL) in various solutions 
at 25oC [48]. 
Solvent H2O HNO3 HCl H3PO4 NaOH 
Conc. (M)  - 0.1 1.0 3.0 0.1 1.0 3.0 0.1 1.0 
Conc. of Mg and 
Si dissolved in 
(mg/50 mL) 
0.0 5.0 12.0 20 4.0 10.0 16.0 0.0 0.0 
 
Magnesium silicate displays low solubility in acids of up to 3 M concentration; above 
this concentration it partially dissolves. It is dissociated in acids forming magnesium 
LRQVDQGVLOLFLFDFLGLQZKDWLVUHIHUUHGWRDV³DFLGOHDFKLQJ´RIVLOLFDWHVHTXDWLRQ 
MgSiO3 + H ĺ+6L23 + Mg2 (4) 
Figure 1.17 shows the conditional solubility product of magnesium silicate as a 
function of pH (at an initial ion concentration of 1 mM). The region above the curve 
represents a system of higher concentration product where bulk magnesium silicate 
precipitation is anticipated. The higher the solution pH is the lower the conditional 
solubility product, and the higher the propensity for magnesium to be precipitated. 
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Figure 1.17 Conditional solubility product of magnesium silicate (initial ion 
concentration of 1 mM) as a function of pH [48]. 
Solubility-pH diagrams for Mg2+-SiO32- can be constructed to show the relationship 
between Mg2+ precipitation and solution pH. For a given solution system, if the 
magnesium ion concentration is above the solubility product limit, the formation of 
magnesium silicate is anticipated, and is governed by equation 5: 
MgSiO3(s) ĺ0J2(aq) + SiO32(aq) Ksp = 4×1012 (5) 
where Ksp is the corresponding solubility product constant, which defines the 
solubility limit. 
According to the USP/NF, the pH of magnesium silicate (10% aqueous dispersion) is 
7.0±10.8. The pH of magnesium silicate is controlled by the degree to which 
magnesium is released from the surface when it comes into contact with water. The 
basicity of magnesium silicate is mainly attributed to the magnesium oxide present. 
1.6.1.4 Surface active sites (adsorption and absorption) 
The surface of magnesium silicate is composed of free hydroxyl groups (silanol 
groups); the most reactive groups on the surface. They provide the sites for the 
physical adsorption of organic particles and can easily react, chemically, with 
multiple substituents. Being substituted with new atom groups, they provide potential 
for surface modification. The surface composition of magnesium silicate is illustrated 
in Figure 1.18. 
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Figure 1.18 Schematic of the functional groups on the surface of magnesium 
silicate [48]. 
The concentration of active acidic and basic sites of synthetic magnesium silicate 
(Magnesol XL) is an important physicochemical characteristic which determines its 
impact on adsorption performance. 
1.6.1.5 Specific surface area, pore volume, and pore size 
The specific surface area, pore volume, and pore size (ASAP 2010, Micromeritics 
Instruments, USA), of synthetic magnesium silicate resulting from the precipitation 
reaction of sodium metasilicate and a magnesium salt are dictated by the type of metal 
salt, the non-ionic surfactant introduced, and the type of silane pro-adhesive 
compounds used in the course of precipitation. Generally, the precipitated magnesium 
silicate manifests a relatively high BET specific surface area. The highest values of 
specific surface area occur with magnesium silicate produced from magnesium 
sulphate and magnesium nitrate (Table 1.24). The lowest value is obtained from 
magnesium chloride in the presence of Rokanol K3. The situation is analogous to 
when the surface is modified using a silane coupling agent. As is the case for non-
ionic surfactants, the presence of silane decreases the specific surface area. Pore 
volume and pore diameter are not affected by the presence of both reagents. The type 
and amount of silane exerts no significant effect on the specific surface area, pore 
volume or mean pore diameter of precipitated magnesium silicate (Table 1.25).  
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Table 1.24 Physicochemical properties of unmodified and modified magnesium silicates [49]. 
Precipit
ating 
agent 
Amount of non-ionic 
surfactant 
Modifying 
agent 
Amount of 
modifying 
agent 
(wt./wt.) 
Specific 
surface area 
BET 
(m2/g) 
Pore 
volume 
(cm3/g) 
Average 
pore 
diameter 
(nm) 
MgCl2 - - - 411 0.80 5.5 
5 wt/wt % of Rokanol K3 - - 197 0.67 6.3 
5 wt/wt % of Rokanol K7 - - 356 0.61 7.9 
Mg(NO3)2 - - - 474 0.83 5.5 
5 wt/wt % of Rokanol K3 - - 347 0.87 6.2 
5 wt/wt % of Rokanol K7 - - 470 0.98 7.3 
MgSO4 - - - 408 0.73 5.5 
5 wt/wt % of Rokanol K3 - - 433 0.85 5.6 
5 wt/wt% of Rokanol K7 - - 453 0.79 5.2 
MgSO4 - U-15 silane 3 401 0.68 5.2 
- 5 384 0.67 5.2 
- 10 332 0.63 5.2 
MgSO4 - U-15 silane 3 384 0.64 4.8 
5 wt/wt % of Rokanol K3 5 376 0.64 4.9 
5 wt/wt % of Rokanol K3 10 364 0.67 4.8 
Rokanol K3 and K7 are non-ionic surfactants (oxyethylenated unsaturated fatty alcohols, of the 
general formula RO(CH2CH2O)nH R=C16-22, where nav=3 or nav=7, respectively). U-15 is silane 
pro-adhesive compound (N-2-aminoethyl-3-aminopropyltrimethoxysilane). 
Table 1.25 Physicochemical properties of unmodified magnesium silicate and magnesium silicate 
modified with silane coupling agents [50]. 
Modifying agent 
Amount of 
modifying 
agent (w/w) 
Specific 
surface area 
BET (m2) 
Pore 
volume 
(cm3/g) 
Mean pore 
diameter 
(nm) 
-- - 515 0.80 5.3 
3-Isocynatepropyltrimethoxysilane 3 536 0.84 5.4 
 5 511 0.76 5.0 
 10 503 0.76 5.0 
3-Thiocyanatepropyltrimethoxysilane 3 506 0.79 5.2 
 5 539 0.83 5.4 
 10 528 0.81 5.4 
N-Phenyl-3-isocynatepropyltrimethoxysilane 3 519 0.85 5.6 
 5 496 0.80 5.6 
 10 486 0.77 3.4 
 
1.6.1.6 Particle morphology 
A scanning electron microscope (SEM) image of magnesium silicate prepared from 
solutions of magnesium sulphate and sodium meta-silicate is shown in Figure 1.19. 
The SEM image shows the presence of large primary agglomerates and numerous 
secondary agglomerates. In addition, numerous primary particles of small diameter 
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are observed. Primary particles exhibit a smooth surface and no sharp edges are 
observed. On the other hand, primary agglomerates of small diameter exhibit a 
tendency to acquire/exhibit spherical shapes. 
 
 
Figure 1.19 SEM photograph of magnesium silicate [51]. 
1.6.2 Preparation of Synthetic Calcium Silicate/ Synthetic Aluminium Sodium Silicate 
(Precipitation Method)  
Synthetic calcium silicates, aluminum silicates and magnesium silicates can be 
prepared from the reaction of the aqueous solution of sodium metasilicate with the 
corresponding water soluble metal salt (e.g., chloride, sulphate, etc.). This reaction 
produce varying contents of sodium oxide, aluminium oxide and silicon dioxide.The 
preparation procedure is shown in Figure 1.20. The content ranges of the oxides after 
ignition are described in Tables, 1.22 & 1.26. 
   Table 1.26 Composition of synthetic calcium silicate and synthetic aluminum sodium 
silicate [43, 52]. 
Parameter 
Wt % 
Aluminium sodium silicate  Calcium Silicate  
SiO2 42 ± 85 50 ± 95 
Na2O 0.2 ± 22 <4.0 
Al2O3 0.2 ± 36 -- 
CaO -- 1 ± 35 
Sulphates  < 1 n.a. 
Fe2O3 < 0.1 < 0.1 
Trace oxides < 0.1 < 0.1 
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Figure 1.20 Preparation procedures for synthetic amorphous metal silicates (wet method) [52]. 
Dilute aqueous solution of 
sodium metasilicate  
Dilute aqueous solution of 
calcium salt (chloride, 
sulphate, etc.) 
Dilute aqueous solution of 
aluminium salt (chloride, 
sulphate, etc.) 
 
Solutions mixed & react in 
stirred precipitation vessel 
Metal silicate precipitates out as 
a suspension 
Precipitate undergoes filtration 
via a filter press 
Filter cake is washed to remove 
co-product, e.g. sodium salt, 
whilst in the filter press 
Washed filtered cake is dried 
using hot air drier 
Dried material is passed through a 
suitable milling sieve  
Result is white, powdered metal 
silicate with controlled particle 
size  
Dilute aqueous solution of 
magnesium salt (chloride, 
sulphate, etc.) 
 
For Mg-Silicate For Ca-Silicate For Al-Silicate 
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1.6.3 Stability and Incompatibilities 
In general, metal silicates are classified as stable compounds (Table 1.27). 
Magnesium silicate exposed to temperatures of 750oC transforms from amorphous 
form to the magnesium silicate minerals enstatite (MgSiO3) and forsterite (Mg2SiO4). 
When the temperature reaches 1100oC and above, others polymorphs (protoenstatite 
and clinoenstatite) are formed. Magnesium silicate in its solid state should be stored in 
a well-closed container in a cool, dry place. When magnesium silicate is stored in 
double-distilled, deionised water for 6 months at 85oC, it maintains its amorphous 
structure with some improvement in the order and maintains its chemical entity. 
Magnesium silicate is readily decomposed by mineral acids. Magnesium silicate may 
decrease the oral bioavailability of drugs such as mebeverine hydrochloride, 
sucralfate, and tetracycline, via chelation or binding, when they are taken together. 
The dissolution rate of folic acid, erythromycin stearate, paracetamol, and chloroquine 
phosphate, may be retarded by adsorption onto magnesium silicate. Antimicrobial 
preservatives, such as parabens, may be inactivated by the addition of magnesium 
silicate 
1.6.4 Biodegradability and Toxicity 
Orally administered magnesium silicate is neutralized in the stomach to form 
magnesium chloride and silicon dioxide; some magnesium is absorbed. Caution 
should be used when greater than 50 meq of magnesium is given daily to patients with 
impaired renal function, owing to the risk of hypermagnesemia. Reported adverse 
effects include the formation of bladder and renal calculi following the regular use, 
for many years, of magnesium silicate as an antacid. It is not explosive, flammable, or 
combustible. It is a mild irritant to eyes, skin, and respiratory passages. It is not 
classified as dangerous under EU Directive 67/548/EEC. In the EEC, magnesium 
silicate is a permitted food additive according to directive 95/2/EC (E 553a). The 
essential physical and chemical properties in addition to toxicological profiles of 
magnesium silicate, calcium silicate, and aluminium sodium silicate are summarized 
in Table 1.27. 
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Table 1.27 Physicochemical properties and toxicological profile of magnesium silicate, calcium 
silicate, and aluminium sodium silicate [43, 52]. 
Test Synthetic magnesium silicate  
Synthetic aluminum 
sodium silicate  
Synthetic calcium 
silicate 
PHYSICO-CHEMICAL PROPERTIES 
CAS  Number 1343-88-0 1344-00-9 1344-95-2 
Chemical structure MgO.SiO2.nH2O 
Na2O.SiO2.nH2O/ 
Al2O3.SiO2.nH2O 
CaO.SiO2.nH2O 
Form  Solid powder 
Melting Point [°C]   Approx. 1910 (m) Approx. 1700 
Partition Coefficient  
(log Pow)  Not relevant (inorganic , non-lipophilic substance) 
Water Solubility 
(Saturation) [mg/l] (m)*  
  
Insoluble in cold and hot 
water  
Approx. 68 ± 79 at 20 °C, 
pH ~9 (Sum of soluble 
SiO2, Na and Al ions)   
Approx. 260  at 20 °C, 
pH ~9.7 (Sum of soluble 
SiO2, Na and Ca ions)   
pH (m)*  7± 10.8 5 ± 11 7 ± 11 
ENVIRONMENTAL FATE  and  PATHWAY 
Photo-degradation  Stable in water and air 
Stability in Water   Stable: ion exchange processes possible 
Stability in Soil  Stable: silicates = soil components; ion exchange processes possible 
Biodegradation  Not  applicable, inorganic substance 
Bioaccumulation  Not bio-accumulating due to inherent substance properties 
ECOTOXICOLOGY 
Acute/Prolonged 
Toxicity to Fish   Not a known pollutant 
96h LL0=10000 mg/l 
(limit test) No data: analogy  
Acute Toxicity to 
Aquatic Invertebrates  Not a known pollutant No data: analogy 
Toxicity to Aquatic 
Plants, e.g. Algae  Not a known pollutant 72h NOEL= 10000 mg/l  No data: analogy  
TOXICOLOGY 
Acute Oral Toxicity   On rabbit: LD50 >10000 
mg/kg LD50 >5000 mg/kg 
Acute Inhalation 
Toxicity   Slightly hazardous  No data: analogy 
Acute Dermal Toxicity   On albino rabbit: LD50 
>10000 mg/kg   
LD50 >5000 mg/kg  (limit 
test) 
No data: analogy  
Primary Irritation (skin, 
eye)  
On rabbit: primary 
irritation index 0.80, no 
erythema (skin redness) 
Not irritating No data: analogy  
Sensitization  No data 
Repeated Dose Toxicity 
(inhalation)  
Causes damage to lungs No data: analogy 
Repeated Dose Toxicity 
(oral)   
No substance-related 
abnormalities in rat: 
NOAEL(6 months) = 
~9000 mg/ kgbw  
 
Chronic: no data: analogy   
 no gross signs of toxicity 
in rat and mouse,  no 
death: NOAEL (14 d) 
>5000 mg/kgbw  
No gross signs of 
toxicity in rat, no death  
NOAEL (2 years)  = 
approx. 5000 mg/kgbw   
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Table 1.27 (continued) 
Test Synthetic magnesium 
silicate  
Synthetic aluminum 
sodium silicate  
Synthetic calcium 
silicate 
Genetic Toxicity in Vitro 
A.  Bacterial Test  (Gene mutation)  Not mutagenic No data: analogy Not mutagenic 
B.  
Non-Bacterial  In-
Vitro Test (Gene 
Mutation)  
Not mutagenic No data: analogy No data: analogy 
C.  
Non-Bacterial  In-
Vitro Test 
(Chromosomal 
Aberration)  
Not mutagenic No data: analogy Not mutagenic 
Genetic Toxicity in- 
Vivo  Not mutagenic No data: analogy Not mutagenic 
Carcinogenicity 
(inhalation)  Inconclusive No data 
Carcinogenicity (oral)  Not carcinogenic in rat 
and mouse No data: analogy Not carcinogenic in rat 
Carcinogenicity 
(intrapleural)  No data: analogy Not carcinogenic in rat No data: analogy 
Toxicity to Fertility  No effects in limited 
study in rat No data: analogy 
Developmental / 
Teratogenicity  
No adverse effects in rat, 
mouse, rabbit and hamster  
No adverse effects in rat, 
mouse, rabbit and hamster  
No adverse effects in rat, 
mouse, and hamster  
Photo-degradation Stable in water and air 
Stability in Water Stable: ion exchange processes possible 
Stability in Soil Stable: silicates = soil components; ion exchange processes possible 
Biodegradation  Not applicable, inorganic substance 
Bioaccumulation Not bio-accumulating due to inherent substance properties 
1.6.4 Applications 
Due to their inert nature and non-toxic properties, metal silicates are widely used in 
different applications including cosmetics, pharmaceuticals, foods, chromatography, 
rubber, paints, paper and plastic industries (Table 1.28). 
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Table 1.28 Applications of metal silicates in various industries [43, 52]. 
Industry Function 
Pharmaceutical Synthetic magnesium silicate is used in oral pharmaceutical formulations and food 
products as a glidant and an anti-caking agent while calcium silicate is widely use as filler 
and disintegration promoter in tablet formulation [53]. Other uses of metal silicates can be 
summarized as follows. 
x Magnesium silicate and aluminium silicate are used in anti-acid, anti-ulcer and anti-
obesity preparations.  
x Magnesium silicate is used as a component of anti-epileptic drugs, in the treatment 
of alimentary intoxication, indigestion and in the inflammatory conditions of the 
small intestine.  
x In topical preparations, magnesium silicate is used as anti-fungal agent. 
x Magnesium sodium silicates are used in cosmetics especially in toothpastes, gels, 
facial creams, body washes, cosmetic creams, sunscreens, shampoo, and blush. 
x Magnesium sodium silicate is also used in treatment of acne and function as facial 
moisturizer.  
x Arginine silicate (The reaction product of arginine and magnesium silicate) is highly 
soluble in water and can be used as source of the essential amino acid arginine and 
as a source of silicate, both of which exert anti-atherosclerotic effects and also 
promotes bone and cartilage formation in mammal. 
Food Metal silicates function as a carrier for fragrances or flavors. They are also used in beer and 
wine clarification. In animal feed, synthetic amorphous silica and silicates serve as carriers 
and anti-caking agents in vitamins and mineral premixes. Synthetic magnesium silicate and 
calcium silicate are used as bleaching agent in animal and vegetable oils production. It is 
also used in the production of confectionery as an anti-adhesive and anti-caking agent 
(molding powder or a component of anti-glitter paste). As far as whiteness is concerned, 
the white color of magnesium silicate may easily compete with titanate based pigments, 
which eliminates partially or totally the use of titanium dioxide. 
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Table 1.28 (continued) 
Industry Function 
Rubber and 
Silicones  
Magnesium silicate, calcium silicate and aluminum silicate are used as reinforcing fillers 
for many non-staining and colored rubber and silicones products. 
Paints Magnesium silicate and aluminum silicate can be used as filler and pigment in dispersive 
paints. 
Chromatography Magnesium silicate is used as an adsorbent in affinity chromatography. 
Paper Magnesium silicate and aluminium silicate are used as filler in paper manufacturing to 
improve printability and opacity that result in glossy paper used in most magazines. 
Insecticide, micro 
biocide & 
fungicide 
Magnesium silicate has been used against juvenile and adult store product pests, 
predominantly exerting their lethal activity on juvenile and adult forms by sorption of the 
cuticular lipid layer, thus causing dehydration of the insects. 
Cements Cement is made by forming a calcium silicate product from limestone and clay minerals 
in a kiln which requires very hot temperatures, releasing high levels of CO2 as it burns. 
Most low carbon cements on the market are based on magnesium silicate, which takes less 
energy to heat. 
Other uses x Sodium silicate together with magnesium silicate is used in muffler repair and fitting 
paste. When dissolved in water, both sodium silicate, and magnesium silicate form a 
thick paste that is easy to apply. When the exhaust system of an internal combustion 
engine heats up to its operating temperature, the heat drives out all of the excess water 
from the paste. The silicate compounds that are left over have glass like properties, 
making a temporary brittle repair. 
x Highly dispersed magnesium silicates can be used as polymer fillers or active 
adsorbents. 
x Magnesium silicate is an amphoteric compound with a huge specific area capable of 
absorbing either acid or alkali metal catalyst. It is an efficient refining and purifying 
agent in the production of polyols for its excellent depicking, deodorizing, potassium 
ion absorbing effects and function as filter medium. In addition it is used as an 
adsorbent to regenerate frying oils and purify biodiesel. 
x Magnesium silicate, aluminium silicate and calcium silicate are used as filler and 
pigment extender in fingernail lacquers and in plastic industries. 
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1.7 Sugar Alcohols 
Sugar alcohols are brittle materials having unique physicochemical properties. They 
are ideal candidates for the co-processing with chitin to produce an excipient with 
improved physical properties. Sugar alcohols are carbohydrates which are also called 
"polyols". Part of their chemical structure resembles sugar, and part of it resembles 
alcohol hence the name is sugar alcohol. Examples of common sugar alcohols are 
mannitol, maltitol, sorbitol, isomalt, and xylitol. They occur naturally in plants 
(sorbitol is extracted from corn syrup and mannitol from seaweed), but they are 
mostly manufactured from sugars and starches. Sugar alcohols are not completely 
absorbed by the body like sugars. Because of this, the blood sugar impact of sugar 
alcohols is less and they provide fewer calories per gram [54, 55].  
Table 1.29 Comparison of the properties of sugar and sugar alcohols. 
Ingredient Sweetness (relative to 
sucrose) % 
Glycemic 
Index (GI) 
Cal/g Derived from 
Sucrose (sugar) 100 60 4 Plant sources (sugar 
beets, sugar cane,..) 
Hydrogenated Starch 
Hydrolysate 
33 39 2.8 Partial hydrolysis of 
starch 
Maltitol 75 36 2.7 High maltose corn syrup 
Xylitol 100 13 2.5 D-xylose 
Isomalt 55 9 2.1 Sucrose 
Sorbitol 60 9 2.5 Glucose 
Lactitol 35 6 2 Lactose 
Mannitol 60 0 1.5 Fructose 
Erythritol 70 0 0.2 Glucose 
Additionally, sugar alcohols don't induce tooth decay as sugars do, so are often used 
to sweeten chewing gum. Sugar alcohols have fewer calories than sugar, and most of 
them are less sweet than sugar except for xylitol which have the same sweetening 
factor [54]. The glycemic index is an indicator of how a food is likely to affect blood 
sugar (Table 1.29). 
1.7.1 Mannitol: sugar alcohol with added functionality 
Mannitol is a naturally occurring six-carbon sugar alcohol or polyol (Figure 1.21) 
[56]. It is the most abundant polyol in nature occurring in bacteria, yeasts, fungi, 
algae, lichens and several plants like pumpkins, celery, onions, grasses, olives and 
mistletoe. Mannitol (C6H14O6) is widely used in pharmaceutical formulations and food 
products [57]. In pharmaceutical preparations it is primarily used as a diluent in tablet 
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formulations, where it is water soluble, non-hygroscopic (Can be used with moisture-
sensitive active ingredients) and produces a sweet, smooth, cool taste and it can be 
advantageously combined with other direct compression excipients. 
 
 
Figure 1.21 Chemical structure of mannitol [56]. 
 
In ODT formulation, the direct compression grade of mannitol is prefered to obtain a 
fast disintegrating hard tablets withstand processing and transportation. Specially 
treated directly compressible, spray-dried, or granulated mannitol excipients have 
been designed to meet these needs. Figure 1.22, shows the scanning electron 
microscopic images of granular, powder and spray dried mannitol.  
Processing of treated mannitol (Figures 1.22.a and 1.22c) produced under defined 
manufacturing conditions give them a highly porous and friable external particle 
structure. Upon compression, the particles break into finer particles, which fill the 
interstitial spaces between larger porous particles which give harder ODTs using 
direct compression at low pressure.  
 
Figure 1.22 SEM images of a) granular mannitol, b) mannitol powder and c) spray-
dried mannitol [56]. 
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Untreated crystalline mannitol has some limitations including the poor aqueous 
solubility, bad flowability and the high friability of tablets obtained. Figure 1.23, 
shows the water solubility of mannitol in comparison with other excipients. 
 
 
Figure 1.23 The aqueous solubility of mannitol versus other excipients [58]. 
Figures 1.24, 1.25 and 1.26 show the physical properties of different types and grades 
of mannitol. 
 
Figure 1.24 Tablet compression profiles of different grades of mannitol [58]. 
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Figure 1.25 Friability versus compression profile for different grades of mannitol [58]. 
 
Figure 1.26 Moisture sorption profiles of different sugar alcohols at 20qC [58]. 
One major limitation of most currently marketed ODTs is their requirement for 
special and expensive packaging to protect them during transportation and handling. 
Furthermore, the consumer must follow specific instructions to remove fragile tablets 
from specialized blister packs to ensure added protection and to retain the quick 
dispersibility of the tablets even after exposure to unfavorable humidity and 
temperature conditions. These challenges could be addressed by [58]: 
x Using binders with the mannitol powder may increase the disintegration time of 
the ODT and accordingly disintegrant(s) should be added to reduce the 
disintegration time.  
x Co-processing of mannitol with other excipients or material is a way to create 
an excipient that exhibits a flowability and compressibility. Additionaly, the 
slow disintegration properties of mannitol can be significantly improved by 
the right selection of the co-processing candidate.   
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1.7.1.1 Toxicology 
Mannitol is GRAS listed material. The use of mannitol in food is permitted by FDA 
food additive regulations (21 CFR 180.25). The Joint Food and Agriculture 
Organization/World Health Organization Expert Committee on Food Additives 
(JECFA) has reviewed the safety data and concluded the safety of mannitol. JECFA 
has allocated an acceptable dietary intake of 0-50mg/kg. Mannitol has monographs in 
the United States Pharmacopoeia/National Formulary (USP/NF), as well as the 
various pharmacopoeias around the world. In addition, mannitol is included in the 
Food Chemical Codex (FCC) [56, 59]. 
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1.8 Project: Hypothesis, Aims and Work Plan  
1.8.1 Hypothesis 
In powder form, chitin is a highly compressible material due to the presence of pores 
on the surface and it is a well known disintegrant for tablet formulation [42]. 
However, chitin is not compactible.  It would be beneficial, therefore, to form 
inclusion complexes of guest material inside the chitin pores to improve its 
compactibility without affecting its disintegration properties.  
1.8.2 Aims 
Improvements in the compaction properties of chitin by co-processing with a guest 
material could be verified as follows: 
- co-processing of chitin with metal silicates, by incorporating the metal silicate inside 
the chitin pores, could produce a multi-functional super-disintegrant (excipient that 
can achieve fast disintegration while preserving the binding properties of the tablets).  
- by examining the effect of lubricant on powder compaction of co-processed       
chitin-metal silicate excipients.   
- co-processing of chitin with mannitol (as an example of a compound representing a 
non-hygroscopic inert excipient) could result in a universal multi-functional excipient 
that could be used with metal-incompatible active pharmaceutical ingredients. 
1.8.3 Work Plan 
(I) To study the physicochemical properties, performance and applications of the co-
precipitates of chitin and metal silicates prepared according to European patent 
(EP1997480) invented by the Jordanian Pharmaceutical Manufacturing CoLtd 
(Chapters 2&3). This work covers the following aspects. 
x Preparation of a solid in solid dispersion of metal silicate within the chitin 
pores. The procedure followed was that in European Patent (EP1997480), by 
dispersing the chitin polymer and an appropriate quantity of monovalent 
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silicate in sufficient quantity of water or a mixture of water and solvent(s). 
Precipitation of the mineral silicate within the structure of the polymer can be 
achieved by the addition of a divalent or trivalent chloride solution to form a 
solid in solid dispersion of mineral silicate within the chitin high surface 
pores. The divalent or trivalent chloride solution can be magnesium chloride, 
calcium chloride, aluminum chloride, etc.  
x Preparation of different grades of the silicate-chitin material (different salts) 
with respect to the particle size and physical properties. In addition to study 
the effect of these properties on the performance of this material. 
x Characterization and identification of the obtained chitin silicates (different 
salts) using different analytical techniques such as scanning electron 
microscopy, x-ray powder diffraction, powder flow analysis, FTIR 
spectroscopy, NMR, etc. 
x Investigate the prepared co-precipitated excipient properties including the 
compactibility, flowability and density.  
x Testing the physical properties of the tablet formulations containing the co-
precipitated excipient such as compressibility, granules flowability and 
disintegration properties will be evaluated in comparison with reference 
formulations containing commercially available super-disintegrants such as 
sodium starch glycolate, pregelatinized starch, PVP-XL and croscarmelose 
sodium. 
x Designing tablet formulations containing the co-precipitated chitin-metal 
silicate excipient using different techniques including, direct compression, wet 
and dry granulation. The co-processed excipient functionality, compatibility 
with APIs and compression profiles of the tablets produced will be evaluated.  
x Determination of the recommended working range(s) of the silicate-chitin 
material, which can be used in solid state pharmaceutical formulations in order 
to attain the optimal function as a super-disintegrant and pharmaceutical aid in 
tablet formulation. 
x Investigate the effect of lubricant on the overall physical properties of the        
co-precipitated chitin-metal silicate excipient. 
CHAPTER ONE  INTRODUCTION  
 
 68  N.H.M.Daraghmeh±PhD Thesis 
  
(II) To study the physicochemical properties, performance and applications of the co-
processed excipients consisting of chitin and mannitol prepared according to the 
European patent (EP2384742) invented by the Jordanian Pharmaceutical 
Manufacturing CoLtd (Chapters 3 & 4) This work covers the following aspects. 
x Preparation of a co-processed excipient consisting of chitin and mannitol by 
following the procedure as in the European Patent (EP2384742). Two types of 
excipients were prepared according the formentioned patent including: i) a 
multifunctional immediate release tablet base (Chapter 4) and ii) an ODT 
multifunctional base (works as disintegrant, binder, filler) (Chapter 5). 
x Optimizing the ratio of chitin and mannitol within the co-processed excipient 
and selecting the proper processing technique to be used. 
x Characterization and identification of the prepared co-processed excipients 
using different analytical techniques such as scanning electron microscopy, x-
ray powder diffraction, powder flow analysis, FTIR spectroscopy, NMR, etc..   
x Characterization of the obtained excipients regarding the physical properties 
including flowability, compressibility, functionality, disintegration and 
wetting properties. 
x Evaluation of the tablets prepared from the co-processed chitin-mannitol 
excipients. 
x Studying the applications of the obtained co-processed excipients in tablet 
formulation containing different APIs.     
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2. CHARACTERIZATION OF CHITIN±METAL SILICATES AS 
BINDING SUPER-DISINTEGRANTS 
2.1 Introduction 
There is increasing interest in exploring new commercial uses for chitin, a polymer 
which is normally regarded merely as a waste product from, for example, the sea food 
industries. This is due to the fact that, next to cellulose, chitin is the most abundant 
polysaccharide on earth [1]. In relation to the pharmaceutical industry; chitin has been 
reported to play different roles in tablet formulations, for example, as an excipient for 
direct compression and as a disintegrant [2, 3]. However, for many pharmaceutical 
formulations there is a need to improve compression properties in order to make them 
acceptable to the formulator [4, 5]. Recently, chitin was modified by precipitation of 
silicon dioxide on its surface [6]. The foregoing concept was based upon the high 
water absorption capacity and surface modification properties of silicon dioxide when 
co-processed with polymers [7, 8]. Co-precipitation of silicon dioxide onto chitosan 
or chitin particles resulted in high mechanical strength of compacts with super-
disintegration properties [6]. When modified in this manner, tablet disintegration was 
characterized by superior water uptake and penetration, with no gelling hindrance 
effects; this makes silicon dioxide different from other known super-disintegrants. 
However, there are disadvantages associated with silicon dioxide polymer 
preparations. For example, co-precipitation of colloidal silicon dioxide onto chitin or 
chitosan particles involves the use of large volumes of concentrated hydrochloric acid 
and sodium hydroxide solutions not to mention high temperature [6, 9]. This imposes 
a high cost burden during industrial processing. Furthermore, the disintegration 
properties of chitin±silica powder are strongly dependent on its compactability. 
Finally, the chitin±silica particles are highly hygroscopic at humidity conditions above 
70% RH. Such drawbacks necessitated an exploration of the use of an alternative 
industrial processing strategy. We hypothesized that metal silicates could represent a 
suitable alternative to silicon dioxide. In fact, metal silicates have been tested as 
disintegration promoters (Rxcipients FM 10001 application bulletin). Specifically, the 
use of amorphous synthetic calcium silicate (Rxcipients FM10001) has been 
advocated; one reason for FDOFLXPVLOLFDWH¶VSRWHQWLDODVDIDVWGLVLQWHJUDQW may be its 
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highly porous nature. It has been found that the combined use of calcium silicate, in 
concentrations up to 30% (w/w), with super-disintegrants, provides acceptable tablet 
hardness whilst concomitantly allowing rapid tablet disintegration; in less than 30 s in 
the mouth [10]. The combined use of chitin and metal silicate could fulfill the dual 
role of superdisintegrant and filler in pharmaceutical formulations. However, it is well 
documented that commercially available super-disintegrants lose their function as 
disintegrants when their concentration exceeds certain limits (3±15%, w/w) [9]. 
Therefore, their use as fillers or binders in solid dosage form formulations  could be 
deleterious. Chitin exhibits super-disintegration properties that depend, mainly, upon 
a high water uptake rate, [3] so it can be presented over a higher concentration range 
compared to other commercial super-disintegrants without affecting the disintegration 
properties [6, 9]. However, chitin shows poor powder compressibility [11]. 
Ultimately, the combination of one of the most abundant naturally occurring polymers 
with metal silicates could represent a practical and invaluable choice of an industrial 
excipient in terms of disintegration and compaction properties. In this regard, if co-
precipitation is the desired methodology to ensure an effective distribution of silicon 
dioxide onto chitin particles, then replacing silicon dioxide with an insoluble metal 
silicate should be considered. Indeed poor (aqueous) solubility is a useful property for 
a disintegrant and it just so happens that this is a general characteristic of most metal 
silicates, except for sodium silicate [12, 13]. Therefore, it was hypothesized that by 
carrying out a simple chemical displacement reaction, that is, by adding a soluble salt 
of the appropriate metal to a sodium silicate solution in which chitin particles are 
suspended, an insoluble metal silicate could be produced. Thus, chitin particles could 
provide the surface on which metal silicate precipitation takes place. The work 
reported herein aims to test such an assumption as well as to characterize the resulting 
co-precipitates produced using different metal silicates and its utilization as a super-
disintegrant and a single component additive in immediate release tablets. 
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2.2 Experimental 
2.2.1. Materials 
Chitin (200 mm, JBICHEM, Shanghai, China), Avicel® 200 (FMC BioPolymer, 
Philadelphia, PA), Na2SiO3.5H2O (BDH, Poole, England), AlCl3.6H2O (MERCK 
KGaA, Darmstadt, Germany), MgCl2.6H2O (SIGMA Chemical Co, St. Louis, MO), 
CaCl2.2H2O (ACROS Organics, Geel, Belgium), paracetamol (Sri Krishna 
Pharmaceutical Ltd, Hyderabad, India), metformin HCl (Hercules Plaza, Wilmington, 
DE), mefenamic acid (Shinpoong Pharma, Seoul, Korea), PonstanTM Forte 500 mg 
tablets (Chemidex Pharma Ltd, Surrey, UK). All reagents used were of analytical 
grade. 
2.2.2 Methods 
2.2.2.1. Preparation of Metal silicate-Chitin powder 
Into three separate solutions, each containing 10.0 g of sodium silicate dissolved in 
400 mL of deionized water, 7.5, 10, and 11.5 g of chitin were suspended under 
stirring conditions. Respectively, 6.0 g of aluminium chloride, 9.6 g of magnesium 
chloride, 6.9 g of calcium chloride were added to stochiometrically react with sodium 
silicate to produce suspended particles of the insoluble metal silicate that co 
precipitated onto chitin. The particles were filtered out using 20-25 Pm filter papers 
(ALBET 135, Quantitative, Barcelona, Spain) then washed with deionized water until 
the filtrate conductivity, measured using a conductivity meter (METTLER TOLEDO 
MPC227, Greifensee, Switzerland), was less than 20 PS. The product was dried in the 
oven at 90ºC for 3 hours, and finally passed over a mesh of 425µm size and kept for 
further testing and characterizations of the obtained material. The final Al, Mg, and 
Ca silicate mass content was fixed at 32% (wt/wt). 
2.2.2.2  FT-IR Spectroscopy 
Infrared spectroscopy was used to follow the molecular interaction between chitin and 
the metal silicates. For Fourier transform infrared spectroscopy (Perkin±Elmer, 
Buckinghamshine, UK), Al silicate, Mg silicate, Ca silicate, their corresponding       
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co-precipitates with chitin particles, a physical mixture of chitin and magnesium 
silicate, with a Mg silicate content of 32% (w/w), and chitin were all separately mixed 
with dried KBr (1%, w/w). Then a small portion of the mixture was compressed in a 
15 mm dye at 1 × 105 kPa to yield a transparent disk. The disk was mounted in the 
instrument beam for spectroscopic examination. 
2.2.2.3. X-ray diffraction 
The XRPD patterns of Al, Mg, and Ca silicates, their corresponding chitin particle co-
precipitates chitin, a physical mixture of chitin and magnesium silicate at a Mg 
silicate content of 32% (w/w), and chitin, were all investigated using an X-ray 
diffractometer (Philips PW 1729 X-Ray Generator; Philips, Eindhoven, the 
Netherlands). XRPD spectra were acquired on a Scintag Pad V X-ray Powder 
Diffractometer using CuKĮ radiation on a T ± 2T goniometer equipped with a 
germanium solid-state detector, using acquisition conditions of 35 kV and 30 mA. 
Scans were typically obtained from 10 to 70 2T, with step size or integration range of 
0.05T, and a count time of 5 s. 
2.2.2.4. Scanning electron microscopy 
Chitin and chitin±Mg silicate samples were mounted on aluminum stubs and then 
coated with gold by sputtering at 1200 V, 20 mA for 105 s using a vacuum coater. A 
FEI Quanta 200 3D SEM (FEI, Eindhoven, The Netherlands) instrument was used. 
2.2.2.5  Water penetration rate 
Chitin-Mg silicate and Avicel® 200 were separately poured into graduated cylinders. 
In order to visualize and measure the water penetration into the samples, 50 mL of 
0.1% (wt/vol) of sunset yellow solutions were prepared and added on top of each of 
the chitin-Mg silicate and Avicel® 200 samples. The penetration rate was calculated 
by measuring the speed of water in mL/min penetrating the samples column. This 
method was validated upon changing the dye concentration (0.1-1%), dye solutions 
added volume (10-100 mL) and the samples volume (50-200 mL). This test was 
performed at the following powder parWLFOHVL]HRIȝPIRUFKLWLQ-
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Mg silicate and Avicel® 200. In order to obtain different particle size of Avicel® 200 
(particle size was 180 ȝP and chitin-Mg silicate (particle size of 425 ȝP), initially 
each powder was compressed into 12 mm circular tablets and then the tablets were 
crushed in a dry granulator (Erweka TG IIS) coupled to a Erweka AR 400 
multipurpose motor (Erweka GmbH, Heusenstamm, Germany) to obtain granules 
with a particle size < 2.00 mm. Finally, the slugs were ground manually, using a 
pestle, over separate sieves of mesh particle size ȝP. 
2.2.2.6  Chitin-Mg silicate hygroscopicity 
Different samples of chitin±Mg silicate (initial weight of 2.0 g) were stored in 
desiccators containing saturated salt solutions at room temperature for a week. The 
media compositions were set according to the Handbook of Chemistry and Physics 
[14]. Samples were stored in desiccators under equilibrium conditions for one week. 
The percentage gain in weight compared to the original weight was measured for each 
humidity setting. 
2.2.2.7  Water infiltration rate 
Infiltration of water into the chitin, chitin-Mg silicate, Mg silicate, and Avicel® 200 
powders at tap density was performed in capillary rise experiments [15]. Each powder 
was poured into a glass tube supported by a clamp attached on top of a beaker 
containing a reservoir of water. The water was once more dyed with sunset yellow 
solution to visualize the ascending water from bottom to top of the tube. A glass wool 
was placed at the bottom of the tube to allow water to pass while supporting the 
powder. The tube was lowered in the beaker up to the point that the fluid level 
reached the top of the glass wool. Time zero was chosen when the liquid first meets 
the powder. The infiltration rate was calculated by measuring the speed of ascending 
water in mL/min penetrating the samples column from bottom to top. 
2.2.2.8. Particle size influence on disintegration and hardness measurements of 
chitin-Mg silicate 
Chitin-Mg silicate granules were initially produced by co precipitation and then 
ground manually (using a pestle) over separate sieves, after drying, of mesh particle 
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VL]H  ȝP  ȝP DQG  ȝP (DFK RI WKH WKUHH SRZGHU VDPSOHV RI VSHFLILF
particle size was subjected to compression using a single punch tableting machine 
(Manesty, Merseyside, UK) at the compression forces 30, 35, 40, 45, and 50 KN, in 
which a 12 mm circular punch was fitted, producing tablets of 400 mg weight. Tablet 
hardness and disintegration time were examined for all tablets produced at each 
compression force. Tablet hardness was measured using a hardness tester (Copley, 
Nottm Ltd, Therwil, Switzerland), whereas disintegration time was measured using a 
disintegration tester (Caleva, Dorset, UK). The average hardness and disintegration 
readings of 10 tablets were considered for each particle size at the specific 
compression force. 
2.2.2.9  Mass content influence of metal silicates on tablet hardness and 
disintegration time 
For chitin-Al silicate samples preparation: 7.5, 11.2, 15, 22.6, and 30.1 g of chitin 
were respectively suspended in five separate solutions, each containing 10 g of 
sodium silicate dissolved in 400 mL of deionized water. 6 g of aluminum chloride 
were added to each of the chitin suspensions to ensure complete precipitation of Al 
silicate. The method was repeated using same concentration of sodium silicate 
separate solutions containing 10, 15, 20, 30, and 40 g of chitin for chitin-Mg silicate 
and 11.5, 17.2, 23, 34.6 g of chitin for chitin- Ca silicate preparations. 9.6 g of 
magnesium chloride and 6.9 g of calcium chloride were respectively added to each of 
the chitin suspensions. All the resulted chitin-metal silicate suspensions were filtered 
out, washed with deionized water, dried in the oven at 90ºC for 3 hours, and finally 
passed over a mesh of 425µm size. All the samples produced were compressed using 
the single punch tabletting machine in which a 12 mm circular punch was fitted, 
producing tablets of 400 mg weight. Tablet hardness and disintegration time were 
measured for each tablet. An average of 10 tablets was considered for each test. The 
percentage content of metal silicate for the prepared samples was calculated as 
follows: 32, 23.9, 19.0, 13.5, 10.5 % (wt/wt). 
2.2.2.10. Characterization of the compression process of chitin±metal silicate 
Chitin, chitin-Al silicate, chitin-Mg silicate (at the Mg silicate contents of 13, 19, 24, 
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32 % (wt/wt) in the chitin-Mg silicate compacts) and chitin-Ca silicate were 
separately compressed by direct compressing using the universal testing machine 
(UTM, RKM 50, PR-F system, ABS Instruments Pvt., Ltd., Leipzig, Germany). This 
was achieved without lubrication of the upper and lower punches as well as the die. 
The punch speed was fixed at 10 mm/min. Different compression forces from 80 to 
390 MPa were applied. Three tablets were prepared to ensure reproducibility. The 
tablets were flat, round of 12 mm diameter and 400 mg weight.  
The compression behavior of the samples was evaluated using the Kawakita analysis 
of powder compression data. The Kawakita equation (Equation 1) is used to study 
powder compression using the degree of volume reduction, C. The basis for the 
Kawakita equation for powder compression is that particles subjected to a 
compressive load in a confined space are viewed as a system in equilibrium at all 
stages of compression, so that the product of the pressure term and the volume term is 
a constant [16]:  
C = [V0 ± V/V0]  =  [abP/1 +  bP]      (1) 
Where, C is degree of volume reduction, V0 is the initial volume, V is the volume of 
powder column under the applied pressure P. The constant, a LV WKH PDWHULDO¶V
minimum porosity before compression while the constant b UHODWHV WR WKHPDWHULDO¶V
plasticity. The reciprocal of b defines the pressure required to reduce the powder bed 
by 50% [17, 18].  The equation above can be re arranged in linear form as: 
P/C = P/a +  1/ab        (2) 
The expression of particle rearrangement could be affected simultaneously by the two 
Kawakita parameters a and b. The combination of these into a single value, i.e. the 
product of the Kawakita parameters a and b, may hence be used as an indicator of the 
expression of particle rearrangement during compression [19]. 
2.2.2.11. Formulations using chitin-Mg silicates 
The composition and the type of formulation process (direct compression and wet 
granulation) of formulas containing paracetamol, metformin HCl, and mefenamic acid 
are listed in Table 2.1. Formulas F1, F3, F4, F6, and F7 were formed by direct 
FRPSUHVVLRQZKHUHE\WKHOXEULFDQWZDVLQLWLDOO\SDVVHGWKURXJKDȝPVLHYHDOO
the other components were mixed using an Erweka mixer (Erweka AR 400, 
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Heusenstamm, Germany), then passed through a 0.8 mm sieve and finally the 
lubricant was added to the mixture. For the case of wet granulation, purified water 
was used as the granulating fluid of formulations F2 and F5 using a graduated 
measuring cylinder. The wetted granules were passed through a 2.5 mm sieve. The 
granules were dried in a hot-air oven at 40 °C for 1 hour. The dried granules were 
passed through a 0.8 mm sieve. Finally, the lubricant (magnesium stearate) was added 
to the mixture. All formulas were compressed using a single punch tabletting machine 
(Manesty F3 single stroke tablet press, West Pharmaservices Ltd, Dorset, UK) in 
which a 13 mm shallow concave punch was fitted. Compression was carried out using 
a load of 40 KN.  
Table 2.1 Composition of paracetamol, metformin HCl, and mefenamic acid tablets 
formulations. 
Formula 
No. Drug 
Manufacturing 
Process 
Active 
Ingredient 
(mg) 
Chitin-
Mg 
Silicate 
Quantity 
(mg) 
Calcium 
Silicate 
Quantity 
(mg) 
Magnesium 
Stearate 
Quantity (mg) 
1 Paracetamol Direct 
Compression 
500 385 -- 2 
2 Paracetamol Wet Granulation 500 385 -- 2 
3 Paracetamol Direct 
Compression 
500 -- 358 2 
4 Metformin HCl Direct 
Compression 
500 375 -- 5 
5 Metformin HCl Wet Granulation 500 375 -- 5 
6 Metformin HCl Direct 
Compression 
500 -- 375 5 
7 Mefenamic Acid Direct 
Compression 
500 470 -- 3 
8 Ponstan Forte 
500 mg 
-- 500 -- -- -- 
For hardness and disintegration testing, an average of 20 tablets from each formula 
was considered using the hardness and disintegration testers respectively. For drug 
dissolution, an average of 8 tablets was considered using the USP specifications of the 
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dissolution media and apparatus for each drug [20]. PonstanTM Forte 500 mg tablets 
were used for comparison purposes with formula F7 of mefenamic acid with respect 
to hardness, disintegration and dissolution in its designated USP media 
2.3 Results and Discussion 
Metal ions react with silicate ions and form insoluble metal silicates [21]. 
Accordingly, co-precipitation of Al, Mg and Ca silicate followed the following 
reactions: 
2AlCl3 + 3Na2SiO3                                           Al2(SiO3)3    +     6NaCl 
MgCl2 + Na2SiO3                                              MgSiO3        +     2NaCl 
CaCl2 + Na2SiO3                                               CaSiO3         +     2NaCl 
Consequently, the soluble sodium silicates changed to larger molecules of metal 
silicates that precipitated onto chitin. The pH of the compacts (5% (w/v) aqueous 
dispersion)  resulting from the co- precipitation of Ca, Mg, and Al silicates onto chitin 
particles was measured as 10.5, 8.5, and 6.0 respectively. All these metal silicates are 
composed of silicon dioxide (Ksp of 10-3 in water) linked randomly to the metal oxide 
which has a degree of solubility that depends on the type of metal. In water, these 
metal oxides are characterized by the solubility product constant Ksp of metal 
hydroxide which has the values of 5.0x10-6, 6.0x10-12, and 3.0x10-34 for Ca, Mg, and 
Al hydroxides respectively. The Ksp for the Al(OH)3 is the lowest of all, thus the 
acidic nature of Al silicate is mainly attributed to the silicon dioxide which is very 
slightly soluble in water and acidic in nature. Alternatively, Ca and Mg silicates 
basicity is mainly attributed to the metal Ca and Mg oxides present [22, 23]. The 
nature of chitin-metal silicate association resulting from the co-precipitation process 
was investigated using FTIR and x-ray diffraction analysis. 
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Figure 2.1 FTIR of Al, Mg, Ca silicates prepared by precipitation of the metal 
silicates through replacement reaction of sodium meta-silicate with 
the metal chlorides. 
Infrared spectra of the prepared precipitates of Al silicate, Mg silicate, and Ca silicate 
are shown in Figure 3.1. All these metal silicates showed common IR features with 
respect to the absorption band at 1039 cm-1 which is due to a Si-O-Si symmetrical 
stretching vibration. In addition, the Si-O bending vibration of the metal silicate can 
be observed at 432 cm-1 in the spectrum. The other bands in the spectrum around 654 
cm-1 and 3450 cm-1 are probably associated with various metal-O modes and water 
molecules, respectively [24]. However, Ca silicate had two distinctive bands in the 
1400-1480 cm-1 region that can be assigned to the O-H bending mode [25] .These two 
bands were not present in the Al and Mg silicates. In general, the cation 
electropositivity and ionic radius play important roles in the stretching and bending 
modes, respectively [26]. On the other hand, chitin (Figure 2A) showed split 
absorption bands at 1660 and 1620 cm-1 corresponding to the amide I region (C=O 
stretching ) and an absorption band at 1560 cm-1 corresponding to the amide II region 
(N-H bending vibrations) [27]. 
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Figure 2.2 FTIR of chitin, chitin-metal (Al, Mg, Ca) silicate co-precipitates, and 
chitin-Mg silicate physical mixture. 
All these bands were identical in both chitin and chitin-metal silicate co-precipitates 
on the one hand (Figures 2.2B, C, & D for chitin-Al, Mg, and Ca co precipitates 
respectively), and chitin-Mg silicate physical mixture (taken as an example of a 
chitin-metal silicate) on the other (Figure 2.2E). This suggests no chemical reactivity 
is present between chitin and all the tested metal silicates when the later underwent   
co-precipitation. The difference between the co-precipitate (Figures 2.2B, C, & D) 
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and the physical mixture (Figure 2.2E) could be clearly demonstrated by the 
sharpness of the peaks of the physical mixture and the broadness of the peaks of the 
co-precipitate. It seems that this difference is related to the precipitation of Mg silicate 
onto the chitin surface. The silanol groups, which are known to have a hydrogen 
bonding potential with some substances, [28] present on the surface of Mg silicate 
could attribute to the broadening of IR peaks of both chitin and Mg silicate for the co 
precipitate. Generally, the impact of hydrogen bonding is to produce significant band 
broadening and to lower the mean absorption frequency [29]. The investigated chitin-
metal silicates co precipitates and their physical mixtures were tested using x-ray 
diffraction in order to evaluate the role of co precipitation on crystallinity. The x-ray 
diffraction patterns of synthetic Al, Mg, and Ca silicates produced by the reaction of 
sodium silicate with their corresponding metal salts are presented in Figure 2.3. In 
JHQHUDO WKH WHUP µVLOLFDWH¶ UHIHUV WR FU\VWDOOLQH PDWHULDOV ZLWK NQRZQ FRPSRVLWLRQ
However, Al and Mg silicates clearly showed amorphic characters with broad peaks 
all over the diffraction pattern range. A fairly more ordered pattern was noticed for Ca 
silicate, which showed a distinctive broad peak at 30º ș This suggests that Ca 
silicate could have a little more than a two-dimensional short-range order [30]. Such 
crystallographic diversities of metal silicates could be attributed to the fact that 
different alkaline cations favor different structures. More specifically, the crystalline 
lattice structure of different metal silicates is dependent upon the type, size and atomic 
weight of the metal cation which defines the orientation of the metal-O-Si domains 
[31]. Hence, the resulted amorphous patterns of the tested metal silicates could be a 
result of the predominance of metal-O-Si bonds, rather than phase separated metal 
oxide/SiO2 mixtures [32]. 
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Figure 2.3 X-ray powder diffraction results for Al, Mg, Ca-silicate precipitates. 
This difference was crucial for the proper choice of amorphous metal silicates instead 
of the natural crystalline silicates with regard to the mechanical strength of the 
complex compacts. In this perspective, naturally occurring metal silicates, specifically 
phyllosilicates, are generally brittle and of weak binding capacity. Alternatively, they 
would represent improper candidates when used as pharmaceutical fillers in solid 
dosage forms. Such weakness could be theoretically attributed to the crystalline lattice 
structure of metal silicates as they are composed of stacks of individual silicate layers 
held together by weak van der Waals forces resulting in gap spacing between the 
layers [33, 34]. On the other hand, chitin (Figure 2.4) displayed six broad peaks at 
9.4q, 12.9q, 19.3q, 23.5q, 26.9q and 39.8q, which are likely caused by polycrystalline 
domains or disturbed crystal structure [35]. Such domains originate from the anti-
parallel arrangement of chitin molecules in the D form which is stabilized by a high 
number of hydrogen bonds formed within and between the molecules [36] 
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Figure 2.4 X-ray powder diffraction spectra for chitin-metal (Al, Mg, Ca) silicate  
co-precipitates, chitin Mg silicate physical mixture, and chitin. 
 
Co-precipitation of the metal silicates onto the chitin particles did not alter the 
position of the amorphous domains of both chitin and metal silicates, as shown in 
Figure 2.4. However, there was a decrease in the peak intensities of chitin in all the 
chitin-metal silicates diffraction patterns when compared to that of chitin. This could 
be attributed to dilution effect caused by the content of metal silicates in the complex. 
Similarly, the x-ray diffraction patterns of chitin and magnesium silicate (taken as an 
example for demonstration) physical mixtures prepared using a magnesium silicate 
content of 32% (wt/wt) showed no alteration in the amorphous domain positions. In 
addition, there were no noticeable differences with regard to the x-ray diffraction 
patterns between the co precipitate and the physical mixtures in the case of chitin-Mg 
silicate. This further demonstrates the physical association between chitin and metal 
silicates.
CHAPTER TWO   
 
 88  N.H.M.Daraghmeh±PhD Thesis 
  
The chitin±metal co-precipitate was screened, after drying and sieving the powder, by 
SEM and compared with the original chitin powder, as shown in Figure 2.5. Chitin, 
Figure 2.5.A, had changed its native structure from thin smooth, flat surface structure, 
with folded edges, to three-dimensional compacts with the metal silicate co 
precipitate, Figure 2.5.B for chitin-Mg silicate. Figure 2.5.C shows a larger view of 
chitin-Mg silicate indicating the presence of inter-particulate voids and channels. 
 
 
(A) 
 
(B) 
 
(C) 
Figure 2.5 SEM of chitin (A), chitin-Mg silicate co-precipitate (B) and (C). 
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The disintegration mechanism of chitin-metal silicates was investigated by examining 
the water uptake driving force of the powder. This was achieved by performing water 
penetration rate and water infiltration experiments for chitin-Mg silicate as a 
demonstrating example of chitin-metal silicate co precipitate. 
Water penetration rate of chitin-Mg silicate at different particle size was carried out 
and compared with Avicel® 200 at the same particle size (Figure 2.6). The choice of 
using Avicel® 200 was based upon its free allowance to water passage without any 
hindrance caused by gelling. Water penetration rate increased from 20 to 30 mL/min 
with decreasing the particle size from 1400 Pm to 125 Pm of chitin-Mg silicate, 
whereas the water penetration rate of Avicel® 200 increased from 7 mL/min to  
18 mL/min with increasing the particle size from 125 Pm to 1400 Pm. Generally, 
increasing a powder particle size allows larger voids between particles, thus higher 
penetration rates as in the case of Avicel® 200. This case was the opposite for chitin-
Mg silicate. It seems that the voids between the particles have a little significance to 
increase the passage of water amongst them. In spite of its high water penetration rate, 
Figure 2.6 demonstrates that chitin-Mg silicate was found to be slightly hygroscopic. 
Polymers with a higher moisture uptake capacity will be expected to be more prone to 
accelerate tablet disintegration.  
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Figure 2.6 Water penetration rate of chitin-Mg silicate and Avicel® 200 as a
function of particle size (primary axis). Hygroscopicity of chitin-Mg 
silicate co-precipitate performed using standard salt solutions of different
humidity conditions stored inside desiccators at room temperature for 1
week (secondary axis). Error bars presented as ± RSD. 
 
The hygroscopicity measured for chitin-Mg silicate (Figure 2.6) clearly indicated that 
chitin-Mg silicate only gained maximum moisture content up to 9.4% of its initial 
weight at the 98% humidity condition. Water infiltration through capillary rise 
experiment gave a clearer explanation to such behaviour when chitin-Mg silicate, 
chitin, Mg silicate, and Avicel® 200 were allowed to come in contact with water from 
the bottom side across a glass wool pledget. Capillary action seemed to have a major 
contribution to the water uptake of chitin-Mg silicate (a measured rate of 0.145 
mL/min) and almost similar to chitin (a measured rate of 0.15 mL/min). This indicates 
that the capillary action is mainly contributed to chitin as the rate was measured to be 
0.015 mL/min for Mg silicate. Avicel® 200, which showed a significant water 
penetration (Figure 2.6), had no significant capillary action which was almost similar 
to Mg silicate. This may suggest that decreasing the particle size of chitin-Mg silicate 
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(Figure 2.6) may have increased the water uptake through capillary action. As the 
particle size was decreased more intra particulate voids may have come into contact 
with each other giving rise to more capillary channels (see Figure 2.5.C for 
illustration) for water to penetrate. 
This investigation was further illustrated when studying tablets hardness versus 
compression force for varying powder particle sizes; 125 Pm, 425 Pm, 1400 Pm 
(Figure 2.7). Generally, a reduction in particle size is associated with an increase in 
tablet mechanical strength. This increase is attributed to an increase in the surface area 
available for inter-particulate attractions, as the particles become smaller [37]. 
However, when chitin-Mg silicate was used, it was found that varying the particle size 
had no effect in increasing the mechanical strength of the tablets produced. Generally, 
for materials with a fragmentation tendency, such as dibasic calcium phosphate 
dihydrate and saccharose, the mechanical strength of the tablet seems to be almost 
independent on particle size [38]. This could be the case for the chitin-metal silicate 
particles which undergo fragmentation, as will be illustrated later, at early 
compression stages which normally lead to a limited effect on tablet tensile strength 
when varying the particle size.  
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Figure 2.7 Hardness and disintegration time as a function of compression force 
for different particle size of chitin-Mg silicate co-precipitate. Tablets 
were 12 mm in diameter and 400 mg weight. 
With respect to tablets disintegration, chitin-Mg silicate, as shown in Figure 2.7, 
showed a unique and distinctive characteristic whereby disintegration was 
independent upon particle size and tablet hardness. Chitin-Mg silicate tablets, 
produced from initial powder particle sizes of 125 Pm, 425 Pm, and 1400 Pm at 
compression forces between 30-50 KN for each particle size, showed a superior 
disintegration time, i.e. no longer than 5 seconds. This was achieved for tablet 
hardness values ranging from 40-220 N. Once more, this may suggest that capillary 
action was the dominant mechanism for disintegration irrespective of tablets tensile 
strength. Therefore, the inter-particulate voids, as previously mentioned, would have 
remained intact and unchanged through varying the powder particle size and the 
compression force.  
3URFHVVLQJ FKLWLQ ZLWK PHWDO VLOLFDWHV ZDV IRXQG WR FDXVH DOWHUDWLRQV WR FKLWLQ¶V
powder compressibility and compactability. Regarding powder compactability, metal 
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silicates within the chitin-metal silicate complex have demonstrated an effective mean 
to establish hard tablets while maintaining super-disintegration power, as could be 
deduced from Figure 2.7. In the absence of metal silicates, chitin showed a maximum 
tablet hardness of 73 N at a compression force of 50 KN. Increasing the content of 
metal silicates resulted in an increase in tablet hardness (at the same compression 
force) which followed the pattern shown in Figure 2.8 for Al, Mg, and Ca silicate-
chitin compacts. All types of chitin-metal silicates tablets showed a sharp increase in 
the compaction properties (tablets hardness >140 N) while maintaining a low 
disintegration time (<10 seconds) when the metal silicate content was increased up to 
30% (wt/wt). Above this value, the increase in tablet hardness values became slower 
whereas disintegration time increased sharply to values greater than 7 minutes for all 
the chitin-metal silicates compacts. Pure metal silicates (100% metal silicate content 
in Figure 2.8) showed good compaction properties but disintegration was slow (about 
10 minutes for all chitin-metal silicates). This behaviour could, in a way, justify the 
hypothesis that the optimum metal silicate content in chitin-metal silicates should not 
exceed 30% (wt/wt) in order to maintain good compaction and super disintegration 
characteristics. Figure 2.8 further indicates that the tensile strength of chitin-metal 
silicates compacts was dependant upon the type of metal cation. The increasing 
hardness of compacts was as follows: chitin-Al silicate > chitin-Mg silicate > chitin-
Ca silicate. 
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Figure 2.8 Hardness and disintegration time as a function of chitin-metal (Al, 
Mg, and Ca) silicate content. Tablets were 12 mm in diameter and   
400 mg weight. 
The trend of increase in compacts mechanical strength is mainly attributed to the 
compacts porosity. Generally, tablets of low porosity will have a high mechanical 
strength [39]. The incorporation of metal silicates onto the chitin particles through the 
co precipitation process has established some modifications to the physical properties 
of the chitin powder. This will be clearly demonstrated by powder compressibility 
analysis of various chitin-metal silicates. Early investigation of the Heckel plots 
indicated non-log-linearity of compression data. Therefore, Heckel analysis was not 
adopted in this work as it may result in misinterpretation to the estimated intercept 
and slope parameters. Therefore, the Kawakita analysis was adopted instead in order 
to linearize the compression data.  
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Figures 2.9 and 2.10 show representative Kawakita plots for chitin-Mg silicate at 
different concentrations of Mg silicate and for the three investigated types of metal 
silicates in the chitin-metal silicates powders.  
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Figure 2.9 Kawakita plots for different concentrations of Mg silicate in the 
chitin-Mg silicate co precipitate. Tablets were 12 mm in diameter and 
400 mg weight. 
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Figure 2.10 Kawakita plots for chitin-metal (Al, Mg, Ca) silicate co precipitates. 
Tablets were 12 mm in diameter and 400 mg in weight. 
From the the data in the plots, the Kawakita constants a and 1/b are listed in Table 
2.2. In terms of a constant, chitin showed the highest compressibility (highest a 
value). Increasing the Mg silicate content from 13% to 32% (%wt/wt) lowered the a 
value and therefore compressibility was decreased. In terms of metal type, chitin-Al 
silicate had the highest compressibility followed by chitin-Mg silicate which in turn 
was higher than chitin-Ca silicate.  
Values of 1/b, which are an inverse measure of the amount of plastic deformation 
occurring during the compression process increased with increasing the Mg silicate 
content. This implies that increasing the Mg silicate content exhibited a lower degree 
of total plastic deformation during the compression process. Hence, it would appear 
that chitin exhibited a faster onset of plastic deformation during compression. On the 
other hand, chitin-Al silicate had a higher degree of plastic deformation than chitin-
Mg silicate whereas chitin-Ca silicate showed the lowest degree.  The product ab, 
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which is a measure of the extent of particle rearrangement, is shown in Table 2.2.  
Table 2.2 Kawakita parameters for different concentrations of Mg silicate 
precipitates in the chitin-Mg silicate co precipitate and for chitin-metal 
(Al, Mg, Ca) silicate co precipitates. 
Material 
Metal silicate 
(% wt/wt) 
Kawakita Parameters 
a 1/b ab 
Chitin 0 0.82 10.60 0.077 
Chitin-Mg silicate 13 0.80 11.86 0.067 
Chitin-Mg silicate 19 0.77 14.00 0.055 
Chitin-Mg silicate 24 0.76 15.68 0.048 
Chitin-Mg silicate 32 0.75 17.37 0.043 
Chitin-Al silicate 32 0.78 14.82 0.052 
Chitin-Ca silicate 32 0.70 23.89 0.029 
It appears that the degree of particle rearrangement of chitin decreased with increasing 
the Mg silicate content. This may imply that the metal silicate precipitated onto the 
chitin particles may have reduced the surface micro-irregularities of chitin and 
facilitated particle rearrangement during the densification phase of compaction. On 
the other hand, chitin-Ca silicate showed the lowest degree of rearrangement (Table 
2.2). It appears that chitin-Ca silicate had the highest degree of packing. Such a trend 
could be correlated to the fact that chitin-Ca silicate had the highest true density 
(1.766) of all the examined chitin-metal silicates. 
Finally, the good compaction characteristics provided by chitin-metal silicates was 
tested for their binding capabilities, disintegration time, and drug dissolution over 
poorly compressible drugs such as paracetamol and metformin HCl as examples of 
hydrophilic drugs and mefenamic acid as an example of a hydrophobic drug. Direct 
compression and wet granulation processing formulations were tested for the 
hydrophilic drugs. In addition, the performance of formulas containing paracetamol 
and metformin HCl drugs directly compressed with Ca silicate was tested (see Table 
2.1). Results are summarized in Table 2.3. 
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Table 2.3 Hardness, disintegration, and dissolution results for the paracetamol, metformin 
HCl, and mefenamic acid tablets formulations. 
Formula * Hardness (N) Disintegration Time (Sec) Dissolution (% Drug Release at times 10, 20 min) 
F1 103 44 91, 100 
F2 118 48 86, 100 
F3 144 261 67, 86 
F4 98 41 94, 100 
F5 112 50 90, 100 
F6 159 336 75, 96 
F7 126 84 60, 90 
F8 131 300 42, 71 
* See Table 2.1. 
The dilution capacities (percentage of incompressible material) of paracetamol and 
metformin HCl were 58.1% (wt/wt) and 56.8% (wt/wt), respectively, for direct 
compression and wet granulation formulas containing chitin-Mg silicate as the 
investigated binder. Hardness values for F1, F2, F4, and F5 (see Table 2.4) indicated 
high binding capabilities with less than a minute of disintegration time for all the 
formulas. Full drug release (% assay measured) was attained at the 20 minute 
dissolution of both drug formulas. When Ca silicate was included in the paracetamol 
and metformin HCl formulas (same drug dilution capacities as F1 and F4) as a filler 
in direct compression mode (see F3 and F6 in Table 2.4), tablets displayed higher 
hardness values with much higher disintegration time. This may indicate that metal 
silicates functionality as disintegration promoters necessitated the presence of other 
superdisintegrants (chitin in this case) to enhance tablet disintegration.  
The performance of chitin-metal silicates was evaluated in formulations with 
mefenamic acid as a model hydrophobic drug. Mefenamic acid was reported to be 
soluble in alkali hydroxides [40]. Direct compression of mefenamic acid with chitin-
Mg silicate at the dilution capacity of 51.7% (wt/wt) resulted in hard tablets and 90% 
drug release within 20 minutes of dissolution. In comparison with PonstanTM Forte 
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500 mg, as the commercial drug reference, percentage drug release at the 20 minutes 
dissolution was much lower (71%). Therefore, the use of chitin-Mg silicate of alkaline 
nature (pH 8.5 for 5% w/v aqueous dispersion) could improve the solubility of 
mefenamic acid while maintaining intact physical properties of the tablets produced. 
For example, disintegration time of the mefenamic acid formula, F7, was even lower 
than PonstanTM Forte (F8) in which it was reported to compose of lactose, maize 
starch, sodium lauryl sulphate, and pregelatinized starch as fillers, binders, and 
disintegrants in addition to croscarmellose as the superdisintegrant [41]. Formula F7 
was composed of one excipient, in addition to mefenamic acid and the lubricant, 
which enhanced better binding, disintegration, and dissolution properties to the tablets 
produced  
2.4 Conclusions  
Co-precipitation of a metal silicate on chitin particles offers industrial potential for 
use as a single filler which has binding as well as super-disintegration properties and 
can be used in directly compressed tablets or in wet granulation methodologies. The 
co-precipitation process causes physical adsorption of the metal silicates onto chitin 
particles as illustrated by the SEM data without any chemical interaction as evidenced 
by the IR and XRPD analysis. The good disintegration property of the highly non-
hygroscopic product is most likely to be related to capillary action. Disintegration and 
binding properties were found to be independent of particle size and compression 
force applied. The final pH of the complex, the mechanical strength of the tablets 
produced, and the powder compressibility and plasticity were all found to be 
dependent on the identity of the metal silicate. Pharmaceutical applications using 
formulations containing paracetamol, metformin HCl, and mefenamic acid indicated 
the good binding and disintegration abilities of chitin±metal silicates with poorly 
compressible and/or non-polar drugs. 
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3. CHARACTERIZATION OF THE IMPACT OF MAGNESIUM 
STEARATE LUBRICATION ON THE TABLETING PROPERTIES OF 
CHITIN-MG SILICATE AS A SUPERDISINTEGRATING BINDER WHEN 
COMPARED TO AVICEL 200 
3.1 Introduction 
Solid dosage forms, e.g. tablets and capsules, are the most popular and preferred drug 
delivery systems. Tablet dosage forms are mainly composed of the API/APIs (active 
pharmaceutical ingredient) and excipients [1]. Excipients include diluents, binders, 
disintegrants, glidants and lubricants; the latter i.e. lubricants are usually added in the 
final stages of mixing of the formulation components prior to compression. The main 
function of lubricants is to prevent adhesion of compacts to the surface of the punches 
and dies, used in pharmaceutical manufacture, thus facilitating their ejection from the 
die cavity [2]. Furthermore, the presence of lubricants in formulated powder mixtures 
reduces inter-particulate friction leading to improved flow properties [3]. Such effects 
are mainly attributed to the ability of lubricants to be distributed as a surface film on 
the base/carrier material [2]. Magnesium stearate (MgSt) is the most widely used 
lubricant in pharmaceutical formulations [4]; the amount used is assessed during the 
early stages of pharmaceutical formulation development, and does not usually exceed 
2% of the total powder weight used in tablet manufacturing [5]. In the case of MgSt 
the surface area per unit mass of powder mixture can be as high as 20% (w/w), 
depending on the other ingredients present in the pharmaceutical formulation [6]. In 
spite of the importance of lubricants in solid dosage forms, problems can occur when 
lubricants are added to excipient/API mixtures. The compaction and/or disintegration 
time of binders, fillers, and disintegrants has been reported to be negatively affected  
by the presence of lubricants [7]. The possible deleterious effects of MgSt have been 
attributed to the formation of a hydrophobic lubricant film on the surface of 
formulation component particles resulting, effectively, in a physical barrier [8]. 
Hence, the binding properties of the particles are altered and the wettability of the 
tablet ingredient particles will be negatively affected. This can result in retardation of 
water penetration into tablets and thereby cause delayed dissolution of the API, as the 
pore surfaces in the tablets become more hydrophobic [9, 10]. A decrease in crushing 
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strength is manifested in compacts made from microcrystalline cellulose (Avicel® 
200) when concentrations of MgSt exceeding 2% (w/w) are used [11]. In addition, the 
physico-chemical effects of MgSt are dependent on the mixing time of the lubricant 
with the formulation components due to the redistribution of the lubricant on the 
mixture of particles [10]. Use of pregelatinized starch (Starch® 1500), calcium 
sulphate dihydrate, and amylase resulted in a large decrease in crushing strength, 
accompanied by an increase in mixing time with the lubricant [12]. The extent of 
lubricant sensitivity is dependent on a large number of factors, such as the nature and 
physico-chemical properties of the lubricant and other tablet ingredients. Therefore, in 
order to limit lubricant sensitivity, these factors must be considered in determining the 
optimal level of lubricant(s) in a formulation. In this regard, minimal effect of 
lubricant on powder compaction was reported for dicalcium phosphate dihydrate 
particles due to the very irregular surface of the excipient preventing the formation of 
a continuous film on blending with MgSt [13]. Moreover, low lubricant sensitivity is 
displayed by materials (for example brittle materials such as dicalcium phosphate 
GLK\GUDWH DQG ȕ-lactose) which undergo high levels of fragmentation upon powder 
compression [14]. In addition, the presence of other formulation components can 
influence the film formation properties of lubricants and thereby minimize the 
deleterious effects of the lubricant. For example, mixing of excipient particles with 
MgSt and colloidal silica (Aerosil 200) can significantly suppress the negative effect 
of the lubricant on the interaction between lubricated particles [15]. 
Processing of chitin with silica products offers significant advantages for the 
exploitation of multifunctional excipients in the pharmaceutical industry. For 
example, chitin-metal silicate co-precipitates have, recently, been reported to be 
useful excipients, with appropriate binding and disintegration characteristics, when 
compared to conventional super-disintegrants and fillers [16, 17, 18]. However, the 
impact of chitin-metal silicate lubrication with MgSt has not been reported, especially 
in cases where MgSt causes undesirable changes in tablet properties (as described 
above). In the current investigation, the compaction and disintegration properties of 
chitin-metal silicates at different concentrations of MgSt are reported. Comparison 
with lubricated and unlubricated microcrystalline cellulose and its co-precipitated 
form with magnesium silicate are also examined. In addition, the effect of MgSt on 
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the ejection force of chitin-Mg silicate and on the dissolution profiles of ibuprofen 
and gemfibrozil (as model drugs exhibiting poor compactability/water solubility) 
formulated with chitin-Mg silicate are evaluated. 
3.2 Experimental 
3.2.1 Materials 
Chitin (measured 50th percentile diameter d(0.5) = 216 µm, JBICHEM, Shanghai, 
China), Avicel® 200 (measured d(0.5) = 201 µm, FMC BioPolymer, Philadelphia, 
PA, USA), calcium hydrogen orthophosphate CaHPO4 (CHO) (measured d(0.5) = 203 
µm after being passed through a 250 µm mesh sieve and collected on a 200 µm mesh 
sieve, BDH Laboratory Supplies, Poole, UK), Na2SiO3.5H2O (BDH, Poole, UK), 
MgCl2.6H2O (SIGMA Chemical Co, St. Louis, MO, USA), MgSt (d(0.5) = 3.1 µm, 
Mallinckrodt Corporation, Raleigh, NC, USA), ibuprofen powder (d(0.5) = 82.5 µm, 
Sigma, St. Louis, MO, USA), gemfibrozil powder (of a wide particle size distribution 
from 40 to 300 µm with a d(0.5) = 110 µm,  Zhejiang Excel Pharmaceutical Co., Ltd., 
Zhejiang, China), and Lopid 600 mg gemfibrozil tablets (batch number: 0212027, 
expiry date: 01/2010, manufactured by Goedecke AG, Freiburg, Germany under 
license from Parke-Davis, Pontypool, Gwent, U.K) were used. All reagents used were 
of analytical grade. 
3.2.2. Methods 
3.2.2.1  Preparation of chitin-magnesium silicate and Avicel-magnesium silicate 
powders 
Into a solution containing 10.0 g of Na2SiO3.5H2O (dissolved in 400 mL of deionized 
water), 10 g of chitin or Avicel® 200 were suspended under stirred conditions. 9.6 g 
of MgCl2.6H2O was added to stoichiometrically react with sodium silicate to produce 
suspended particles of the magnesium silicate, which co-precipitated onto chitin or 
Avicel® 200. The particles were filtered using 20-25 Pm filter papers (ALBET 135, 
Quantitative, Barcelona, Spain) then washed with deionized water until the filtrate 
conductivity, measured using a conductivity meter (METTLER TOLEDO MPC227, 
Greifensee, Switzerland), was less than 20 PS. The product was dried in an oven at 
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90ºC for 3 h, passed through a 250 µm mesh sieve, collected on a 200 µm mesh sieve  
and kept for further testing and characterization. If it is assumed that 1 mol of 
Na2SiO3.5H2O reacts, stoichiometrically, with 1 mol of MgCl2.6H2O to produce          
1 mol of MgSiO3, the final magnesium silicate mass content is calculated to be 32% 
(w/w). 
3.2.2.2. Tablet compression, crushing strength and disintegration testing 
100.0 g of six powder blends of chitin-Mg silicate or Avicel® 200 or CaHPO4 or 
Avicel-Mg silicate physically mixed with MgSt at concentrations of 0.25, 0.5, 1.0, 2, 
5, and 10% (w/w) were prepared. Mixing was performed manually in a 2L Mini-blend 
v-blender (GlobePharma, New Brunswick, NJ, USA). The v-blender was operated at 
30 rpm for a period of 5 min. Each of the powder samples was subjected to 
compression using a single 12 mm circular punch tableting machine (Manesty, 
Merseyside, UK) at compression pressures of 156, 182, 208, 234 MPa. Tablet weight 
was fixed at 400 mg. The crushing strength of the compacts was used to study the 
compactibility of the manufactured tablets. By measuring crushing strength, it is 
possible to compare results obtained for tablets formulated with different 
ingredients/compositions or under different compaction pressures. Crushing strength 
was calculated using the measured maximum force, F (N), which was applied 
diametrically to fracture the tablet, using a hardness tester (Copley, Nottm Ltd, 
7KHUZLO6ZLW]HUODQG7KHFUXVKLQJ VWUHQJWKıZDV FDOFXODWHd using the following 
equation [19]: 
ı 
dL
F
S
2
          (1) 
where d (m) is the tablet diameter and L is the tablet thickness (m). The average 
crushing strength of 10 tablets was recorded for each sample. Using the tablet 
hardness measurement equipment, tablets were subjected to a diametrical 
compression test after they had been allowed to remain at room temperature for 24 h 
in a desiccator. Disintegration times were measured for chitin-Mg silicate, Avicel® 
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200, and Avicel-Mg silicate tablets produced using a disintegration tester (Caleva, 
Dorset, UK) in accordance with the USP 31 disintegration procedures for uncoated 
tablets. Comparison of disintegration times between different materials was carried 
out for tablets (12 mm diameter) compressed to reach a fixed crushing strength value 
of 0.6 MPa (equivalent to the maximum crushing strength for Avicel® 200 at 10% 
(w/w) MgSt concentration). 
3.2.2.3. Compression data acquisition and analysis 
Unlubricated and lubricated chitin-Mg silicate and Avicel® 200 samples, at MgSt 
concentrations of 1 and 5% (w/w) for the lubricated samples, were separately 
compressed by direct compression using a universal testing machine (UTM, RKM 50, 
PR-F system, ABS Instruments Pvt., Ltd., Leipzig, Germany). The punch speed was 
fixed at 10 mm/min. Different compression pressures from 10 to 70 MPa were 
applied. Three tablets were prepared to ensure reproducibility. The tablets were flat, 
12 mm in diameter and 400 mg in weight. Bulk density was determined using a 
weighed 100 mL cylinder and a volumeter (Erweka GmbH, Heusenstamm, Germany). 
20 g of the powder was gently filled into the cylinder. Bulk volume was read and bulk 
density calculated, as the average of five measurements. 
The powder compression behaviour of the samples was evaluated using Kawakita 
analysis which was performed on three preparations of chitin-Mg silicate powder and 
on three Avicel® 200 samples. All the tested samples were unlubricated and lubricated 
(1 and 5% w/w) with MgSt. The Kawakita equation describes powder compression 
using the degree of volume reduction, C [20]: 
C = 
bP
abP
V
VV
 »¼
º«¬
ª 
10
0
 
(2) 
Vo is initial volume and V is the volume of the powder column under an applied 
pressure, P. The constant a is the minimum porosity of the material before 
compression while the constant b relates to the plasticity of the material. The 
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reciprocal of b defines the pressure required to reduce the powder bed volume by 50% 
[21, 22]. Equation (2) can be rearranged in linear form as: 
aba
P
C
P 1  (3) 
Particle rearrangement can be affected simultaneously by the two Kawakita 
parameters a and b. The combination of these into a single value, i.e. the product of 
the Kawakita parameters a and b, may be used as an indicator of particle 
rearrangement, and hence the powder packing density during compression. The 
average P/C values and their relative standard deviation at compression pressures 
between 10-70 MPa of the three tested un-lubricated and lubricated preparations and 
samples were ascertained. 
3.2.2.4. Particles sized distribution analysis 
The particle size distribution of chitin, chitin-Mg silicate, Avicel® 200, and Avicel-
Mg silicate at MgSt concentrations of 0, 0.5, 1, and 5% (w/w), in the powder phase, 
was measured (Malvern Mastersizer 2000; Malvern, Worcestershire, UK), using dry 
powder, in the 0.02 µm to 2000 µm range. The instrument is equipped with a Scirocco 
2000 unit as the dry powder feeder, with compressed air to transport the particles. The 
optimum air pressure was set at 0.1 bar, which ensured no breakup of agglomerates; 
the foregoing was verified by repeating the measurement five times for the same 
sample collected at the end of each run. Moreover, reproducibility was tested for three 
powder samples of chitin and Avicel 200 and for different preparations of chitin-Mg 
silicate and Avicel-Mg silicate. Three diameter values were used to characterize the 
particle population: d (0.1) 10th, d (0.5) 50th, and d (0.9) 90th percentile diameter, 
respectively. The average of fifteen particle size distribution measurements for each 
powder and the percentage relative standard deviation for the d (0.9) were recorded. 
3.2.2.5. Specific surface area 
A gas sorption analyzer (Nova 2000, Quantachrome Co., Syosset, NY, USA) capable 
of measuring surface areas from 0.01 to more than 2,000 m2/g was employed to obtain 
nitrogen vapor adsorption isotherms at 77 K. Chitin, chitin-Mg silicate, Avicel® 200, 
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and Avicel-Mg silicate samples were heated to 60°C while being purged under a 
stream of pure nitrogen. Purging was continued for 24 h prior to analysis and the 
experiments were undertaken in duplicate. 
3.2.2.6. Scanning electron microscopy 
Chitin-Mg silicate and Avicel
®
 200 samples at MgSt concentrations of 0 and 5% 
(w/w) were mounted on aluminum stubs and then coated with gold by sputtering at  
1200 V and 20 mA for 105 sec using a vacuum coater. Samples were examined using 
a FEI Quanta 200 3D SEM (FEI, Eindhoven, Netherlands) 
3.2.2.7. Compression of chitin-Mg silicate using a high speed tablet press  
The procedure used to prepare chitin-Mg silicate in section 2.2 was scaled up using 
Na2SiO3.5H2O (2.5 kg), deionized water (100 L), chitin (2.5 kg), and MgCl2.6H2O 
(2.4 kg). Stirring was carried out using a vertical mixer (Wuxi Mingzhou 
Environment Protection Machinery & Equip Factory, Jiangsu, China) in a 100 L 
stainless steel container  The magnesium silicate suspension was filtered out using a 
filter fabric (Varun Tex, Inc., Madhya Pradesh, India) fitted on top of a 100 L empty 
container. Washing, drying, and sieving of the filter cake was carried out as described 
in section 2.2. The preparation was repeated until 10 kg of chitin-Mg silicate were 
produced. A 5 kg batch of the prepared chitin-Mg silicate was compressed using a 
Fette P2100 rotary tablet press (Fette, Schwarzenbek, Germany) into which 43 
circular punches (12 mm) were fitted. Compression was carried out without MgSt at 
press speeds of 30,000, 50,000, 100,000, and 150,000 tablets / hr. A compression trial 
with MgSt was carried out at a press speed of 150,000 tablets / hr. The ejection force 
displayed on the instrument panel was recorded. Stickiness was visually observed on 
the upper and lower punches. 60 tablets were randomly taken out, weighed, tested 
using disintegration (10 tablets) and tensile strength (10 tablets) testers, and visually 
observed for the appearance of any surface cracking
. 
3.2.2.8. Dissolution testing of ibuprofen and gemfibrozil tablets 
The effect of MgSt on the dissolution profile of ibuprofen tablets composed of  
400 mg ibuprofen and 300 mg of either of the following excipients: chitin-Mg silicate, 
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Avicel® 200, and Avicel-Mg silicate was examined. The excipients were either 
lubricated with 1 or 5% (w/w) MgSt, or unlubricated. Excipients were physically 
mixed with ibuprofen and directly compressed into 13 mm circular tablets (700 mg 
tablet mass) using a single punch tableting machine at a compression pressure of  
182 MPa. Five tablets were used for each dissolution profile test. The dissolution 
media was composed of phosphate buffer (pH 7.2). USP Apparatus II was used at a 
paddle rotary speed of 50 rpm. For dissolution studies of gemfibrozil, the tablets were 
composed of 600 mg gemfibrozil directly mixed with 224.5 mg of chitin-Mg silicate 
and 25.5 mg of MgSt (3% w/w) followed by direct compression into 13 mm circular 
tablets (850 mg tablet weight) using a single punch tableting machine at a 
compression pressure of 182 MPa. Five tablets were used for each dissolution profile 
test. The dissolution media was composed of a phosphate buffer (pH 7.5). USP 
Apparatus II was used at a paddle rotary speed of 50 rpm. 
3.3 Results and Discussion 
3.3.1. Effect of magnesium stearate concentration on the crushing strength of 
chitin and Avicel co-processed with magnesium silicate   
The effects of the lubricant MgSt on powder compression for chitin-Mg silicate, 
Avicel® 200, calcium hydrogen orthophosphate and Avicel-Mg silicate are shown in 
Figure 3.1. The data show a general trend of decrease in tablet crushing strength as 
the amount of MgSt added to powder blends increases. However for blends composed 
of chitin-Mg silicate there is no significant change in crushing strength for MgSt 
compositions up to 2% (w/w). We therefore see no evidence for a decrease in tablet 
crushing strength when the MgSt concentration is increased up to 2% (w/w) for the 
chitin-Mg silicate and MgSt blends (Figure 3.1). This contradicts the general notion 
that tablet crushing strength decreases with increase in the MgSt concentration. For 
example, it has been reported that for a cyclodextrin/calcium silicate/MgSt tablet 
formulation, as the concentration of MgSt is increased above 1.5% (w/w), the 
crushing strength of an optimized fast disintegrating tablet formulation decreases [23]. 
In addition to the concentrations of MgSt normally used, Figure 3.1 includes two 
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extreme concentrations, i.e. 5 and 10% (w/w) of MgSt. The aforementioned 
concentrations of MgSt were included for the purpose of determining the extent of 
any deleterious effect of MgSt on the compaction of chitin-Mg silicate powder. It is 
clear, from the data in Figure 3.1 that the crushing strength of the compacts made of 
chitin-Mg silicate decreases to almost half of the values recorded for the compacts 
containing 0-2% (w/w) MgSt. Nevertheless, the addition of MgSt, up to 5 or 10% 
(w/w), to chitin-Mg silicate powder still results in hard tablets with crushing strength 
values reaching 2.0 MPa at a compression pressure of 234 MPa. Hence, chitin-Mg 
silicate is able to accommodate up to 10% (w/w) of MgSt and still maintain intact 
solid tablets. 
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Figure 3.1 Effect of MgSt concentration on tablet crushing strength of chitin-Mg silicate, Avicel ®200, calcium hydrogen orthophosphate, and 
Avicel-Mg silicate co-precipitates at different compression pressures. Tablets, 12 mm in diameter and weighing 400 mg each were used. A, B, 
C, and D represent compression pressures of 156, 182, 208, 234 MPa, respectively. 
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The importance of this finding is clearly demonstrated when MgSt is added to separate 
powders of Avicel® 200 and CaHPO4. The data in Figure 3.1 illustrate the fact that when 
MgSt is added to microcrystalline cellulose or CaHPO4, the resultant tablet crushing 
strength decreases. For example, in the case of MgSt concentrations of 0.25, 0.5, 1.0 and 
5% (w/w), there was a 6, 48, 63, and 86% decrease, respectively, in tablet crushing 
strength of Avicel® 200 compacts at a compression pressure of 182 MPa. However, the 
percentage decrease in tablet crushing strength for lubricated CaHPO4 was 31, 29, 22, 
and 16% for the 0.25, 0.5, 1.0 and 5% (w/w) MgSt concentrations, respectively, at a 
compression pressure of 182 MPa. It is generally accepted that MgSt has a more negative 
effect on the crushing strength of tablets constituted of deformable materials (e.g. Avicel® 
200) than brittle ones (e.g. CaHPO4). Brittle materials are more likely to fracture and 
fragment during compaction. As more fresh surfaces, not covered by lubricant particles, 
are generated, they tend to bond together. Film formation on deformable particles, on the 
other hand, weakens the bonding of the granules as there are less fresh surfaces formed 
during compaction [14]. Therefore, the sensitivity of CaHPO4 to MgSt was less when 
compared to Avicel® 200; especially at MgSt concentrations greater than 0.5% (w/w). 
However, it is noted that the percentage decrease in tablet crushing strength for lubricated 
CaHPO4 undergoes a significant decrease with increasing MgSt content. This behavior is 
suggested to be a typical example of the combination of brittle (e.g. CaHPO4) and plastic 
(e.g. MgSt) materials which plays a significant role in altering the physico-mechanical 
characteristics of a material [24, 25]. Optimum tableting performance is generally 
achieved by using such a combination which produces a synergistic effect; thus 
improving functionalities such as compaction performance, flow properties, lubricant 
sensitivity etc. Therefore, the small increase in tensile strength (detected mostly at the 
10% (w/w) MgSt concentration for all working pressures in the data shown in Figure 3.1 
and in particular for the mixtures compressed at 234 MPa) encountered with CaHPO4 as 
the mass of MgSt was increased is, presumably, a result of a combination of CaHPO4 as a 
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brittle material, with magnesium stearate as a plastic material.  
In performing the same powder compaction tests for lubricated Avicel® 200 on which 
magnesium silicate was co-precipitated, powder sensitivity appeared to be insignificant. 
This was evident from the lower decrease in tablet crushing strengths, up to MgSt 
concentrations of 2% (w/w), when compared to Avicel® 200. Moreover, the data in 
Figure 3.1 illustrates the finding that lubricated Avicel-Mg silicate maintains highly 
compactable tablets at MgSt concentrations of 2 and 5% (w/w). Hence, the low lubricant 
sensitivity of chitin-Mg silicate is likely to be due to the presence of Mg silicate co-
precipitated on chitin particles. Arguably, this behavior resembles the improved lubricant 
sensitivity of coprocessed silicified microcrystalline cellulose (Prosolv®). Prosolv® is 
microcrystalline cellulose containing 2% (w/w) colloidal silicon dioxide. Tablets 
prepared with Prosolv have been reported to maintain crushing strength profiles when 
MgSt (0.5% w/w) was added [26].  
3.3.2. Effect of magnesium stearate concentration on the disintegration time of chitin 
and Avicel co-processed with magnesium silicate  
Comparison of the influence of composition on disintegration time between chitin-Mg 
silicate, Avicel® 200, and Avicel-Mg silicate at the 0, 0.25, 0.5, 1.0, 2, 5, and 10 % (w/w) 
MgSt (Figure 3.2) is only possible for tablets with the same crushing strength (in MPa). 
Since the maximum possible crushing strength attained for lubricated Avicel® 200 was 
recorded as 0.6 MPa, and since the disintegration time for chitin-Mg silicate is 
independent of crushing strength [18], disintegration time testing was carried out up to 
this value of crushing strength for all the tested materials. Although short disintegration 
times are often associated with tablets with poor crushing strength, this crushing strength 
UDQJHZDVXVHGWRLQRUGHUWRIDLUO\H[DPLQHWKHFRQWULEXWLRQRIOXEULFDWLRQRQWKHWDEOHWV¶
disintegration time. The hydrophobic character of MgSt appears to have little effect on 
chitin-Mg silicate powder; whereas in the case of Avicel® 200 the influence of the 
lubricant on its disintegration time is, by comparison, distinctly noteworthy (Figure 3.2). 
The super-disintegration power of chitin-Mg silicate is retained at a MgSt concentration 
of 2% (w/w). Above this concentration, disintegration did not exceed a maximum time of 
5 min at 10% (w/w) concentration of MgSt. Even though tablet crushing strength values 
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for Avicel® 200 decreased, due to the presence of MgSt, the disintegration time remained 
high. The results for the 5 and 10% (w/w) concentrations of MgSt clearly demonstrate the 
hydrophobic hindrance of the lubricant coat towards water penetration, as tablets 
disintegrated within 17 and 30 min, respectively. 
 
Figure 3.2 Effect of MgSt concentration on the disintegration time of chitin-Mg silicate, 
Avicel® 200, and Avicel-Mg silicate tablets. Tablets were 12 mm in diameter and 400 mg 
in weight, compressed to reach a fixed crushing strength value of 0.6 MPa. 
On the other hand, the data shown in Figure 3.2 indicates that modification of Avicel® 
200 with Mg silicate co-precipitate does not decrease the long disintegration time 
encountered with lubricated Avicel® 200 when the former is also lubricated. The 
aforementioned finding gives more credence to the use of chitin-magnesium silicate, 
when disintegration time and drug dissolution are significant parameters in formulations. 
The difference in disintegration time between tablets formulated with chitin-Mg silicate 
or Avicel® 200 highlights the difference in particle-particle (MgSt-excipient) distribution 
(as will be discussed below). 
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3.3.3. Compressibility analysis of chitin and Avicel co processed with magnesium 
silicate  
In order to attain an understanding of the effects of lubricant on powder compression, at 
the particulate level, it was important to carry out Kawakita plot analysis (Table 3.1) of 
the two plastically deforming materials chitin-Mg silicate (Figure 3.3) and Avicel® 200 
(Figure 3.4).    
Table 3.1 Kawakita parameters for lubricated (with MgSt) and unlubricated chitin-Mg 
silicate and Avicel® 200. 
Magnesium Stearate 
(%,w/w) Slope Intercept a ab b 1/b 
 Chitin-Mg silicate 
0 1.33 23.217 0.74 0.043 0.05757 17.37 
1 1.34 9.6623 0.74 0.103 0.138963 7.19 
5 1.35 8.5486 0.73 0.116 0.158669 6.30 
 Avicel® 200 
0 1.49 11.899 0.66 0.084 0.125767 7.95 
1 1.37 12.707 0.72 0.078 0.10798 9.26 
5 1.40 18.592 0.71 0.0537 0.075307 13.27 
 
The choice of the Kawakita plot is based on the fact that different densification changes 
from the bulk density state to compressed state of powders, on the assumption of e.g. the 
appearance of agglomerates, will directly influence the powder volume reduction upon 
compression. For chitin-Mg silicate, the insignificant change in the value of the constant 
a for the unlubricated chitin-Mg silicate, at MgSt concentrations of 1 and 5% (w/w), 
indicates that chitin-Mg silicate shows no change in compressibility. Theoretically, the 
FRQVWDQW µa¶ LV WKHPLQLPXPSRURVLW\RI DPDWHULDO EHIRUH FRPSUHVVLRQ7KHUHIRUH Whe 
porosity of chitin-Mg silicate remains unchanged for the unlubricated powder and at the 1 
and 5% (w/w) concentrations of MgSt. 
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Figure 3.3 Kawakita plots for unlubricated (0% w/w) and lubricated (1%, 5% w/w) 
chitin-Mg silicate with MgSt. Tablets were 12 mm in diameter and 400 mg in weight. 
 
 
Figure 3.4 Kawakita plots for unlubricated (0% w/w) and lubricated (1%, 5% w/w) 
Avicel® 200 with MgSt. Tablets were 12 mm in diameter and 400 mg in weight. 
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The foregoing result can be accounted for by the lack of change in bulk density of chitin-
Mg silicate (illustrated in Table 3.2) and indicates that the initial particle size remains 
unchanged for both lubricated and unlubricated chitin-Mg silicate. 
 
Table 3.2 Physical parameters for unlubricated and lubricated chitin, chitin-Mg silicate, 
Avicel® 200 and Avicel-Mg silicate powders.  
Excipient 
Magnesium 
Stearate 
(%, w/w) 
Bulk density 
(g/mL) 
Particle size distribution ȝP Specific surface 
area 
(m2/g), %RSD d(0.1)         d(0.5)             d(0.9)  % RSD 
 
Chitin 
 
 
0.0 
0.5 
1.0 
5.0 
0.17 
0.17 
0.17 
0.18 
70.7          216.6           418.6   0.46 
72.5          217.5           416.4   0.37 
71.3          217.9           413.5   0.51 
60.6          218.9           414.6   0.38 
48.80, 1.70 
43.81, 1.29 
37.94, 1.90 
29.52, 1.08 
 
Chitin-Mg 
silicate 
0.0 
0.5 
1.0 
5.0 
0.32 
0.32 
0.33 
0.33 
50.8          206.8           392.3   0.37 
49.0          207.0           388.0  0.34 
37.1          202.6           394.3   0.43 
15.9          202.1           391.4   0.41 
17.60, 1.48 
22.60, 1.27 
20.30, 1.41 
20.90, 1.35 
 
Avicel® 200                 
0.0 
0.5 
1.0 
5.0 
0.35 
0.41 
0.43 
0.41 
74.2          201.6           367.4   0.45 
76.5          217.3           596.4   0.51 
83.2          220.4           648.9   0.36 
36.5          204.9           439.6   0.44 
0.78, 3.20 
0.53, 3.80 
0.54, 3.31 
0.58, 3.90 
  Avicel-Mg 
  silicate 
 
0.0 
0.5 
1.0 
5.0 
0.41 
0.41 
0.41 
0.41 
74.1          201.0           383.2   0.41 
60.7          206.9           394.7   0.39 
45.6          209.2           397.0   0.48 
32.8          212.3           406.3   0.38 
21.20, 1.29 
18.20, 1.76 
18.32, 1.21 
19.80, 1.13 
 
On the other hand, Avicel® 200 exhibits an increase in the a value, i.e. a higher increase 
in porosity, when MgSt is added at concentrations of 1 and 5% (w/w); thus highlighting 
the increase in particle size when Avicel® 200 is subjected to lubrication. It should be 
noted that the minimum porosity attained (maximum particle size before compression) 
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for Avicel® 200 was recorded for the powders in the order: lubricated Avicel® 200 (1% 
(w/w) MgSt> lubricated Avicel® 200 (5% (w/w) MgSt) > unlubricated Avicel® 200 (this 
trend in particle size will be examined further throughout the discussion). 
Values for the product ab, which is a measure of the extent of particle rearrangement 
during compression, are shown in Table 3.1. The degree of particle rearrangement of 
chitin-Mg silicate increases with increasing MgSt content. Generally, particle 
rearrangement is determined by the flow of smaller particles into the voids between larger 
particles; therefore it would be expected that the presence of a lubricant would minimize 
inter-particle friction and facilitate particle slippage. Apparently, from the elevation shift 
(downward in this case) of the gradient of the data for the lubricated, when compared to 
unlubricated, chitin-Mg silicate (Figure 3.3), at any fixed pressure value, the degree of 
volume reduction (C) increases when MgSt is added to chitin-Mg silicate; allowing 
improved consolidation behavior. This, presumbably, brings the particle surface areas 
into closer proximity as new surface and denser compacts are formed. However, this was 
not the case for Avicel® 200 which, when lubricated, produced a decreased level of 
particle rearrangement as shown by the decreased ab values (Table 3.1) for the 1 and 5% 
(w/w) MgSt concentrations. On the other hand, the elevation of the gradient of the data 
for the 5% (w/w) lubricated Avicel® 200 is shifted (upward in this case) when compared 
to unlubricated Avicel® 200 (Figure 3.4) indicating a decrease in volume reduction of the 
Avicel, when lubricated to this extent. It is hypothesized, from the a and ab values, that 
for Avicel® 200 the degree of particle-particle interaction increases when lubricated with 
MgSt. The foregoing suggestion is in agreement with the data of Faqih et al., [27] who 
reported an improvement in powder flow properties of microcrystalline cellulose due to 
the presence of coarse particles of Avicel agglomerates when MgSt was present at a 
concentration of 0.25% (w/w). In the case of chitin-Mg silicate, a similar effect of 
lubricant was not observed.  
Values of 1/b, which are an inverse measure of the amount of plastic deformation 
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occurring during the compression process, decrease with increasing MgSt content (Table 
3.1) for chitin-Mg silicate (i.e. increase in plasticity). But, the plasticity of Avicel 
decreases with increasing MgSt content (increasing 1/b values in Table 3.1). The 
increased level of chitin-Mg silicate particle rearrangement, accompanied by its increased 
level of plasticity upon lubrication, indicates an increased tendency for particle 
fragmentation during compaction. The extent of particle fragmentation will have a 
considerable influence on susceptibility to lubrication [28]. Generally, the bonding 
properties of a highly fragmenting material seem not to be significantly affected upon 
lubrication as clean, lubricant-free surfaces are created by fragmentation [14]. 
Nevertheless, lubricated Avicel® 200 (which showed a decreased level of particle 
rearrangement and plasticity) may undergo a decreased number of surface contact points 
between the compressed particles upon fragmentation. The extent of this decrease was 
highly significant at 5% (w/w) MgSt concentration resulting in the lowest powder volume 
reduction and the lowest tablet crushing strength values. Such behavior is the most likely 
reason for the weakness of lubricated Avicel® 200 compacts compared to lubricated 
chitin-Mg silicate. The aforementioned hypothesis is further supported by the b values in 
Table 3.1. The constant b is inversely related to the yield strength of the particles and the 
higher the value of b, the greater the total plastic deformation occurring during 
compression [29]. Total plastic deformation creates more contact points for inter-particle 
bonding [30]. Thus, higher b values indicate high tablet crushing strength. It is clear, 
from the data presented in Table 3.1, that lubricated chitin-Mg silicate has higher b values 
when compared with Avicel® 200.   
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3.3.4. Particle size distribution, bulk density, and specific surface area 
measurements of unlubricated and lubricated chitin and Avicel co-processed with 
magnesium silicate 
Evidence for the lack of change in particle size of chitin-Mg silicate, when lubricated 
with MgSt, is illustrated in Table 3.2. The measured d (0.5) and d (0.9) values for chitin-
Mg silicate particle size remain almost unchanged at MgSt concentrations of 0.5, 1, and 
5% (w/w), respectively, when compared to unlubricated chitin-Mg silicate. The same 
behavior occurs for the d (0.5) and d (0.9) values of lubricated and unlubricated chitin. 
For Avicel® 200, there is an increase in the d (0.5) values at 0.5 and 1% (w/w) MgSt 
concentrations; reaching a maximum of 220 µm (at the 1% (w/w) lubricant 
concentration). In addition, at the same lubricant concentrations (0.5 and 1% w/w), the d 
(0.9) values for lubricated Avicel® 200 indicate the presence of larger particles, reaching 
a particle size of 649 µm (at 1% w/w lubricant concentration). This is evidence for the 
presence of Avicel agglomerates at these concentrations of MgSt. However, at the 5% 
(w/w) lubricant concentration, Avicel® 200 undergoes a decrease in the d(0.5) and d (0.9) 
values (205 µm and 440 µm, respectively) when compared to Avicel® 200 lubricated 
with MgSt at the 0.5 and 1% (w/w) concentrations (Table 3.2). Nevertheless, 
agglomerates, albeit to a lesser extent when compared to the 0.5% lubricant concentration 
sample, may still be present as indicated by the d(0.9) value of 440 µm. The differences 
in particle size distribution are reflected in the measured bulk densities for the 
unlubricated and lubricated chitin, chitin-Mg silicate and Avicel® 200 (Table 3.2). The 
bulk densities of chitin and chitin-Mg silicate, when lubricated with MgSt, remain almost 
unchanged; similar to the particle size distribution behavior. Whereas, Avicel® 200 shows 
an increase in bulk density when lubricated with MgSt, thereby indicating the 
contribution of the formed agglomerates to the increase in powder bulk density; as more 
particles result in more mass occupying the same volume. 
The effect of co-precipitated magnesium silicate on particle size distribution and bulk 
density was examined for Avicel® 200. It is evident from the fixed bulk density and the 
slight increase in the d (0.9) values for lubricated Avicel-Mg silicate compared to 
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lubricated Avicel® 200 (Table 3.2) that magnesium silicate minimizes the adhesion 
potential of lubricated Avicel® 200. Therefore, the increase in particle size of Avicel® 
200 can be correlated to the cohesive tendency of MgSt to enhance particle 
agglomeration [31]. The most probable mechanism, for lubricated Avicel® 200, starts by 
partial filling of particle cavities, then quasi-total filling of cavities, and, finally, the 
formation of a peripheral layer of varying composition around the particles [32]. The 
particle size distribution results, Table 3.2, illustrating such agglomeration were measured 
at a MgSt concentration of 1% (w/w) added to Avicel® 200. However, at higher 
concentrations (in this case 5% w/w) of MgSt, the interaction favors de-agglomeration. 
At the 5% (w/w) MgSt concentration, agglomerates reach a critical size where an 
equilibrium occurs between breakdown and size increase of the agglomerates [32]. The 
absence of an increase in particle size distribution for the lubricated chitin-Mg silicate, in 
the presence of MgSt, indicates the absence of agglomeration. This conclusion is based 
on the assumption that chitin-Mg silicate has a higher uptake capacity for MgSt inside its 
cavities before forming the peripheral layer around the particles. Such an assumption is 
based on the fact that chitin and its derivates (like chitosan) are well characterized by 
their high absorption capacities for fatty acid materials (e.g. MgSt). In this context, it 
should be noted that chitin does not necessarily need to be converted to chitosan in order 
to absorb/adsorb fatty acids [33].  
The decrease in the crushing strength values of lubricated Avicel® 200, the observed 
agglomeration and lack of agglomeration for lubricated Avicel® 200 and chitin-Mg 
silicate, respectively, are theoretically considered to be related to their interaction with 
MgSt. This hypothesis is based upon the physical, chemical and geometric properties of 
the particles. For example, the agglomeration of particles when lubricated with MgSt is 
related to the electrostatic charging of particles during blending of dry powders [28, 34]. 
In this regard, it is suggested that the cohesive characteristics of MgSt may enable MgSt 
auto-agglomerates to stick to oppositely charged particles and thus form larger 
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agglomerates of high MgSt content. In relation to the foregoing statement, the 
physicochemical properties of the chitin surface are important. The surface of chitin has 
been reported to possess a greater tendency for the adsorption of highly hydrophobic 
materials compared to materials of low hydrophobicity. It has also been suggested that 
the difference is likely to be due to partitioning of the compounds into the chitin particles 
and not due to adsorption at the surface of the particles [33]. Therefore, the distribution of 
MgSt on the surface of Avicel (as a peripheral layer) will not be the same as that on the 
surface of chitin or chitin-Mg silicate; most probably because of their high adsorption or 
partitioning tendencies towards MgSt. With regard to geometric structure, Ohta et al. [35] 
suggested that the deleterious effect of MgSt on tablet hardness cannot be attributed to 
the hydrophilic structure of silica particles but to the geometric structure which they 
defined as a three-dimensional property such as porosity, particle size and specific 
surface area. They concluded that the increase in tablet hardness of lubricated Avicel® 
PH-101 with MgSt was due to the presence of hydrophilic porous silica of high surface 
area. This explains the role of co-precipitated magnesium silicate onto chitin or Avicel 
particles in minimizing the deleterious effect of MgSt on tablet hardness. Such an 
assumption is based on the fact that synthetic magnesium silicate has a highly porous 
structure [36]. Studies reported by Late et al. [23] lend support to this idea by 
hypothesizing that the combined use of calcium silicate (Rxcipients FM 1000®) with 
superdisintegrants, provides acceptable tablet hardness whilst concomitantly allowing 
rapid tablet disintegration; in less than 30 seconds in the mouth. Furthermore, the co-
precipitated synthetic magnesium silicate has a high adsorption capacity for fatty acids 
(MgSt in this case) [36, 37]. This is due to the presence of the negatively charged silanol 
groups (Ł6LíOH) as the most active groups on the surface; they normally provide the site 
for physical adsorption of organic particles [38], more specifically those which carry a 
positive electrostatic charge e.g. MgSt [39]. Hence, the lack of agglomeration of chitin-
Mg silicate could be correlated to the peripheral layer formation of MgSt in a different 
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manner than for Avicel® 200 particles. This is due to the fact that chitin and Mg silicate 
have adsorption/absorption tendencies for MgSt. As stated earlier, MgSt can partition 
inside chitin particles. In addition, the minimal extent of aggregation and decrease in 
tablet crushing strength values for Avicel-Mg silicate particles accounts for the role of 
magnesium silicate in hindering peripheral layer formation.   
The extent of MgSt distribution onto particle surfaces can be correlated with their specific 
surface areas, illustrated in Table 3.2, since surface coverage is related to the geometric 
structure of the particles [35]. Chitin exhibits a high specific surface area (48.8 m2/g) 
when compared to Avicel® 200 (0.78 m2/g) in spite of a similar particle size (Table 3.2). 
When chitin is lubricated with MgSt, the particles undergo a decrease in specific surface 
area from that of unlubricated particles, but this parameter (for unlubricated and 
lubricated chitin) remained significantly higher than that for unlubricated and lubricated 
Avicel® 200 (Table 3.2). This suggests that chitin has a highly porous structure giving 
rise to more surface area for MgSt distribution than is the case for Avicel® 200. Co-
precipitation of magnesium silicate onto chitin particles results in a decrease in the 
specific surface area (17.6 m2/g) compared to chitin, but it still remains ~23 times higher 
than Avicel® 200 (specific surface area of 0.78 m2/g). Upon lubrication with MgSt (at 
concentrations of 0.5% and 5.0% w/w), the specific surface area of Avicel® 200 
decreases, as expected, due to the coverage of the micro-irregular surface by the added 
lubricant. However, it would be hard to judge the extent of this decrease for different 
lubricant concentrations as Avicel particle size varies at all concentrations of MgSt 
(Table 3.2). In the case of chitin-Mg silicate, lubrication caused no significant alteration 
in the high specific surface areas found for the chitin-Mg silicate particles (Table 3.2). 
This finding further confirms the high uptake capacity of the particles towards coverage 
with MgSt. Finally, co-precipitation of magnesium silicate on Avicel particles results in a 
higher specific surface area (21.2 m2/g) when compared to Avicel® 200 (0.78 m2/g), as 
illustrated in Table 3.2. Upon lubrication with MgSt, at 0.5 and 5.0% (w/w), the 
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measured specific surface area did not change significantly from that for unlubricated 
Avicel-Mg silicate. This explains the lower reduction in crushing strength values of 
lubricated Avicel-Mg silicate when compared to lubricated Avicel® 200 (Figure 3.1) as 
the surface of Avicel-Mg silicate provides more contact area upon compression than 
Avicel® 200. 
In summary the high lubricant uptake capacity of chitin-Mg silicate, due to its high 
surface area, displays minimal (if any) agglomeration as indicated by the particle size 
distribution. This is confirmed by the lack of change in values of a but increased ab 
values obtained from the Kawakita analysis. On the other hand, the relatively low surface 
area of Avicel® 200 results in complete coverage with MgSt giving rise to an increased 
level of agglomeration, as indicated by the increased a and decreased ab parameter values 
from the Kawakita analysis. The change in particle size, therefore, contributes to the 
change in particle behavior towards compression. Theoretically, the tensile strength of 
agglomerates decreases with increase in particle size [40]. Therefore, the observed 
decrease in the tablet crushing strength, for Avicel® 200 when lubricated with MgSt, can 
be correlated to its tendency towards agglomeration.  
3.3.5. Scanning electron microscopy of lubricated and unlubricated chitin and Avicel 
co processed with magnesium silicate 
Particle shape and size were examined using scanning electron microscopy (Figure 3.5). 
When comparing the surface of chitin powder, Figure 3.5.A, with the surface of chitin-
Mg silicate, Figure 3.5.B, it is clear that chitin undergoes a change in topography from a 
flat, smooth surface to a more irregular three dimensional compact. The addition of MgSt 
did not change the visual appearance of chitin-Mg silicate particles when observed at the 
same magnification level (Figure 3.5.C). However, for Avicel® 200 particles visually 
observed at the magnification level of 400x (Figure 3.5.D) can only be clearly observed 
at a lower magnification level of 200x (Figure 3.5.E). In other words, a reduced depth of 
focus was used to visualize large particles (agglomerates). Therefore, the massive particle 
of Avicel® 200 in Figure 3.5.D could be an agglomerate of more than one particle.  
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Figure 3.5 SEMs of un-lubricated chitin (A), un-lubricated chitin-Mg silicate (B), 
lubricated particles of chitin-Mg silicate up to 5% (w/w) MgSt (C), un-lubricated Avicel® 
200 (D), and lubricated Avicel® 200 up to 5% (w/w) MgSt (E).  
3.3.6. Performance of chitin-Mg silicate on the high speed tablet press machine and 
the role of MgSt 
The performance of a batch of chitin-Mg silicate powder on the Fette high speed tableting 
machine was tested. The output parameters are shown in Table 3.3. At all the Fette press 
speeds, used in steps 1-4 in Table 3.3, no stickiness was observed on the lower and upper 
surfaces of the punches. This is further quantitatively indicated by the constant weight of 
the tablets. Tablet crushing strength and disintegration time remained relatively constant 
at all press speeds. With respect to the ejection force values, these typically increased 
with increasing press speed. Fortunately, they still remained below the maximum 
acceptable limit of 300 N in tablet compression [41]. 
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Table 3.3 Effect of Fette P2100 tablet press compression speed on unlubricated and 
lubricated (up to 0.5% w/w with MgSt) ejection force for chitin-Mg silicate, stickiness to 
the punches, tablet crushing strength, disintegration time, appearance of cracks and tablet 
weight. Tablets were 12 mm circular. 
Step Action Speed, 
tablet/hr 
Force 
applied 
(kN) 
Ejection 
Force, 
(N) 
Stickiness Tablet 
crushing 
strength, 
(MPa) 
Tablet 
disintegration 
time, (s) 
Cracks Tablet 
average 
weight, 
(mg) 
1 - 30,000 9.9 140 
N
o 
st
ic
ki
ne
ss
 
 
1.5-2.1 12 Exist 640±2 
2 Increase 
Fette speed 
50,000 8.1 182 1.5-2.0 12 Exist 640±3 
3 Increase 
Fette speed 
100,000 9.6 242 1.2-1.5 12 Exist 640±4 
4 Increase 
Fette speed 
150,000 9.6 278 1.5-1.8 12 Exist 640±5 
5 With Mg 
stearate, 
0.5% (w/w) 
150,000 10.7 53 1.5-2.1 12 None 640±3 
 
However, the appearance of surface cracks was the major defect observed. Crack 
formation is usually caused by the shear stress generated by die-wall friction during 
ejection of the tablets [42]. To reduce die-wall friction, MgSt was applied (step 5 in Table 
3.3) to the formula at a concentration of 0.5 % (w/w). It is clear from the data presented 
in Table 3.3 that MgSt plays a significant role in reducing die-wall friction and thus 
eliminating the development of cracks. 
3.3.7. Dissolution of ibuprofen and gemfibrozil tablets formulated by direct 
compression with chitin and Avicel co-processed with magnesium silicate   
The extent of MgSt sensitivity was investigated in relation to the dissolution profile of 
two model drugs: ibuprofen and gemfibrozil. In addition to their poor compressibility, the 
two drugs were chosen because of the high cohesive characteristics of their bulk powders. 
Therefore, they may require high concentrations of MgSt in order to overcome such 
behavior [43]. However, this could negatively affect the crushing strength of the tablets. 
In the case of ibuprofen using lubricated (1% and 5% w/w) and unlubricated chitin-Mg 
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silicate, Avicel® 200, and Avicel-Mg silicate results in the drug dissolution profiles 
shown in Figure 3.6.  
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Figure 3.6 Dissolution profiles for ibuprofen (400 mg strength) tablets formulated with 
unlubricated and lubricated (1% and 5%, w/w) chitin-Mg silicate (CMS), Avicel®, and 
Avicel-Mg silicate (AMS) using physical mixing and direct compression. MgSt was used 
as the lubricant. Tablets (700 mg) were 13 mm in diameter and compressed at 182 MPa.  
Tablet crushing strength values are included in the legend for each specific powder. 
It is clear from the data shown that ibuprofen tablets (400 mg strength) containing 
lubricated and unlubricated chitin-Mg silicate exhibit full drug release within 5 min of 
dissolution time. The measured tablet crushing strength remained almost unchanged for 
the lubricated and unlubricated tablets (around 2.27 MPa). This finding indicates that the 
fast drug release of ibuprofen tablets is unaffected by lubricated chitin-Mg silicate, which 
maintains its super-disintegration and tensile strength powers when lubricated. Ibuprofen 
tablets, with an average crushing strength value around 2.0 MPa, containing unlubricated 
Avicel® 200 showed slow drug release (Figure 3.6). But, when Avicel® 200 was 
lubricated with 1 and 5% (w/w) MgSt the tablet crushing strength values decreased to 
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1.27 and 0.85 MPa, respectively. Thus faster dissolution profiles result, as expected, from 
weak crushing strength tablets. When Avicel® 200 was replaced by Avicel-Mg silicate 
co-precipitate, the tablet lubricant sensitivity towards decreased crushing strength values 
was minimized, as the ibuprofen tablets retained a crushing strength of 1.93 MPa. This 
was achieved for the 1 and 5% (w/w) concentrations of MgSt within the Avicel-Mg 
silicate powder. With regard to drug dissolution, ibuprofen drug release was almost 
unaffected when 1% (w/w) MgSt was used. However, when 5% (w/w) MgSt was used, 
drug dissolution was found to be slower as the tablets maintained their high crushing 
strength values, but with slower disintegration time (as indicated in Figure 3.2). 
In the case of gemfibrozil (a lipophilic drug), the data in Figure 3.7 shows that 
gemfibrozil (600 mg) tablets containing chitin-Mg silicate and 3% (w/w) of MgSt display 
a similar dissolution profile to the Lopid tablets when the later is used as a reference. 
According to the United States Patent 5726201, Lopid tables are composed of calcium 
stearate and talc (both as lubricants) at the percentages of 1.9 and 2.8 (%w/w) 
respectively. Therefore, the importance of such dissolution similarity finding lies in the 
fact that in a formulation containing chitin-Mg silicate (as filler, binder, and disintegrant) 
together with a water insoluble and highly hydrophobic active ingredient (gemfibrozil), a 
high concentration of MgSt can be safely used to attain the desired dissolution profile.  
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Figure 3.7 Dissolution profile of gemfibrozil (600 mg strength) tablets formulated with 
chitin-Mg silicate by physical mixing and direct compression. The lubricant (MgSt) 
concentration was 3% (w/w). Tablets (850 mg) were 13 mm in diameter and, compressed 
at 182 MPa. Lopid tablets (600 mg strength and 850 mg weight) were used as a reference. 
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3.4 Conclusions 
Magnesium silicate co-precipitated on chitin and Avicel provides advantageous 
formulation processing, by minimizing the deleterious effects of MgSt. The addition of 
MgSt as a lubrication aid did not show a significant variation in disintegration, 
dissolution, and crushing strength of compacts made from chitin-Mg silicate. Such 
variation was clearly observed when a comparison was made with Avicel® 200. This may 
be attributed to the high surface area and porous structure of chitin and Mg silicate. In 
this respect, co-precipitation with magnesium silicate changes Avicel® 200 into a less 
lubricant sensitive excipient, whilst the disintegration time remains high. Unlike Avicel® 
200, lubrication with MgSt shows improved powder consolidation behavior and powder 
properties for chitin-Mg silicate with no effect on particle size distribution. MgSt proved 
to be highly efficient in lowering the ejection force and eliminating the appearance of 
surface cracks in chitin-Mg silicate tablets, at high compression speeds. A slight 
deleterious effect of MgSt was evident when two hydrophobic drugs were prepared in 
compacts made from chitin-Mg silicate. 
Despite the fact that the studies reported in this chapter have shown that chitin-metal 
silicates can be used as efficient multifunctional excipients, it is important to note that 
some active pharmaceutical ingredients (APIs) are chemically incompatible with metal 
ions [44-46]. Therefore, in order to be able to use such APIs another multifunctional 
excipient based on mannitol, which is a common tablet excipient, and chitin is proposed 
and has been investigated. The results of such studies are reported in Chapters 4 and 5 of 
this thesis.  
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4. PREPARATION AND CHARACTERIZATION OF A NOVEL           
CO-PROCESSED EXCIPIENT OF CHITIN AND CRYSTALLINE 
MANNITOL 
4.1 Introduction 
In the pharmaceutical industry, solid dosage formulations require different types of 
excipients to be added to the active pharmaceutical ingredient(s) in order to facilitate 
manufacturing and to achieve the required physicochemical properties (e.g. flowability, 
compressibility, disintegration, dissolution, stability, etc.). Excipients are incorporated in 
formulations using different techniques such as direct compression, wet or dry 
granulation as well as spray or freeze drying [1]. 
Single-component excipients do not always provide the requisite 
performance/physicochemical properties to allow certain active pharmaceutical 
ingredients to be formulated or manufactured adequately. As a result, drug formulation 
scientists have relied on excipients used in combination and often introduced 
commercially by excipient manufacturers. Such combinations fall into two broad 
categories: physical mixtures and co-processed excipients. Co-processed excipients are 
combinations of two or more excipients that possess performance advantages that cannot 
be achieved using a physical admixture of the same combination of excipients [2]. The 
use of different co-processed excipients has been investigated to overcome deficiencies 
arising from single-component excipients and existing formulations [3-5]. For example, a 
co-processed excipient containing microcrystalline cellulose (MCC; Avicel PH 102) and 
mannitol was prepared by wet granulation with hydroxypropyl cellulose (HPC) using 
high-shear mixing [3]. The prepared excipient exhibited the necessary characteristics of 
pharmaceutical filler compared with co-processed lactose and calcium phosphate-
containing formulations. Both lactose and calcium phosphate can give rise to physical 
and chemical problems (e.g. the Maillard reaction) [3]. A novel co-processed excipient 
has been prepared by spray drying the aqueous slurry of MCC and mannitol to provide a 
system with reduced lubricant sensitivity, higher compactibility and a lower tablet 
ejection force profile, relative to its individual components or the physical mixture. The 
prepared co-processed excipient exhibited reduced reactivity towards actives and is 
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particularly useful as a binder for tablet formulations processed by direct compression 
[4]. 
In order to overcome the problem of the loss in compressibility of MCC when used in 
wet granulation formulations, silicon dioxide particles have been integrated with MCC 
particles using a spray-drying process [5]. The co-processed excipient shows better 
flowability, compressibility and disintegration properties compared to commercially 
available MCC or a physical mixture of MCC and silicon dioxide, specifically in wet 
granulation formulations. However, using the aforementioned co-processed excipients in 
tablet formulations needs a disintegrant to enhance the disintegration and subsequent 
release of the active pharmaceutical ingredients from the tablets [5]. 
There is increasing interest in exploring new commercial uses for chitin, a 
SRO\JOXFRVDPLQH ZKLFK FDQ H[LVW LQ WKUHH SRO\PRUSKLF IRUPV Į ȕ DQG Ȗ WKH PRVW
DEXQGDQWQDWXUDOO\RFFXUULQJSRO\PRUSKLVĮ-FKLWLQ2IWKHWKUHHSRO\PRUSKLFIRUPVĮ-
chitin has the highest compressibility [6]. Chitin is natural, non-toxic, non-allergenic, 
anti-microbial, and biodegradable material and as such does not present any known health 
risks [7, 8] 7KH FRPSDFWLELOLW\ YDOXHV RI Į-chitin powder are very similar to those of 
MCC and significantly higher when compared to dibasic calcium phosphate or 
pregelatinized starch. This is because chitin is less plastic and more elastic than 
microcrystalline cellulose, as well as being more plastic and elastic than dibasic calcium 
phosphate [9]. 
Recently chitin has been used to prepare different co-processed excipients with a range of 
metal silicates and silicon dioxide [10, 11]. The excipients obtained offer formulations 
with the requisite physical properties (e.g. non-hygroscopic, highly compactable, and 
highly disintegrable). As a result of such modifications, tablet disintegration is 
characterized by superiority in water uptake and penetration, with no gelling hindrance 
effects [11]. Furthermore, chitin can be used at higher concentrations than commercially 
available superdisintegrants without negatively affecting the disintegration properties 
[10,11]. It is reported that commercially available superdisintgrants loose their function, 
as disintegrants, when their concentration exceeds certain limits (3-15% w/w); thereby 
excluding their use as fillers or binders in solid dosage formulations [12]. 
Mannitol is a naturally occurring sugar alcohol found in animals and plants; it is present 
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in small quantities in almost all vegetables. An acceptable daily intake of mannitol has 
not been specified by the World Health Organization (WHO) since the amount consumed 
as a sweetening agent is not considered to represent a hazard to health. Mannitol is 
widely used in pharmaceutical formulations and as such it is primarily used as a diluent 
(10±90% w/w) in tablet formulations, where it is water soluble, non-hygroscopic and 
produces a semi-sweet, smooth, and cool taste [13]. Because of its low hygroscopicity, 
mannitol is potentially an excellent excipient since it is compatible with the majority of 
active pharmaceutical ingredients. However, crystalline mannitol is excessively friable, 
leading to the formation of fine particles that are particularly detrimental to its flow 
properties. In addition, because of its compact crystal structure, mannitol obtained by 
crystallization from water exhibits poor solubility. This slow dissolution rate is a major 
disadvantage and thus restricts its use in pharmaceutical formulations [14]. Recently, 
QRYHOSKDUPDFHXWLFDOIRUPXODWLRQVFRQWDLQLQJERWKĮ-chitin and crystalline mannitol have 
been developed in order to eliminate such disadvantages [15]. It is expected that such 
formulations will result in the co-processed excipient displaying no adverse effect on 
human health, because the proposed novel co-processed excipient is produced in the 
absence of any chemical reactions between the individual components [2]. As a result the 
combination of chitin with mannitol (a non-hygroscopic inert material) may offer a 
valuable and practical industrial choice as an excipient in terms of disintegration and 
compaction properties [15]. 
The majority of commercially available co-processed excipients are produced by spray-
drying [16], which is a costly and complicated technique. In the present work, an easily 
useable, dry or wet granulation procedure is expected to be advantageous for preparing a 
co-processed excipient from crystallinHPDQQLWRODQGĮ-chitin that can be used as a multi-
purpose superdisintegrant, filler and binder in solid dosage formulations. From an 
industrial perspective, the production of co-processed excipients using classical 
techniques results in a less expensive method of manufacturing compared to spray drying. 
Further, the machines used in such technique are practically available in almost every 
industrial facility. Consequently, the use of such technique would not imply any further 
costing to the manufacturer. The studies reported herein aim to test the foregoing 
assumption and to characterize and optimize the composition and preparation procedure 
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IRUPDQQLWROĮ-chitin mixtures. The overall properties, functionality and applications of 
the co-processed mixture are also investigated. 
4.2 Experimental 
4.2.1. Materials 
Commercial chitin, average molecular mass 1000 KD and degree of acetylation about 
0.96, was obtained from Zhejiang Jiande Biochemical, (China). Crystalline grade  
D-mannitol (Pearlitol), with a mean particle size of 160 Pm, was obtained from Roquette 
(France). Purified water of British Pharmacopeia grade was obtained from the Jordanian 
Pharmaceutical Manufacturing Co. (Jordan). Co-spray dried microcrystalline cellulose 
with D-mannitol (Avicel® HFE 102) was obtained from FMC BioPolymer (Germany); 
magnesium stearate from Mallinckrodt (USA) and Opadry OY-1350 film coat from 
Colorcon (UK). All the active ingredients used were of pharmaceutical grade. These 
included: amlodipine besylate (Matrix Lab., India), methyldopa (Xinshiji pharma, China) 
and rosuvastatin calcium (Bicon, India). Aldomet 250 tablets (Merck & CO., Inc), 
Norvasc 10 tablets (Pfizer Inc.) and Crestor 20 tablets (AstraZeneca UK Limited) were 
obtained from a market in Jordan. All other reagents used were of analytical grade. 
4.2.2. Methods 
4.2.2.1. Preparation of Co-Processed Mannitol-Chitin 
Three co-processed mixtures (each 1 kg) of mannitol and chitin of different ratios (1:9, 
2:8, and 3:7, w/w) were prepared using different processing techniques i.e. direct mixing, 
as well as spray, wet and dry granulation. 
Direct mixing 
The components of each mixture were individually passed through a 710 Pm mesh sieve 
(Fritsch, Germany) and then mixed together for 5 min at 10 rpm using a 7.5 liter cubic 
blender equipped with a motor drive machine (Erweka, Germany). 
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Dry granulation 
The three mixtures prepared by direct mixing were compacted using a roll compactor 
equipped with DPS type rolls (TFC-labo, Vector Corporation, USA), set at about 5 MPa 
roll pressure, 4 rounds/minutes roll speed and 20 rounds/minutes screw control speed. 
The compacted powder was collected and sieved through a 710 Pm sieve using a milling 
machine equipped with a motor drive machine. Finally the granules were mixed for 5 min 
at 10 rpm using a 7.5 liter cubic blender equipped with a motor drive machine. 
Spray granulation 
A 20% (w/v) aqueous mannitol solution was prepared. Chitin was passed through a     
710 Pm sieve and fluidized in a fluid bed granulator vessel (Strea 1, Niro Aeromatic, 
Germany) using an air pressure and drying temperature of 1.5 bar and 60qC, respectively. 
The appropriate volumes of mannitol solution (0.5, 1, and 1.5 liter for 1:9, 2:8, and 3:7 
(w/w) mannitol-chitin mixtures, respectively) were sprayed into the fluidized chitin at a 
spray rate of 5 mL/min. The granules were then sieved and mixed using the same 
parameters as for the dry granulation procedure. 
Wet granulation 
Different mannitol solutions (6, 12 and 16% w/v) were prepared by dissolving the 
required quantity of mannitol to be used to prepare the mannitol-chitin mixtures (1:9, 2:8 
and 3:7 w/w ratio, respectively) in sufficient amount of water to achieve a suitable 
granulation end point. The sieved chitin was placed in granulation pan (Erweka, 
Germany) and granulated with the mannitol solution using a mixing speed of 200 rpm. 
The wet mass was passed through a 9.5 mm sieve. Granule drying was performed at 60qC 
using a drying oven (UT6200, Heraeous, Germany). The granules were sieved and mixed 
using the same procedures as used for the dry granulation procedure. 
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4.2.2.2  Characterization of Cop-MC 
Fourier transform infrared spectroscopy (FT-IR) 
FT-IR measurements were undertaken using an FT-IR instrument (Paragon 1000, Perkin 
Elmer, UK) using thin pellets containing 1 mg of each sample dispersed in 100 mg of 
KBr. The spectra were recorded at room temperature as an average of 30 scans, in the 
400±4000 cm-1 range with a spectral resolution of 1 cm-1. In order to minimize the effects 
of traces of CO2 and water vapour from the atmosphere of the sample compartment, the 
spectrometer was purged with N2. 
X-ray powder diffractometry (XRPD) 
The XRPD profiles were measured using an X-ray diffractometer (PW1729, Philips, 
Holland). The radiation was generated using a CoKD source and filtered through Ni 
filters; a wavelength of 1.79025 Å at 40 mA and 35 kV was used. The instrument was 
operated over the 2T range of 5-60o. The range and the chart speed were set at 2 × 103 
cycles/sec DQGPPșUHVSHFWLYHO\ 
Scanning-electron microscopy (SEM) 
Sample morphology was determined using a scanning electron microscope (Quanta 200 
3D, FEI, Eindhoven/Netherland) operated at an accelerating voltage of 1200 V. The 
sample (0.5 mg) was mounted onto a 5×5 mm silicon wafer affixed via graphite tape to 
an aluminum stub. The powder was then sputter-coated for 105 s at a beam current of  
20 mA/dm3 with a 100 Å layer of gold/palladium alloy. 
4.2.2.3  Testing of the Cop-MC Containing Tablets 
The compressed tablets containing Cop-MC were tested for crushing strength (6D, 
Schelenuiger tester, Germany), disintegration (2T31, Erweka tester, Germany) and 
friability (Erweka tester, Germany) following the general tests in the British 
Pharmacopeia [17]. 
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4.2.2.4  Physical and Chemical Properties of Cop-MC 
Bulk density and particle size distribution 
The bulk density and particle size distribution were measured using a powder volumeter 
(SVM, Tapped volumeter, Erweka, Germany) and a powder particle size analyzer 
(Vibratory sieve, shaker analysette 3PRO and 1000 to 63 Pm sieves, Fritsch, Germany), 
respectively. 
pH and water content measurements 
The pH of a 5% (w/v) aqueous dispersion and powder water content were measured using 
pH meter (Seven-multi pH-meter, Mettler, Switzerland) and titrator (DL38, Karl Fischer 
Titrator, Mettler, Switzerland), respectively. 
Hygroscopicity 
Samples (each 2.5 g) were stored in desiccators containing water saturated salt solutions 
at room temperature (20qC) for 10 and 14 days. The media compositions were set 
according to the Handbook of Chemistry and Physics [18] WRREWDLQUHODWLYHKXPLGLW\¶V
(RHs) of 52, 62, 75, 84 and 95% using Ca(NO3).4H2O, NH4NO3, NaCl, KCl and 
Na2HPO4.12H2O, respectively. The samples were withdrawn after a fixed time period 
and stored at 20qC for 1 and 24 hr before weighing and calculating the percentage gain in 
weight from the original weight under the different RH conditions. 
4.2.2.5  Influence of Particle Size on Compression Characteristics 
Samples of Cop-MC were passed through either 710 Pm or 853 Pm sieves and 
individually dry-mixed with 0.5% w/w magnesium stearate for 3 minutes and then 
compressed using a single punch tabletting machine (SFS, Chadmach machinery, India) 
at different crushing strength values of: 30, 50, 70, 90, 110, 130 and 150 N, using a 9 mm 
circular punch to produce tablets of 180 mg weight. The disintegration time and friability 
were measured at each tablet crushing strength point. Avicel® HFE 102 NF was treated in 
the same way and used as a reference. 
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4.2.2.6  Effect of Lubricant Quantity on TablHW¶V3K\VLFDO3roperties 
Samples of Cop-MC were physically mixed for 3 minutes with different percentages of 
magnesium stearate (0.25 - 5% (w/w)) in a 7.5 liter cubic blender equipped with a motor 
drive machine. The powder was compressed at an adjusted upper punch scale of 25 KN, 
in which a 8 mm circular punch was fitted and tablet weight was fixed at 180 mg. The 
disintegration time and friability were measured. 
4.2.2.7  Functionality 
To study the functionality of the Cop-MC tablets of rosuvastatin calcium (RSC) were 
prepared by different procedures including direct mixing as well as dry and wet 
granulation. The tablets contained RSC (7.6% w/w), Cop-MC (91.7% w/w) and 
magnesium stearate (0.7% w/w). For the direct mixing procedure (Formula 1), RSC and 
Cop-MC were first mixed for 2 min and then magnesium stearate was added and further 
mixed for another 3 minutes. For the dry granulation procedure (Formula 2), RSC (7.6% 
w/w), Cop-MC (25% w/w, intra-granular) and magnesium stearate (0.2% w/w) were 
compacted with a DP roll type using 10 MPa roll pressure, 3 rounds/minutes roll speed 
and 43 rounds/minutes screw control speed, and then passed through a 710 Pm sieve. The 
remaining amount of Cop-MC (66.7% w/w) was added and mixed for 2 minutes; 
magnesium stearate (0.5% w/w) was added. The preparation was further mixed for 2 
minutes. For the wet granulation procedure (Formula 3), RSC (7.6% w/w) and Cop-MC 
(35% w/w, intra-granular) were granulated with 50% (w/v) ethanol solution, dried at 
60oC, and then passed through 710 Pm. The remaining amount of Cop-MC (56.7%) was 
added and mixed for 2 minutes; magnesium stearate (0.7%) was then added and the 
preparation mixed for a further 2 minutes. The three formulations were compressed at 
290 mg tablet weight, for which 10 mm shallow concave punches and dies were used. 
Dissolution testing [19] (DT80; Erweka tester, Germany) was performed according to the 
U.S. Food and Drug Administration published dissolution method [20] for rosuvastatin 
calcium tablets. The percentage release of rosuvastatin calcium was determined 
spectrophotometrically (Du-650i UV/Visible spectrophotometer, Beckman, USA) by 
measuring the absorbance at a Omax of 240 nm. 
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4.2.2.8  Compressibility of the Cop-MC (Kawakita Equation) 
Cop-MC was compressed using a universal testing machine (RKM 50, PR-F system, 
ABS Instruments, Germany) equipped with 12 mm round, flat face upper and lower 
punches as well as dies. The punch speed was fixed at 10 mm/min. Different compression 
forces from 80 to 390 MPa were applied. Three tablets were prepared to ensure 
reproducibility. Compression was carried out at 400 mg tablet weight. The compression 
behavior of the samples was evaluated using Kawakita analysis. The Kawakita equation 
(Equation 1) is used to study powder compression using the degree of volume reduction, 
C. The basis for the Kawakita equation for powder compression is that particles subjected 
to a compressive load in a confined space are viewed as a system in equilibrium at all 
stages of compression, so that the product of the pressure term and the volume term is a 
constant [21]: 
o
o
(V -V) abPC = =
V (1+ bP)  (1) 
where Vo is the initial volume and V is the volume of powder column under an applied 
pressure, P. The constants a and b represent the minimum porosity before compression 
and plasticity of the material, respectively. The reciprocal of b defines the pressure 
required to reduce the powder bed by 50% [22, 23]. Equation 1 can be re-arranged in 
linear form as: 
P P 1
= +
C a ab
 (2) 
The expression for particle rearrangement can be affected simultaneously by the two 
Kawakita parameters a and b. The combination of these into a single value, i.e. the 
product of the Kawakita parameters a and b, may hence be used as an indicator of particle 
rearrangement during compression [24]. 
4.2.2.9  Compatibility Study of Cop-MC with Methyldopa 
Differential scanning calorimetry (DSC 25, Mettler Instruments, Switzerland) can be 
used for a wide range of pharmaceutical applications ranging from the characterization of 
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materials to the evaluation of drug excipient interactions via the appearance, shift, or 
disappearance of endothermic or exothermic peaks [25-27]. DSC was used to study the 
compatibility of the methyldopa active pharmaceutical ingredient in a tabletted dosage 
form with Cop-MC and magnesium stearate (Formula 4). The tablets were packed in 
either open or closed glass containers and stored at 40qC/75% RH for a 6 month period. 
The reference formula was prepared without methyldopa according to Formula 4 using 
the same composition ratio of excipients. All the samples were tested before and after 
storage, under defined conditions. DSC samples were hermetically sealed in aluminum 
pans and scanned over a range temperature of 0 to 300°C at a rate of 5°C/min. The 
instrument was calibrated using indium and the calorimetric data was analyzed using 
STAR software (version 9).  
4.2.2.10 Applications 
The Cop-MC was used to formulate methyldopa and amlodipine besylate active 
ingredients into a tabletted dosage form; tablets were prepared using direct mixing. The 
methyldopa formulation (Formula 4) comprised the active ingredient (63.3% in its 
hydrated form), Cop-MC (32.8%), and magnesium stearate (0.6%). Tablets were film-
coated using Opadry OY-1350 (Colorcon-UK) coating material (3.3%) and sufficient 
water as solvent. The amlodipine besylate formulation (Formula 5) comprised the active 
ingredient (7.0% as besylate), Cop-MC (92.5%), and magnesium stearate (0.5%). 10 mm 
shallow concave and 8 mm flat face beveled edge punches were used for tabletting the 
methyldopa and amlodipine besylate containing formulations, respectively. Tablets of 
Formulas 4 and 5 were tested for crushing strength, disintegration and dissolution. 
Methyldopa tablets (250 mg) were further tested for their stability after being stored at 
40oC/75% RH for 6 months using HPLC instrument equipped with a P1000 pump and a 
UV1000 detector (TSP/USA). A stability indicating and validated HPLC method was 
used to determine methyldopa, O-3-methylmethyldopa (synthetic impurity) and other 
related compounds [28]. A mixture of 50% (v/v) aqueous methanol and 1% (v/v) 
perchloric acid (350:650 v/v) was used as the mobile phase and an octyl silane column as 
the stationary phase (Lichrosphere 100 RP-8, 250×4 mm, 10 Pm). UV detection at 230 
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nm, a flow rate of 1 mL/min and a 20 PL injection loop were used. The HPLC method 
was initially tested for system suitability (i.e. peak symmetry, repeatability, and 
resolution) and for validation parameters (i.e. specificity, recovery, stability in solution, 
linearity and limit of quantitation (LOQ)) according to USP guidelines [29]. The stored 
tablet samples in addition to methyldopa active ingredient (as a reference) were packed in 
either open or close amber glass bottles. Aldomet 250 and Norvasc 10 tablets were 
used as reference materials for comparison purposes. The U.S. FDA published 
dissolution method [20] for amlodipine besylate tablets was adopted for the dissolution 
analysis. The dissolution method states the use of USP apparatus II (Paddle), 75 rpm 
speed, 500 mL of 0.01N hydrochloric acid as the dissolution medium and 10, 20, 30, 45 
and 60 min sampling times.  The dissolution testing of methyldopa tablets were 
performed according to the United States Pharmacopeia (USP 32), following the 
methyldopa tablet official monograph [30]. The dissolution system states the use of USP 
apparatus II (Paddle), 50 rpm speed and 900 mL of 0.1N hydrochloric acid as the 
dissolution medium. The percentage release of amlodipine besylate and methyldopa was 
determined spectrophotometrically by measuring the absorbances at Omax of 250 (1st 
derivative) and 280 nm, respectively. 
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4.3 Results and Discussion 
4.3.1  Co-Processed Mannitol-Chitin with Low Lubricant Sensitivity 
Lubricant sensitivity is the ratio of the un-lubricated to the lubricated compactibility of 
the tablet formulation. Addition of lubricant reduces the heat produced and tablet ejection 
force during compression, which is related to the reduction in inter-particulate interaction 
during compaction; as a result powder compactibility is decreased. Lubricant sensitivity 
also refers to the reduction in interaction between the plastically deforming particles in 
the powder, due to the addition of lubricant, which leads to a reduction in tablet crushing 
strength [31]. 
Chitin powder exhibits poor flow and produces fragile tablets upon compression, while 
pure crystalline mannitol displays undesirable compaction properties and results in tablet 
capping. To obtain the optimal ratio of co-processed mannitol-chitin mixture, three 
different ratios of mannitol: chitins were used: 10:90, 20:80 and 30:70 (w/w). These 
mixtures were prepared by different processing techniques i.e. direct mixing, dry, spray 
and wet granulation. The prepared granules were lubricated using different weight 
fractions of magnesium stearate ranging from 0.25% to 5.0% (w/w). The mixtures were 
compressed at 25 kN scale of the upper punch and the tablets obtained were tested for 
crushing strength, friability and disintegration time. The results indicate that 
improvements in the physical properties of mannitol and chitin mixtures follow the order: 
wet and spray granulation > dry granulation > direct mixing. The mixtures prepared by 
direct mixing have unacceptable physical properties (e.g. poor powder flow, powder non-
uniformity (segregation), friable and low crushing strength tablets). Additionally, the 
results indicate that the properties of mannitol/chitin mixtures are improved by dry 
granulation but they were still not optimal. Moreover it was noted that friability was 
sensitive to the fraction of magnesium stearate added. As a result, excipients produced by 
direct mixing and dry granulation methods were no longer used since the addition of 
active ingredients having critical properties (e.g. poor flow, incompressible, fragile, etc) 
could have a negative impact on compressed tablets. 
The main objective thus became to find the most appropriate mixture that could be used 
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to overcome the poor flow and weak compressibility of its components. The method of 
integrating two components is an important factor in obtaining a suitable mixture that is 
needed to act as a diluent for the active ingredient. 
From the preliminary results physical mixing and direct compaction of the two 
components proved unsatisfactory; consequently spray and wet granulation were used to 
produce the new excipient, whereby the properties of the two components are able to 
overcome poor flow and compression properties. In addition the compatibility of the 
mixture towards lubrication sensitivity was tested. 
In the case of spray and wet granulations, the physical properties were improved with 
respect to the mannitol: chitin ratio used in the following order: 2:8 > 3:7 > 1:9 (w/w 
mannitol/chitin). The mixtures prepared using ratios of 1:9 and 3:7 (w/w) showed 
relatively high friability and sensitivity to the weight fraction of magnesium stearate 
added as a lubricant. The optimal ratio with respect to physical properties improvement is 
the 2:8 (w/w) ratio (mannitol: chitin). All the physical properties at this ratio prepared 
using dry granulation as well as spray and wet granulation in comparison with               
co-processed microcrystalline cellulose (Avicel HFE 102) as a reference are shown in 
Figure 4.1.  
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Figure 4.1 Plots of the physical properties (crushing strength, disintegration time and 
friability) of the co-processed mannitol-chitin mixture prepared by different granulation 
techniques versus the amount of magnesium stearate added. 
It is clear from the data presented in Figure 4.1 that the physical properties of mixtures 
prepared by spray and wet granulation are not very sensitive to the amount of magnesium 
stearate added due to the presence of folding (e.g. high surface area) (Figure 4.2), while 
those prepared by dry granulation and Avicel HFE 102 are relatively sensitive to the 
lubricant content.  
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Figure 4.2 SEM images of Cop-MC lubricated with (a) 0.5% and (b) 3.0% (w/w) 
magnesium stearate; Avicel HFE 102 powder lubricated with (c) 0.5% and (d) 3.0% 
(w/w) magnesium stearate. 
For further investigation, the mixture prepared by wet granulation was used and the other 
preparations were excluded because from a manufacturing process perspective, the 
former is conventional and more practical compared with using spray granulation and/or 
compaction. 
4.3.2 Characterization of Cop-MC 
4.3.2.1  Fourier Transform Infrared Spectroscopy (FT-IR) 
The FT-IR spectra of mannitol, chitin, the corresponding 2:8 physical mixture and  
Cop-MC are shown in Figures 4.3a, 4.3b, 4.3c and 4.3d, respectively. It is clear that the 
FT-IR spectra of the physical mixture of mannitol and chitin (Figure 4.2c), is almost a 
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superposition of the FT-IR profile contributed by mannitol and chitin. The dominance of 
the principal bands of chitin in the physical mixture is a result of its high percentage in 
the mixture (80%, w/w). The FT-IR spectra of Cop-MC (Figure 4.2d) showed almost the 
same bands as the physical mixture, which suggests the absence of any detectable 
chemical interaction and the formation of a new solid phase, as shown by scanning 
electron microscopy. 
 
Figure 4.3 FT-IR spectra of (a) mannitol, (b) chitin, (c) physical mixture of mannitol-
chitin (2:8, w/w), and (d) Cop-MC. 
4.3.2.2  X-Ray Powder Diffractometry (XRPD) 
Figures 4.4a, 4.4b, 4.4c and 4.4d show the XRPD profiles of mannitol, chitin, the 
corresponding 1:1 physical mixture and Cop-MC, respectively.  
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Figure 4.4 XRPD profiles of (a) mannitol, (b) chitin, (c) physical mixture of mannitol-
chitin (2:8, w/w), and (d) Cop-MC. 
It is clear that the XRPD pattern of the physical mixture of mannitol and chitin is almost a 
superposition of the patterns contributed by mannitol and chitin. In contrast, the 
diffraction pattern of Cop-MC showed a reduction in the principal diffraction peaks 
apparent in the XRPD patterns of the physical mixture, which suggests the formation of a 
new solid phase. 
4.3.2.3  Differential Scanning Calorimetry (DSC) 
Figure 4.5 shows the thermal behavior of all samples investigated by DSC.  
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Figure 4.5 DSC thermograms of (a) chitin, (b) mannitol, (c) treated mannitol, (d) non 
treated physical mixture of mannitol-chitin (2:8, w/w), (e) treated physical mixture of 
mannitol-chitin (2:8, w/w) and (f) Cop-MC. 
Mannitol exhibits an endothermic peak at about 167qC (Figure 4.5a), which is retained 
with high intensity in the physical mixture of mannitol and chitin (Figure 4.5c), but a 
significant reduction in the intensity of the mannitol peak in the thermogram of the      
Cop-MC occurs (Figure 4.5d) indicating that some of the mannitol is sequestered in the 
chitin pores. 
4.3.2.4  Scanning-Electron Microscopy (SEM) 
SEM was used to investigate particle surface morphology (Figure 4.6). When comparing 
the surface of chitin (Figure 4.6b) with the surface of the Cop-MC prepared using wet 
granulation (Figure 4.6d), it is apparent that its native structure has changed from a 
smooth, flat surface structure, with folded edges, to three-dimensional compacts for the 
Cop-MC. This folding in the surface of the co-processed chitin creates a bigger surface 
area which can accommodate a larger quantity of lubricant.  
 
CHAPTER FOUR  
 
N.H.M.Daraghmeh±PhD Thesis 154 
a 
 
b 
 
c 
 
d 
 
e 
 
Figure 4.6: SEM images of (a) mannitol, (b) chitin, (c) physical mixture of mannitol-
chitin (2:8, w/w), (d) Cop-MC and (e) Avicel HFE 102. 
Figure 4.6e shows the surface of chitin-mannitol indicating the presence of inter-
particulate voids and channels. Figure 4.6c shows the surface of the AVICEL HFE 102, 
which exhibits a smaller surface area due to the solid surface and the absence of folded 
edges. This is the major reason underlying the clear increase in the disintegration time 
and reduction in the crushing strength of the tablets containing AVICEL HFE 102, as a 
result of increasing the quantity of magnesium stearate present. It is evident that the     
Cop-MC excipient is not chemically altered; consequently it was used in further work. 
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4.3.3 Physical Properties of Cop-MC 
Some of the physical properties of the mixture prepared by wet granulation and sized 
using two different sieves 710 Pm and 853 Pm (corresponding to mesh sizes of 22 and 
18, respectively) were measured. These two sieves were selected in order to obtain      
Cop-MC with particle size distributions capable of improving solid formulation 
characteristics. Generally, in direct compression formulation, excipient flowability and 
compaction performance are critical; therefore excipients used for such applications 
should exhibit narrow particle size distributions with moderate-to-coarse particle size 
(e.g. 100 to 200 µm) [32]. The granules obtained have a bulk density of 0.2-0.3 g/cm3 
with particle size distributions of 20%, 45% and 30% in the range of < 180, 180 ± 355,    
> 355Pm, respectively.  
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Figure 4.7 The water gained by Cop-MC and Avicel HFE 102 kept in an open container 
at different relative humidities and 20oC. 
The pH of a 5% (w/v) aqueous dispersion is 7-8 and a water content of about 6% w/w. 
Cop-MC was found to be slightly hygroscopic with a high moisture uptake capacity, but 
only under extremely high humidity conditions (95% RH). This is expected and explains 
the fast disintegration of the tablets in aqueous media. The data from the water gain vs. 
relative humidity plots (Figure 4.7) clearly indicates that the Cop-MC absorbs a moisture 
content that is up to 37% of its initial weight at 95% RH, but it loses most of this 
moisture after equilibration at ambient conditions of 20oC and 45% RH for a day. 
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4.3.4 Effect of Particle Size on Tablet Disintegration Time, Crushing Strength and 
Friability 
The disintegration time and friability versus the crushing strength for the tablets prepared 
using Cop-MC powders passed through either 710 Pm or 853 Pm sieves are shown in 
Figure 4.8. Generally, a reduction in particle size is associated with an increase in tablet 
mechanical strength. The increase in mechanical strength of the tablets is attributed to an 
increase in the surface area available for inter-particulate attraction, as the particles 
become smaller [33]. However, when Cop-MC was used it was found that varying the 
particle size had a minimal, or no, effect in increasing the mechanical strength of the 
tablets produced. Generally, for materials with a tendency to fragment, the mechanical 
strength of a tablet appears to be independent of particle size [34]. This is likely to be the 
case for the Cop-MC particles which undergo fragmentation at an early stage of 
compression; this normally results in a limited effect on tablet crushing strength when 
varying the particle size. With respect to tablet disintegration, the Cop-MC, as evidenced 
by the data in Figure 4.8, showed a unique and distinctive characteristic whereby 
disintegration was independent of particle size and tablet crushing strength. Tablets, 
produced from Cop-MC powders passed through either 710 Pm or 853 Pm sieves at an 
upper bunch compression scale of 37-42 kN for each particle size, showed a superior 
disintegration time, ranging from 5-145 seconds. This was achieved for tablet crushing 
strength values ranging from 30-150 N, which suggests that capillary action is the 
dominant mechanism for disintegration irrespective of the tablet crushing strength. 
Therefore, the inter-particulate voids within the chitin particle structure in the Cop-MC, 
as previously ascertained by scanning-electron microscopy, remain intact and unchanged 
by varying the powder particle size and tablet crushing strength. 
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Figure 4.8 Effect of Cop-MC particle size on tablet crushing strength, disintegration time 
and friability. The tablets were 9 mm in diameter and 180 mg in weight. All samples 
were lubricated with 0.5% (w/w) magnesium stearate 
Processing chitin with mannitol was found to cause alterations in chitin powder 
compressibility and compactibility. Regarding powder compactibility, mannitol within 
the Cop-MC mixture provides an effective means of obtaining hard tablets with low 
friability while maintaining its super disintegration power, as deduced from the data in 
Figure 4.8. While with the mannitolized microcrystalline cellulose (Avicel HFE 102), it 
can be clearly observed that increasing the tablet crushing strength results in a significant 
increase in disintegration time. 
4.3.5 Kawakita Analysis (Compressibility) 
Initial investigations of mannitol, chitin and Cop-MC using Heckel analysis indicated 
non-log-linearity of compression data. Therefore, Heckel analysis was not adopted in this 
work as it may result in misinterpretation of the estimated intercept and slope parameters 
of the Heckel plots [10]. Therefore, in the present work, Kawakita analysis was adopted 
to linearize the compression data. Figure 4.9 displays representative Kawakita plots for 
mannitol, chitin and Cop-MC. The Kawakita constants a, b, ab and 1/b were calculated 
from the intercept and slope of the plot (Table 4.1).  
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Figure 4.9 Kawakita plot for mannitol:chitin (20:80) Prepared by a wet granulation 
procedure. Tablets were 12 mm in diameter and 400 mg in weight. 
 
Table 4.1  Kawakita Parameters. 
Material 
Kawakita parameters 
Slope Intercept a ab b 1/b 
Mannitol 1.736 17.932 0.576 0.0558 0.0968 10.330 
Chitin 1.223 12.927 0.818 0.0774 0.0946 10.570 
*Cop-MC 1.178 9.182 0.849 0.1089 0.1283 07.795 
*Co-processed mannitol-chitin (2:8 w/w) mixture 
The constant (a), which represents the compressibility, is nearly the same for chitin and 
the Cop-MC (a = 0.818 and 0.849, respectively) and is relatively low for mannitol (a = 
0.576). Co-processing of chitin with mannitol has no significant increase in the 
compressibility of chitin. This is because mannitol (20% of the Cop-MC content) 
occupies only a limited area of the large surface pores of chitin. These pores are 
responsible for the decrease in the volume of chitin powder upon compression [35]. The 
value of the constant (1/b) for Cop-MC (7.795), which is an inverse measure of the 
amount of plastic deformation occurring during the compression process [36], indicates 
that the presence of mannitol increases the plastic deformation of chitin. The higher 
degree of plastic deformation of Cop-MC during compression is most probably due to (a) 
the formation of intermolecular hydrogen bonding between the plastically deformed 
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adjacent particles within the chitin particles and (b) the presence of moisture within the 
porous structure of chitin, which enforces the formation of hydrogen bonds and gives 
Cop-MC high crushing strength values upon compaction and also acts as an internal 
lubricant [37]. 
The relatively high value of ab for Cop-MC (0.1089), which is a measure of the extent of 
particle rearrangement, indicates that, in the presence of mannitol, chitin exhibits a high 
degree of packing during tablet compression. This implies that co-processing reduces the 
surface micro-irregularities of chitin and facilitates particle re-arrangement during the 
densification process of compaction. As a result, co-processing of chitin with mannitol 
has positively improved the compression characteristics of chitin as shown by Kawakita 
analysis. 
4.3.6 Application 
4.3.6.1  Functionality 
The functionality of Cop-MC was investigated by employing different processing 
techniques (dry granulation, wet granulation and direct compression) for the preparation 
of tablet dosage forms. Rosuvastatin calcium (RSC), a drug indicated for primary 
hypercholesterolaemia, was selected as a model for this study. RSC is a hydrophobic 
drug reported to be soluble and stable in the presence of the pH modifier tri-basic calcium 
phosphate as one of the excipients used in the tablet matrix [38]. Crestor 20 tablet 
commercial drug product was used as a reference. These tablets are composed of lactose 
and microcrystalline cellulose as fillers, tri-basic calcium phosphate as alkalinizer and 
stabilizer in addition to crospovidone as the disintegrant [38, 39]. Therefore, the use of 
Cop-MC under neutral/alkaline conditions (pH of 7.0-8.0) is a suitable choice for RSC 
tablet formulation [40-41]. The direct compression procedure for RSC with Cop-MC at a 
dilution capacity of 7.6% (w/w) resulted in hard tablets with more than 90% drug release 
within a 10 min time interval. The disintegration times for the RSC tablets prepared by 
the three different procedures and Crestor 20 tablets were similar and lie in the 120-160 
sec range. The uncoated tablets of RSC, obtained by using the three different methods of 
preparation, have crushing strength values in the range of 90-120 N and friability values 
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of 0.1-0.3%. The foregoing results indicate that the Cop-MC has an improved 
compressibility, whether utilized in direct compression, dry granulation or wet 
granulation formulations. Thus implying that Cop-MC can be used as a single excipient 
acting as filler, binder and disintegrant in tablet formulations. 
Some applications using Cop-MC as the only filler, binder and superdisintegrant were 
also investigated. Two antihypertensive agents, amlodipine besylate (which is a            
1,4-dihydropyridine calcium channel blocker) and methyldopa                                  
(L-3-(3,4-dihydroxyphenyl)-2-methylalanine´ an aromatic-amino acid decarboxylase 
inhibitor), were selected as model drugs for this study as they have special requirements  
in tablet formulation design. Due to the high strength and weak compactibility of 
methyldopa powder, difficulties in the formulation of this active ingredient can occur e.g. 
capping (i.e. ³OD\HULQJ´) of the tablets during ejection in tabletting processing. In 
addition, the particle size and shape of the active ingredient have a major impact on the 
tablet compaction and binding properties during compression.  Usually these unfavorable 
characteristics mean that a granulation procedure has to be used for the preparation of the 
tablets [42]. This is because direct compression procedures cannot overcome the 
aforementioned characteristics by using sufficient quantities of suitable fillers, binder and 
disintegrant while maintaining a low tablet weight. The 355 mg film coated Aldomet 250 
tablets contain calcium disodium edetate, cellulose powder, anhydrous citric acid, 
colloidal silicon dioxide, ethyl cellulose, guar gum and magnesium stearate in the tablet 
core and D&C Yellow 10, hydroxypropyl methylcellulose, anhydrous citric acid, iron 
oxide, propylene glycol, talc, and titanium dioxide for tablet coating [43]. On the other 
hand, lactose is incompatible with amlodipine besylate (Maillard reaction) due to the 
presence of a primary amine group in its chemical structure [44]. Therefore to achieve the 
required binding, while maintaining other tablet physical properties, a multi-excipient 
system is employed LQWKHRULJLQDWRUSURGXFW³1RUYDVF® 10 tablets´XVLQJDKLJKGLOXWLRQ
factor for the amlodipine besylate. The 400 mg tablets of Norvasc® 10 contain 
microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch 
glycollate and magnesium stearate [38]. The performance of Cop-MC in a direct 
compression formulation containing a poorly compressible high strength drug, such as 
methyldopa, and a low strength drug, such as amlodipine besylate, were investigated. The 
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binding and super-disintegration properties, in addition to drug dissolution rate of the 
tablets prepared, were examined and the results are summarized in Table 4.2. Direct 
compression techniques were used to prepare the tablets in which Cop-MC was used as 
the only binder, filler and disintegrant. Crushing strength values of the tablets obtained 
from both formulations showed high internal binding and fast disintegration time. Full 
drug release was obtained at 10 min dissolution time for both drugs. This indicates that 
Cop-MC functions as a binding, disintegration and dissolution promoter. However, it is 
worth mentioning that although methyldopa tablets showed super-disintegrating 
characteristics this did not have an influence on their coating using an aqueous coating 
system. 
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Table 4.2 Physical properties of rosuvastatin 20 mg, methyldopa 250 mg and amlodipine 10 mg tablets. 
Tested Parameter 
Rosuvastatin 20 tablets Methydopa 250 tablets Amlodipine 10 tablets 
Formula 1 Formula 2 Formula 3 Crestor Formula 4 Aldomet Formula 5 Norvasc 
Weight (mg) 290 315 450 355 200 400 
Shape (mm) Round shallow biconvex of 9 mm diameter 
Pink round 
of 9 mm 
diameter 
Round 
shallow 
biconvex of 9 
mm diameter 
Round 
shallow 
biconvex of 
9 mm 
diameter 
Round flat 
faced beveled 
edged of 8.mm 
diameter 
Elongated 
octagon flat 
faced beveled 
edged 
Crushing force (N) 119 120 120 * 140 * 110 112 
Friability (%) 0.35 0.11 0.30 * 0.25 * 0.15 0.24 
Disintegration time 
(Seconds) 120 160 120 180 35 120 30 10 
Dissolution 
(%) 
10 min 
20 min 
30 min 
91 
91 
92 
96 
95 
96 
96 
97 
96 
82 
88 
92 
99 
101 
101 
101 
102 
101 
97 
98 
97 
95 
98 
99 
* Not performed as the tablets are film coated 
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4.3.6.2  Stability of Active Ingredients in the Presence of Cop-MC 
The DSC thermogram obtained for the initial analysis of pure methyldopa (Figure 4.10h) 
shows an endothermic peak at about 124.5qC which corresponds to the loss of water of 
crystallization (sesqui-hydrate). The exothermic decomposition peak observed at about 
300ƕC is assigned to the melting of methyldopa. The DSC thermograms (Figsure 4.10f 
and 4.10g) of a pure methyldopa sample stored for 6 months at 40ƕC/75% RH, in open 
and closed containers, showed an absence of secondary peaks corresponding to 
impurities. The splitting obtained in the endothermic peak of the loss of the hydrate in the 
120-130ƕC temperature range is most likely to be due to different melting patterns of the 
sesqui-hydrate in the methyldopa structure. 
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Figure 4.10 DSC scans of methyldopa 250 mg tablets (Formula 4) (a) after 6 months at 
40oC/75% RH±close amber glass bottles, (b) after 6 months at 40oC/75% RH±open 
amber glass bottles, (c) initial analysis, (d) reference formula (without active ingredient) 
at 40oC/75% RH±close amber glass bottles, (e) reference formula (without active 
ingredient) at 40oC/75% RH±open glass amber bottles, (f) methyldopa at 40/75%        
RH±close amber glass bottles, (g) methyldopa at 40oC/75% RH±open amber glass bottles 
and (h) methyldopa initial analysis. 
The DSC thermograms of Formula 4 (without active ingredient) samples (Figures 4.10d 
and 4.10e) stored for 6 months at 40ƕC/75% RH in open and closed containers showed 
only one endothermic peak obtained at about 167ƕC, which corresponds to mannitol. The 
DSC scan of the samples of methyldopa 250 mg tablets (Formula 4) analyzed initially 
(Figure 4.10c) and the samples stored at 40ƕC/75% RH in closed (Figure 4.10a) and open 
CHAPTER FOUR  
 
N.H.M.Daraghmeh±PhD Thesis 164 
amber glass bottles (Figure 4.10b) for 6 months, showed superimposition whereby no 
secondary peaks were obtained upon storage under the accelerated conditions of 
temperature and humidity (40ƕC/75% RH). 
Mixing methyldopa with Cop-MC lowers the decomposition peak temperature of 
methyldopa from 300ƕC to 270 ƕC; this can be attributed to the interaction of two different 
crystalline structures; such an interaction does not affect the stability of methyldopa as 
indicated by the absence of new/additional DSC peaks (Figures 4.10-a, b and c) [45]. The 
absence of new/additional peaks is an indication of the thermal stability and compatibility 
of methyldopa in the tablet matrix containing Cop-MC. 
The DSC study performed on methyldopa 250 mg tablets (Formula 4) was further 
supported by a HPLC study.  
Table 4.3 Stability data for Į-methyldopa 250 mg film coated tablets at 40oC/75% RH. 
Product Period (months) 
Assay 
(%) 
<5.0%+ 
from 
initial 
Impurities Profile (%) % Drug release 
O-3 MD* 
1.0% 
Total 
(1.0%) 5 min. 
10 
min. 
15 
min 
20 
min 
Methyldopa 
Initial 99.6 0.01 0.19 -- -- -- -- 
6/close 102.2 0.01 0.22 -- -- -- -- 
6/open 99.6 0.01 0.21 -- -- -- -- 
Formula 4 Initial 99.4 0.01 0.18 95.6 99.5 100.5 100.8 
1/close 97.7 0.01 0.20 92.2 98.5 101.5 102.1 
1/open 98.1 0.02 0.16 75.4 92.6 96.1 98.0 
2/close 97.4 0.01 0.17 92.9 97.6 100.0 100.2 
2/open 99.9 0.02 0.16 75.8 97.8 100.5 101.1 
3/close 98.4 0.01 0.22 92.0 98.9 99.8 102.4 
3/open 98.6 0.01 0.17 79.2 96.8 99.5 100.0 
6/close 99.2 0.01 0.16 89.3 96.4 98.4 99.8 
6/open 98.2 0.01 0.31 88.2 95.5 98.3 99.4 
Aldomet 250 
Initial 100.9 0.01 0.14 91.6 101.2 102.1 101.9 
6/close 97.8 0.01 0.29 83.4 94.7 99.1 100 
6/open 98.0 0.01 0.27 57.1 77.5 90.0 95.3 
*O-3 MD represents O-3-methylmethyldopa impurity. 
+
 According to ICH guideline for stability testing of new drug substances and products [39]. 
 
HPLC was used to investigate the chemical stability and compatibility of the tablets 
containing methyldopa and Cop-MC, according to Formula 4. The HPLC method was 
initially validated before use and the results showed a good separation between 
methyldopa and O-3-methylmethyldopa related compound (the resolution R1 is more than 
3) and the relative standard deviation of replicate injections is less than 2%. In addition, 
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analyses of samples obtained from a stress-testing study (0.1N NaOH, 0.1N HCl, and 
0.3% H2O2 at 25oC for 10 days) in solution indicated that the HPLC method is stability 
indicating by a significant decrease in percentage assay of methyldopa in the basic media 
and in the presence of hydrogen peroxide as oxidizing agent (35% and 89% w/w, 
respectively). The accuracy of the method was investigated by testing 6 different sample 
preparations containing methyldopa at two different concentrations (5 and 25 mg/100 
mL) for measuring the percentage impurities and percentage assay, respectively. The 
percentage recovery and RSD for 6 replicates are within the range of 98.1 to 102.9% and 
0.3 to 1.4%, respectively. The method is linear over a concentration range of 1.3±50.0 
mg/100 mL with an r2 value of > 0.999. The LOQ value is 0.7 mg/100 mL. Table 4.3 
shows the analytical data obtained for methyldopa 250 mg tablet (Formula 4) samples 
stored in open and close amber glass bottles at 40qC/75% RH for 6 months. Pure 
methyldopa and Aldomet® 250 tablets were treated in the same manner and analyzed as a 
reference for this study. No significant decrease in the assay of methyldopa 250 tablets 
according to Formula 4 was observed upon storage under the accelerated condition of 
temperature and humidity (40qC/75% RH).  
Co-SURFHVVLQJ RI Į-chitin with crystalline mannitol significantly improves the 
performance and functionality of both components. This offers a potential use of this co-
processed additive as a single tablet excipient displaying super-disintegrating properties. 
The mechanical strength of the tablets and lubricant sensitivity were found to be 
dependent upon the mannitol content and the processing technique used in the 
preparation of the co-processed excipient. 
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Figure 4.11 HPLC chromatograms of (A) methyldopa, (B) methyldopa 250 mg tablets 
(Formula 4) and (C) Aldomet 250 mg tablets. Where (a) is the initial chromatogram (no 
incubation), and (b)/(c) after 3 and 6 months incubation at 40oC/75% RH, respectively in 
closed containers. 
A small increase in the total impurities for samples of Formula 4, stored in open amber 
glass bottles at 40qC/75% RH for 6 months, was observed when compared to the samples 
stored in closed amber glass bottles and Aldomet® 250 tablets (Table 4.3, Figure 4.11). 
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4.4  Conclusions 
The functionality of the Cop-MC is not affected by the tablet preparation procedure 
whether it is direct mixing or dry/wet granulation. Utilization of Cop-MC, as an 
excipient, in tablet formulations containing active pharmaceutical ingredients, offers 
excellent chemical stability, binding and disintegration properties. 
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5. A NOVEL ORO-DISPERSIBLE TABLET BASE: 
CHARACTERIZATION AND PERFORMANCE 
5.1 Introduction 
Tablets are widely used in medication due to their convenience with respect to self-
administration and ease in manufacturing [1]. To improve the performance, functionality 
and quality of pharmaceutical tablets, various excipients are used in their preparation [2]. 
However, pediatric, geriatric and mentally ill patients experience difficulties in 
swallowing conventional tablets, which leads to poor patient compliance. To overcome 
this deficiency, oro-dispersible tablet (ODT) formulations have been developed [3, 4]. In 
the European Pharmacopoeia, an ODT is defined as a tablet to be placed in the mouth 
where it disperses rapidly before being swallowed in less than 3 minutes [5], while the 
FDA consider it as a solid oral preparation that disintegrates rapidly in the oral cavity 
with an in vivo disintegration time of approximately 30 seconds or less [4]. ODTs are 
advantageous due to their administration without water, rapid onset of action and 
improved bioavailability [6, 7]. Various ODT technologies including Orasolv/DuraSolv 
(by direct compression (DC)), Zydis (by freeze drying), FlashTab (Eudragit-
microencapsulation and effervescent couple), FlashDose (cotton candy process) and 
WowTab (compression moulding process) have been patented [8, 9]. ODTs are highly 
friable, due to their compaction at lower crushing force compared to conventional tablets, 
resulting in rapid disintegration; therefore they are commonly packed in special 
packaging materials [10]. A high level of super-disintegrant (up to 20% w/w) is usually 
used in ODT preparations to enhance their disintegration properties. Additional 
excipients including a suitable filler, binder, lubricant, sweetener and color may be added 
to improve product properties [6, 11].  
Mannitol, in crystalline, granulated, or spray dried form, is commonly used in ODT tablet 
formulations due to its sweet cool taste, compatability with a range of active 
pharmaceutical ingredients (APIs), non-hygroscopicity, and the fact that its metabolism 
does not increase blood sugar levels [12-14]. Unlike crystalline mannitol, spray dried 
mannitol is highly compactible, non-friable, and quick dissolving, which facilitates it use 
in DC formulation which facilitate its use in ODTs. Furthermore, crystalline mannitol is 
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widely used in wet granulation (WG) processes due to its low cost and availability [15-
17]. D-Chitin plays several important roles in tablet formulations because it is non-toxic,    
non-allergenic, anti-microbial, non-reactive and biodegradable. Its disintegration power is 
mainly dependent upon a high water uptake rate. Therefore, chitin can be used over a 
higher concentration range than many commercially available disintegrants without 
negatively affecting other tablet properties. However, chitin powder shows poor 
compactibility. D-Chitin is the most abundant form among the three identified 
polymorphs of chitin (D-, E- and J-). It is the second most abundant polysaccharide on 
earth after cellulose [18, 19]. 
Co-processing of pharmaceutical excipients is performed using specialized 
manufacturing processes such as spray drying or melt extrusion in order to produce a 
single excipient with multiple functionalities. In addition co-processing can be utilized 
for improving the undesirable physico-mechanical properties of excipients and their 
performance and is generally undertaken by using a combination of plastic and brittle 
excipients [20]. For example, chitin, a plastic material, has been successfully used to 
prepare different excipients via co-processing with diverse brittle materials including 
mannitol, metal silicates and silicon dioxide [21-23]. In all cases co-processing was 
achieved by incorporating the brittle material ZZLQVLGHWKHSRUHVRIFKLWLQ
70% w/w) using an aqueous vehicle. The result of the foregoing studies showed that the 
extremely large surface pores of chitin were not fully accommodated by the guest 
materials and thus chitin preserved its functionality as a disintegrant. Moreover, the       
co-processed excipients obtained displayed enhanced physical properties, functionality 
and performance (e.g. no-hygroscopicity and highly compactable/disintegrable) [21-23]. 
Recently, a European patent (EP2384742) describing a novel co-processed single 
excipient comprising different ratios of chitin and mannitol has been published [24]. This 
novel co-processed excipient offers a valuable and practical industrial choice in terms of 
super-disintegration and compaction properties of tablet dosage forms. Furthermore, an 
article describing the characterization and application of such a novel co-processed 
excipient in immediate release tablet formulations has been reported in the literature [23]. 
In the aforementioned study, the tablets prepared by using the co-processed excipient 
chitin-mannitol (80:20 w/w) and different APIs displayed excellent chemical stability, 
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binding, and disintegration properties. 
The advantage of using chitin and mannitol in conventional tablets [23] proofs the use of 
such combination in ODT formulation. Due to the ease of manufacturing, ability to 
produce fast disintegration / dissolving properties and the ability of producing hard 
tablets makes this a target to test the suitability to offer an excipient base for ODTs. Roll 
compaction (RC) or WG may then be used to prepare the excipient using mannitol and 
chitin. The studies reported herein aim to test the foregoing hypothesis and to 
characterize the excipient obtained by using a higher ratio of mannitol to chitin than used 
in the previous work [23] by applying RC and WG techniques. The functionality, loading 
capacity, compatibility and applications of the obtained excipient with different APIs are 
also reported. 
5.2  Experimental 
5.2.1 Materials 
Į-Chitin of average molecular weight 1000 KD, degree of acetylation of about 0.96 and a 
mean particle size of 90 Pm (Zhejiang Jiande Biochemical, China) and D-mannitol 
(Pearlitol), crystalline grade, with a mean particle size of 160 µm (Roquette, France) were 
used Purified water of British pharmacopeia grade, Mannogem EZ and Pharmaburst C1 
(SPI, France), Isomalt galenIQTM 721 (BENEO-Palatinit GmbH (Germany), PanExcea 
MHC200G (Avantor Performance Materials, Inc./USA), sodium stearyl fumarate (JRS, 
USA) and Crospovidone (Polyplasdone XL) with an average particle size of 110 ± 140 
(ISP, USA) were also used. All active pharmaceutical ingredients employed i.e., 
montelukast sodium (Matrix Lab., India), domperidone (Xinshiji pharma, China) and 
metronidazole (Hubei Max Pharma, China) were of pharmaceutical grade. All other 
excipients and reagents used were of pharmaceutical or analytical grades, respectively. 
5.2.2 Methods 
5.2.2.1  Preparation of Co-Processed Mannitol-Chitin Excipient 
Three co-processed mixtures (each 1 kg) of chitin and mannitol of different ratios (1:9, 
2:8 and 3:7 w/w) were prepared using different processing techniques i.e., direct mixing, 
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RC and WG. 
Direct mixing 
The three mixtures were separately passed through a 1000 Pm mesh sieve (Fritsch, 
Germany) and then mixed for 5 min at 10 rpm using a 1 liter cubic blender equipped with 
a motor drive machine (Erweka, Germany). 
Roll compaction 
The three mixtures prepared by direct mixing were compacted using a roll compactor 
equipped with DPS type rolls (TFC-labo, Vector Corporation, USA), set at about 5 MPa 
roll pressure, 4 rounds/minutes roll speed and 20 rounds/minutes screw control speed. 
The compacted powders were collected and passed through either the 710 Pm or          
1000 Pm sieves using a milling machine equipped with a motor drive machine. Finally 
the granules were mixed for 5 min at 10 rpm using a 1 liter cubic blender equipped with a 
motor drive machine. 
Wet granulation 
350, 450 and 550 ml of 14.5% (w/v) of aqueous mannitol solutions were used as 
granulating agents to prepare the chitin-mannitol mixtures (1:9, 2:8 and 3:7 w/w ratio, 
respectively). The sieved chitin and the remaining quantity of mannitol were placed in 
granulation pans (Erweka, Germany) and granulated with the mannitol solution using a 
mixing speed of 150 rpm. The wet masses were passed through a 9.5 mm sieve. Drying 
was performed at 60qC using a drying oven (UT6200, Heraeous, Germany). The granules 
were passed through the 1000 Pm sieve and mixed using the same procedures as used for 
the RC preparation. 
5.2.2.2  Characterization of co-processed chitin-mannitol (Cop-CM) 
Fourie-transform infrared spectroscopy (FT-IR) 
FT-IR measurements were undertaken using an FT-IR instrument (Paragon 1000, Perkin 
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Elmer, UK) by means of thin pellets containing 1 mg of each sample dispersed in 100 mg 
of KBr. The spectra were recorded at room temperature as an average of 30 scans, in the 
400±4000 cm-1 range with a spectral resolution of 1 cm-1. In order to minimize the effects 
of traces of CO2 and water vapour from the atmosphere of the sample compartment, the 
spectrometer was purged with nitrogen. 
X-ray powder diffractometry (XRPD) 
The XRPD profiles were measured using an X-ray diffractometer (PW1729, Philips, 
Holland). The radiation was generated using a CoKD source and filtered through Ni 
filters; a wavelength of 1.79025 Å at 40 mA and 35 kV was used. The instrument was 
operated over the 2șUDQJHRI-60o. The range and the chart speed were set at 2 × 103 
F\FOHVVHFDQGPPșUHVSHFWLYHO\ 
Differential scanning calorimetry (DSC) 
Samples (a 5mg) were hermetically sealed in aluminum pans and scanned over a range 
temperature of 0±300°C at a rate of 5°C/min (DSC 25, Mettler Instruments). The 
instrument was calibrated using indium and the calorimetric data were analyzed using 
STAR software (version 9) 
Scanning-electron microscopy (SEM) 
The morphology of the samples were determined using a scanning electron microscope 
(Quanta 200 3D, FEI, Eindhoven/Netherland) operated at an accelerating voltage of 1200 
V. The sample (0.5 mg) was mounted onto a 5×5 mm silicon wafer affixed via graphite 
tape to an aluminum stub. The powder was then sputter-coated for 105 s at a beam 
current of 20 mA/dm3 with a 100 Å layer of gold/palladium alloy. 
Angle of repose 
Angle of repose (q) was determined using the funnel method [25]. The sample blends 
were poured through a funnel that could be raised vertically until a maximum cone height 
(h) was obtained. Radius of the heap (r) was measured and then q was calculated using 
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the formula: 
q =  taní h/r (1) 
Particle size 
The particle size distributions for all samples were measured by using a Malvern 
Mastersizer 2000 instrument (Malvern Instruments Ltd, Worcestershire, UK). 
Approximately 5 mL of powder was used for each measurement. The air pressure was set 
at 2.0 bar, and the feed rate was set at 50%. The particle size distributions D10, D50 and 
D90 were recorded. Each sample was measured 3 times. 
Bulk density (BD) and tapped density (TD) [25] 
Approximately 100 mL of powder was gently poured into a tarred graduated cylinder and 
the initial volume and weight of the material recorded. The graduated cylinder is placed 
on a tap density tester and the final volume is recorded after 200 taps. BD and TD are 
calculated by dividing the initial and final volume of powder by the weight of powder, 
respectively. 
Water content 
The water content of the powders was measured using a DL38, Karl Fischer Titrator 
(Mettler Toledo-Switzerland). 
Hygroscopicity 
 Samples (2.5 g) were stored in desiccators containing water saturated salt solutions at 
room temperature (20qC) for 10 and 14 days. The media compositions were set according 
to the Handbook of Chemistry and Physics [26] WRREWDLQUHODWLYHKXPLGLW\¶V (RHs) of 52, 
62, 75, 84 and 95% using Ca(NO3).4H2O, NH4NO3, NaCl, KCl and Na2HPO4.12H2O, 
respectively. The samples were withdrawn after a fixed time period and kept at 20qC for 
1 and 24 hr before weighing and calculating the fractional gain in mass compared to the 
original mass under the different RH conditions. 
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2.2.3 Physical and chemical properties of tablets prepared from Cop-CM 
Crushing force, disintegration and friability 
The crushing force (6D, Schelenuiger tester, Germany), disintegration (2T31, Erweka 
tester, Germany) and friability (Erweka tester, Germany) were performed following the 
general tests in the British Pharmacopeia [27]. 
Influence of particle size on tablet properties 
Samples of Cop-CM powders were passed using either 710 Pm or 1000 Pm sieves and 
individually mixed with 1.0% (w/w) of sodium stearyl fumarate as a lubricant and then 
compressed using a single punch tabletting machine (SF3, Chadmach Machinery, India) 
at different crushing force values of 30, 50, 70, 90, 110, 130 and 150 N, using a 10 mm 
circular punch to produce tablets of 250 mg weight. The disintegration time and friability 
were measured at each tablet crushing force point. Some of the commercially available 
ODT bases (Pharmaburst C1, Isomalt galenIQTM 721, Mannogem EZ and PanExcea 
MHC 200G) in addition to Mannogem EZ and 3% crospovidone, Isomalt galenIQTM 721 
and 3% crospovidone powders were lubricated using 1% w/w sodium stearyl fumarate 
and used as reference materials. 
Moisture uptake studies 
Moisture uptake studies were conducted in order to assess the physical stability of the 
ODTs composed of Cop-CM base. Twenty tablets were kept in a desiccator over calcium 
chloride at 37qC for 24 hours. The tablets were then weighed and exposed to 75% relative 
humidity, at room temperature for 14 days. The required humidity was achieved by the 
use of saturated sodium chloride solution at the bottom of the desiccators for 72 hours. 
Tablets were weighed and the fractional increase in mass was recorded [26]. 
Wetting time 
A piece of tissue paper (8 cm in diameter), folded twice was placed in a Petri dish (8.5 
cm in diameter) containing 6 ml of water. One tablet was carefully placed on the surface 
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of the tissue paper and allowed to wet completely [26]. The time required for the water to 
reach the upper surface of the tablet was recorded as the wetting time.  
Loading capacity 
A study was undertaken to measure the impact of the API load on the performance of the 
Cop-CM as tablet excipient. Tablets were prepared by DC using a SF3 single punch 
tablet press machine equipped with D-type tooling. The seven experiments were 
performed using Cop-CM and metronidazole, containing, 0%, 10%, 30%, 50%, 70, 90 
and 100% (for comparison) of metronidazole lubricated with 0.3% sodium stearyl 
fumarate. The prepared tablets were circular in shape with a diameter of 12 mm and a 
mass of 500 mg. Tablets from each experiment were evaluated for crushing force and 
disintegration time. 
Functionality 
To investigate the functionality of the Cop-CM, two API model as small strength tablets 
were studied including montelukast sodium (Monte) and domperidone (Domp). The 
tablets for the two APIs were prepared by DC, RC as well as WG methods. The Monte 
and Domo tablets contained 1.77% and 3.4% of API and 94.7% and 93.1% of Cop-CM, 
respectively. In addition, both APIs formulations contained strawberry powder (2.0%), 
aspartame (0.5%) and sodium stearyl fumarate (1.0%). For the DC experiments, Monte 
and all excipients, except sodium stearyl fumarate, were first mixed for 2 min and then 
sodium stearyl fumarate was added and further mixed for another 2 min.  
For the RC procedure, Monte (1.77% w/w), Cop-CM (25% w/w, intra-granular) and 
sodium stearyl fumarate (0.6% w/w) were compacted by employing a DP roll type 
compaction using 10 MPa roll pressure, 3 rounds/minutes roll speed and 43 
rounds/minutes screw control speed and then passed through a 1000 Pm sieve. The 
remaining amount of Cop-CM was added and mixed for 2 min followed by the addition 
of sodium stearyl fumarate (0.4% w/w). The powder was then further mixed for 2 min.  
For the WG procedure, Monte (1.77% w/w) and Cop-CM (35% w/w, intra-granular) were 
granulated with 50% (w/v) ethanol in water, dried at 60oC, and then sieved using the 
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1000 Pm sieve. The remaining amount of Cop-CM was added and mixed for 2 min; 
sodium stearyl fumarate (1%) was then added and mixed for a further 2 min. The same 
procedures were repeated for Domp. The prepared mixtures for each API were 
compressed at 300 mg tablet weight, for which 10 mm shallow concave punches and dies 
were used. Dissolution tests (DT-80; Erweka tester, Germany) for Monte and Domp were 
performed according to the U.S. Food and Drug Administration [28, 29] and British 
Pharmacopeia [30] published dissolution methods. The released fraction of Monte and 
Domp were determined spectrophotometrically (Du-650i UV/Visible spectrophotometer, 
Beckman, USA) by measuring the first derivative absorbance modes at 290 nm for Monte 
and absorbance mode at 280 nm for Domp. 
 Compressibility 
Mannitol, chitin and Cop-CM powder samples were compressed using a universal testing 
machine (RKM 50, PR-F system, ABS Instruments, Germany) equipped with 12 mm 
round, flat face upper and lower punches as well as dies; punch speed was fixed at 10 
mm/min. Different compression forces from 80 to 390 MPa were applied. Three tablets 
were prepared to ensure reproducibility. Compression was carried out at 400 mg tablet 
weight. The compression behavior of the samples was evaluated using Kawakita analysis. 
[31-34]. 
 Stability studies 
Monte and Domp tablets prepared by DC were packed in aluminum/aluminum strips and 
stored at 25oC/60% RH and 40°C/75% RH for 24 and 6 months, respectively. At different 
interval times, tablets were withdrawn and tested for dissolution and content of API and 
its related substances by stability-indicating and validated HPLC methods [35-37]. The 
HPLC instrument was equipped with a P1000 pump and a UV1000 detector (TSP/USA). 
For Monte tablets, a mixture of acetate buffer (0.385% ammonium acetate in water 
adjusted with acetic acid to pH 3.5) and methanol (15:85, v/v) was used as the mobile 
phase and an octadecylsilyl silica column as the stationary phase (250 × 4 PPȝP
UV detection at 254 nm, a flow rate of 1 mL/min, and 20-ȝ/LQMHFWLRQvolumes of the test 
solutions (0.2 mg Monte/ml of 70% ethanol) were used. While for Domp tablets, 
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methanol and 0.5% ammonium acetate in water were used as the mobile phases A and B, 
respectively. A linear gradient elution with a flow rate of 1.5 ml/min was programmed as 
follows: time 0 min: 30, 70, time 10 min: 100, 0, and time 12 min: 100, 0 for mobile 
phases A and B, respectively. A based-deactivated, end capped L7 column was used as 
the stationary phase (Hypersil C8 BDS, 100×4.6 mm, 3 ȝP89GHWHFWLRQDWQPDQG
a 10-ȝ/ LQMHFWLRQ volume of the test solutions (5 mg Domp/ml of 0.1 M HCl in 50% 
ethanol) were employed. The HPLC method was initially tested for system suitability 
(i.e., peak symmetry, repeatability, and resolution) and for validation parameters (i.e., 
specificity, recovery, stability in solution, linearity, and limit of quantitation (LOQ)) 
according to USP guidelines [37]. 
5.3 Results and Discussion 
5.3.1 Selection of process and ratio for co-processed chitin-mannitol excipient 
In order to select the optimal ratio and process for co-processed excipient preparation, 
three different ratios of chitin and mannitol (10:90, 20:80 and 30:70 w/w) and three 
different processing techniques i.e., direct mixing, WG and RC were used. The prepared 
excipients were lubricated with sodium stearyl fumarate (1.0% w/w) and compressed at 
different tablet crushing forces (50 ± 150 N). The tablets obtained were tested for 
friability, disintegration and wetting times versus the corresponding crushing forces. The 
preliminary results of the aforementioned experiments indicated that direct mixing and 
WG were unsuitable, because the mixtures prepared by direct mixing displayed 
unacceptable physical properties (e.g. poor flow and powder non-uniformity). The 
difference in bulk densities of chitin (a0.2 g/cm3) and mannitol (a0.5 g/cm3) is the reason 
underlying such unacceptable physical properties. In the case of WG, the tablets suffered 
from capping and high disintegration times due to the penetration of the dissolved 
mannitol into the chitin pores. Such penetration did not allow the pores to act as as 
functional compression and disintegration enhancers. However, RC gave reasonable 
results. The data in Figure 5.1 shows the effect of crushing force on the friability, 
disintegration and wetting times of tablets produced. Up to a crushing force of 90 N, all 
chitin: mannitol ratios showed acceptable physical properties (low friability and fast 
disintegration and wetting times). While at crushing forces above 90 N, the excipient 
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prepared by using a chitin: mannitol ratio of 1:9 showed capping upon tablet compression 
due to an insufficient amount of chitin, responsible for improving the compressibility. 
Using ratios of chitin: mannitol of 2:8 and 3:7 (w/w) over all the investigated range of 
crushing forces produced tablets with acceptable physical properties. However, a ratio of 
chitin and mannitol of 2:8 (w/w) was chosen in order to obtain beneficial mannitol taste 
properties and to reduce the amount of insoluble chitin in ODT preparations. 
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Figure 5.1 Plots of the crushing force (N) versus (a) disintegration time, (b) friability, 
and (c) wetting time for compacted mixtures prepared using different ratios of chitin and 
mannitol (1:9, 2:8, and 3:7 w/w). Tablets were 10 mm in diameter and 250 mg in weight. 
All powders were lubricated using 1% (w/w) sodium stearyl fumarate. 
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5.3.2 Characterization of Cop-CM Powder 
The FT-IR spectra of chitin, mannitol, the corresponding physical mixtures and co-
processed excipients (Cop-CM) are presented in Figure 5.2.  
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Figure 5.2 FT-IR spectra of (a) mannitol, (b) chitin, (c) physical mixture of              
chitin-mannitol (2:8, w/w), and (d) Cop-CM. 
It is clear that the FT-IR of the physical mixture of chitin and mannitol (Figure 5.2c) is a 
superposition of the vibrational band profiles contributed by chitin and mannitol    
(Figures 5.2a and 5.2b). The dominance of the principal bands of mannitol in the physical 
mixture is a result of its high fractional composition in the mixture (80% w/w). The two 
bands in the 1550-1660 cm1 range corresponding to the chitin amide I and II vibrational 
modes (Figure 5.2a) persist in the spectra of the physical mixture and Cop-CM, while the 
remaining bands are due to mannitol. The absence of any shift in the FT-IR bands of the 
Cop-CM (Figure 5.2d), in comparison with the bands of the physical mixture          
(Figure 5.2c), suggests the absence of chemical interaction due to the use of RC to form 
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the co-processed excipient Cop-CM. 
Further analysis of the Cop-CM by XRPD (Figure 5.3) and DSC (Figure 5.4) techniques 
showed the same results, where the signals corresponding to mannitol are dominant due 
to its high percentage and crystallinity. The absence of new signals or shift in the patterns 
indicates the absence of formation of a new crystal form or chemical interaction. 
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Figure 5.3 XRPD profiles of (a) mannitol, (b) chitin, (c) physical mixture of            
chitin-mannitol (2:8, w/w), and (d) Cop-CM. 
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Figure 5.4 DSC thermograms of (a) chitin, (b) mannitol, (c) physical mixture of chitin-
mannitol (2:8, w/w) and (d) Cop-CM. 
SEM was used to investigate particle surface morphology (Figure 5.5). When comparing 
the particle shape of mannitol (Figure 5.5a) with that of the Cop-CM (Figure 5.5d), it is 
apparent that it has changed from rectangular rod granules to three-dimensional dense 
compacts for the Cop-CM. 
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Figure 5.5 SEM images of (a) mannitol, (b) chitin, (c) physical mixture of chitin-
mannitol (2:8, w/w), and (d) Cop-CM. 
5.3.3 Physical Properties of Cop-CM Powder 
The physical properties of the Cop-CM powders passed through two different mesh size 
sieves (710 and 1000 Pm) were evaluated. The two powders have a water content of 
about 1.5% w/w (DL38, Karl Fischer Titrator, Mettler, Switzerland) and a bulk density of 
0.5-0.55 g/cm3 (SVM, Tapped volumeter, Erweka, Germany). The pH of a 5% (w/v) 
aqueous dispersion is in the range 6-8. The particle size distribution (D10, D50 and D90) 
of Cop-CM is given in Table 5.1. 
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Table 5.1 The physical properties of Cop-CM. 
Parameter Value 
Water content (w/w%) 1.5 
pH 6.0 ± 8.0 
Bulk density (gm/ml) 0.50-0.55 
Tapped density (gm/ml) 0.55-0.65 
Particle size distribution: 
- Milling through 710µm 
- Milling through 1000µm 
 
D10: 5 µm;  D50: 145 µm;  D90: 496 µm 
D10: 7 µm;  D50: 170 µm;  D90: 584 µm 
Hausner¶s ratio 1.13 
&DUU¶VLQGH[ 11.86 
Angle of repose 32° 
 
Particle size and shape are critical parameters in powder characterization, particularly in 
DC formulations affecting powder performance, packing, consolidation, flowability and 
compaction. It is one of the prime considerations in selecting excipients to develop and 
optimize a pharmaceutical formulation. Ideally, DC excipients should exhibit narrow size 
distributions with moderate-to-coarse particle size, having a mean particle size of 100 to 
200 µm [38]. In ODT formulation, the control of particle size is essential for the water 
insoluble excipients to minimize the grittiness feeling during the tablet administration. 
Best results are obtained when using smaller particle size for insoluble excipients. 
Another critical parameter for the DC excipient is the bulk density which can be used to 
describe the packing behavior of granules [38]. Cop-CM powder passed through 710 µm 
mesh size has a mean particle size of about 215 µm. A higher bulk density is 
advantageous in tabletting because of a reduction in the powder-fill volume of the die. 
Cop-CM powder sieved through 1000 µm mesh size has a bulk density of about 0.52 
gm/mL and a tapped density of 0.59 gm/mL.  
2QWKHRWKHUKDQG+DXVQHU¶V5DWLR(H) is an indirect index of ease of powder flow. It is 
calculated by using the formula, [25] 
Ǿ TD/BD (2) 
The simplest method of measurement of free flow of a powder is compressibility; an 
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LQGLFDWLRQ RI WKH HDVH ZLWK ZKLFK PDWHULDO FDQ EH LQGXFHG WR IORZ LV JLYHQ E\ &DUU¶V
Index (I) which is calculated using the formula: 
I = 100 × (TD ± BD)/ TD (3) 
+DXVQHU¶V ratio of 1.0-1.11 indicates excellent flow whereas values of 1.12±1.18 
indicate good flow, while &DUU¶VLQGH[RILQGLFDWHVH[FHOOHQWIORZZKHUHDV,YDOXHV
of 11- LQGLFDWHJRRG IORZ *HQHUDOO\ ORZHU+DXVQHU¶V UDWLR DQG&DUU¶V ,QGH[YDOXHV
represent better flow). 
The density change EHIRUH DQG DIWHU WDSSLQJ FDOFXODWHG DV  FRPSUHVVLELOLW\ &DUU¶V 
LQGH[LVDQLQGLFDWRURIKRZIDVWJUDQXOHVFDQÀRZWRWKHLUKLJKHVWSDFNLQJ7KH&DUU¶V
LQGH[FDOFXODWHGIURPWKHGHQVLW\GDWDVKRZHGDYDOXHOHVVWKDQDQG+DXVQHU¶VUDWLR
RIOHVVWKDQLQGLFDWLQJIXUWKHUWKHJRRGÀRZDELOLW\ZKLFKLVDQLPSRUWDQt factor for 
DC powders. Good flowability of powder is needed for content uniformity and less 
weight variation in final tablets. According to US Pharmacopeia 31, General Chapter 
<1174 >, angle of repose (25-30q) indicates excellent flow, and 31-35q indicate good 
flow. The Hausner`s ratio, Carr`s index and the angle of repose values for Cop-CM 
powder are shown in Table 5.1. From the data obtained, Cop-CM powder showed a good 
flow-ability and compressibility. 
5.3.3.1 Moisture Uptake by Cop-CM 
The data in Figure 5.6 shows the water uptake by Cop-CM and commercial ODT bases 
(Phrmaburst C1, Isomalt 721, and Mannogem EZ) at 25oC and different relative 
humidities.  
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Figure 5.6 The water uptake by Cop-CM in comparison with some commercially 
available ODT bases after incubation at 25o&DQGGLIIHUHQWUHODWLYHKXPLGLW\¶V (a) for 2 
weeks and (b) after equilibration at 25oC/45% relative humidity for one further day. 
Up to 84% relative humidity for 2 weeks, all bases, except Pharmaburst C1, showed 
insignificant increase in water uptake (Figure 5.6a). However, following equilibration for 
1 day at 25oC/45% relative humidity, Pharmaburst C1 lost the excess water absorbed 
(9%) to reach only 0.7% (Figure 5.6b). At high relative humidity (95%), the water uptake 
follows the order: Cop-CM (8%) < Mannogem EZ (14%) < Pharmaburst C1 (46%) < 
Isomalt galenIQTM 721 (66%). Following equilibration for 1 day at 25oC/45% relative 
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humidity, all bases except Isomalt galenIQTM 721 lost the excess water absorbed to give 
values less than 1% (Figure 5.6b). While it is about 14% for Isomalt galenIQTM 721 
which is most probably due to partial dissolution of Isomalt at high relative humidity. 
This difference in water uptake of different bases is due to the difference in their 
components and their morphology (e.g. crystalline versus amorphous). The roller 
compaction of large amount of mannitol (80% w/w) with chitin results in the coverage of 
the outer surface of chitin with mannitol; therefore, the Cop-CM powder was clearly non-
hygroscopic due to the very minimal water uptake of mannitol. 
5.3.3.2 Hygroscopicity of Tablets Prepared from Cop-CM 
The water adsorption study was conducted for tablets prepared from Cop-CM at 75% 
relative humidity and room temperature. Results indicate that the tablets prepared from 
Cop-CM do not sorb water (less than 0.4% w/w). It is advantageous in the 
pharmaceutical industry to have non-hygroscopic ODT preparations, as this will reduce 
the cost of the expensive package which is usually used to obtain the required protection 
against moisture.  
5.3.3.3 Compression Profile of Tablet Prepared from Cop-CM 
Data for the friability, disintegration and wetting times versus the corresponding crushing 
force for tablets prepared using Cop-CM powders passed through either the 710 Pm or 
1000 Pm sieves are shown in Figure 5.7. Generally, a reduction in particle size is 
associated with an increase in tablet mechanical strength. The increase in mechanical 
strength of the tablets is directly reflected in its physical properties (crushing force, 
disintegration time, friability, wetting time, etc.) and attributed to an increase in the 
surface area available for inter-particulate attraction [39]. However, when Cop-CM was 
used it was found that varying the particle size had no impact on the tablet¶s mechanical 
strength. The mechanical strength of the tablets prepared from materials with a tendency 
to fragment, such as mannitol, dibasic calcium phosphate dihydrate and saccharose 
appear to be independent of particle size [40]. This could be the case for the Cop-CM 
particles which contain excess amount of mannitol (80% w/w) and undergo 
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fragmentation [41] at the early stages of compression, thereby causing a minimal effect 
on tablet mechanical strength when varying the particle size. 
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Figure 5.7 Plots of the crushing force (N) versus (a) disintegration time, (b) friability, 
and (c) wetting time for tablets prepared from Cop-CM powders passed through either 
710 Pm or 1000 Pm sieves in comparison with commercially available bases. The tablets 
were 10 mm in diameter and 250 mg in weight. All samples were lubricated with 1% 
(w/w) sodium stearyl fumarate. 
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The disintegration time of ODTs is generally less than one minute and actual 
disintegration time that patients expect is less than 30 seconds. The general compendial 
method of performing disintegration tests for ODTs is not capable of detecting such a 
very short disintegration time. The wetting time of the ODT is another important test, 
which gives an insight into the disintegration properties of the tablet. Lower wetting time 
indicates a quicker disintegration of the tablet [42]. With respect to tablet disintegration, 
the Cop-CM showed a unique characteristic whereby tablet disintegration time was 
independent of particle size and tablet crushing force (Figure 5.7). Tablets produced from 
Cop-CM powders passed through either the 710 Pm or 1000 Pm sieves, at an upper 
punch compression scale of 16-20 kN for each particle size, showed a superior 
disintegration time ranging from 11.5 to 59 seconds and from 14 to 64 seconds, 
respectively. This was achieved for tablet crushing force values ranging from 50-150 N. 
By increasing the crushing strength from 50 to 150 N, the wetting time of the tablet was 
only increased from 9 to 35 seconds. This suggests that capillary action is the dominant 
mechanism for the disintegration of Cop-CM which is irrespective of the tablet crushing 
force [23]. In addition, the inter-particulate voids within the chitin particles in the       
Cop-CM, as previously mentioned, remain intact and unchanged after using the RC 
procedure with mannitol and by varying the powder particle size. Regarding powder 
compressibility, chitin within the Cop-CM mixture provides an effective means of 
obtaining hard tablets with low friability while persisting in its fast disintegration and 
wetting properties, as can be concluded from the data shown in Figure 5.7.  
Four commercially available ODT excipients were used for comparison purposes 
including, Isomalt galenIQTM 721, Mannogem EZ, Pharmabust EZ and PanExcea 
MHC200G. The data in Table 5.2 shows the function and composition of these 
excipients. Crospovidone (a cross-linked polymer of N-vinyl-2-pyrrolidinone is often 
used at concentrations up to 5.0% and is commonly used as an effective disintegrant in 
tablet formulations) is used at 3% w/w level in both Isomalt galenIQTM 721 and 
Mannogem EZ powders [11]. Both PanExcea MC200G and Pharmaburst C1 already 
contain disintegrant in their compositions (calcium silicate and crospovidone, 
respectively). 
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Table 5.2 Function and composition of used ODT excipients. 
Trade Name Composition Manufacturer 
Advantages & 
Function 
PanExcea 
MC200G 
Mannitol (75%), 
calcium silicate 
(25%).  
Particle size: 50% 
 ȝP 
Avantor Performance Materials, 
Inc./USA 
http://www.avantormaterials.com/ 
 
High performance, 
rapid disintegration, 
direct compression 
excipient for oro-
dissolving tablets 
formulation 
MannogemTM  
EZ 
Spray dried direct 
compression mannitol 
Particle size: 60% 
 (75-ȝP 
SPI Pharma TM, Inc., New Castel , 
U.S.A 
http://www.spipharma.com 
 
Assist in 
formulating 
difficult to use  
non-hygroscopic 
ODT containing 
fine APIs 
Pharmaburst TM 
C1 
Mannitol 84%, 
crospovidone 16%, 
silicon dioxide     <1% 
High 
compactibility, high 
loading in small 
diameter tablets, 
smooth mouth feel, 
rapid disintegration 
Isomalt galenIQ- 
721 
1-O--D-
glucopyranosyl-D-
mannitol dehydrate 
and 
6-O--D-
glucopyranosyl-D-
sorbitol (1:3) 
Particle size: 90% 
 ȝP  
ȝP 
BENEO-Palatinit GmbH (Germany) 
http://www.beneo-
palatinit.com/en/Pharma_Excipients 
/galenIQ/galenIQ_Grades/galenIQ721/ 
Highly soluble 
agglomerated 
spherical isomalt 
for fast dissolving 
and very fast 
disintegrating direct 
compression tablet 
preparations 
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In order to obtain a tablet crushing force range of 50-150 N, upper punch compression 
scales of 25.5 to 29.5 kN were applied to all excipients except for PanExcea in which 
case a scale range from 39-42 kN was applied. For all reference excipients used, 
increasing the crushing force from 50 to 150 N resulted in the disintegration and wetting 
time of the tablets increasing linearly. The friability of the tablets was found to be within 
the limit (less than 0.7% for Isomalt galenIQTM 721+3% crospovidone) at the lower 
crushing force (50 N). With increasing tablet crushing force, the friability was 
significantly reduced (less than 0.2%). At 50 N tablet crushing force value, the reference 
excipients except for Mannogem EZ and Isomalt galenIQTM 721 (with and without 
crospovidone) gave a disintegration time of less than 30 seconds. In addition, the wetting 
time for all reference excipients was less than 30 seconds at the same crushing force. The 
data in Figure 5.7 clearly shows that by increasing the tablet crushing force, the 
disintegration times and wetting times were increased accordingly. Only, Isomalt 
galenIQTM 721 plus crospovidone and PanExcea MC200G tablets showed a short 
disintegration time (less than 33 seconds) at the highest crushing force (150 N), whereas 
for the other excipients a disintegration time range of 120-300 seconds were observed. At 
a tablet crushing force of 150 N, only pharmaburst C1 and Mannogem EZ plus 
crospovidone showed a short wetting time of less than 60 seconds (52 and 16 seconds, 
respectively).  
It can be clearly observed that with Cop-CM, the increasing in tablet crushing force up to 
150 N does not significantly affect both disintegration and wetting times. This property is 
extremely advantageous where very fast disintegrating hard tablets can be prepared using 
Cop-CM and simply packed in traditional packaging materials. This prevents the need of 
a special type of packaging to avoid the breakage of the tablets during removal from the 
package. MannogemTM EZ + 3% crospovidone combination has showed similar behavior 
to Cop-CM at high tablets crushing forces. At 150 N tablet crushing force, PanExcea 
MHC300G has preserved the very short disintegration time, while the tablet wetting time 
was significantly increased. On the otherwise, Pharmaburst C1 behave in a different 
manner, where by increasing the tablet crushing force to 150 N the disintegration time 
was relatively high (> 2 min), while the tablets wetting time was not significantly 
affected. 
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5.3.3.4 Powder Compressibility  
The Kawakita equation (Equation 4) is used to study powder compression using the 
degree of volume reduction, C. The basis for the Kawakita equation for powder 
compression is that particles subjected to a compressive load in a confined space are 
viewed as a system in equilibrium at all stages of compression, so that the product of the 
pressure term and the volume term is a constant [31]: 
 
bP
abP
V
VVC o  
 
1
)(
0
 (4) 
 
Where, Vo is the initial volume and V is the volume of powder column under an applied 
pressure, P. The constants a and b represent the minimum porosity before compression 
and plasticity of the material, respectively. The reciprocal of b defines the pressure 
required to reduce the powder bed by 50% [32, 33]. Equation 4 can be re-arranged in 
linear form as: 
aba
P
C
P 1 
 (5) 
The expression for particle rearrangement can be affected simultaneously by the two 
Kawakita parameters a and b. The combination of these into a single value, i.e. the 
product of the Kawakita parameters a and b, may hence be used as an indicator of particle 
rearrangement during compression [34]. Figure 5.8 shows the Kawakita plots for 
mannitol, Cop-CM and chitin.  
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Figure 5.8 Kawakita plot for Cop-CM. Tablets were 12 mm in diameter and 400 mg in 
weight. 
The Kawakita constants a, b, ab and 1/b were calculated from the intercept and slope of 
the plots (Table 5.3).  
Table 5.3 Kawakita parameters for mannitol, chitin and Cop-CM. 
Material 
Kawakita parameters 
Slope Intercept a ab b 1/b 
Mannitol 1.736 17.932 0.576 0.0558 0.0968 10.330 
Chitin 1.223 12.927 0.818 0.0774 0.0946 10.570 
Cop-CM* 1.512 16.880 0.661 0.0592 0.0896 11.164 
*Cop-CM represents the co-processed chitin-mannitol (2:8 w/w) mixture 
The constant a, which represents the compressibility, is the highest for chitin (a = 0.818) 
and this is due to the high internal surface pores. The compressibility of Cop-CM is 
significantly higher than mannitol alone (a = 0.661 and 0.576, respectively) and this is 
ascribed to the addition of the chitin to mannitol. This result emphasizes the fact that 
although the mannitol constitutes 80% of the Cop-CM content, using RC techniques in 
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the preparation of the Cop-CM keeps the large chitin surface pores active and unoccupied 
because mannitol physically adheres at the outer chitin surfaces. 
The increase in the ab value for Cop-CM (0.0592), which is a measure of the extent of 
particle rearrangement, indicates that the addition of chitin has improved the degree of 
particle rearrangement and packing during tabletting. The 1/b parameter is an inverse 
measure of the amount of plastic deformation occurring during the compression process 
[22, 43]. Generally, the low value of 1/b is a reflection of the soft nature of the material 
and that the material is readily deformed plastically under pressure [44].  
Chitin is a highly porous material and forms intermolecular hydrogen bonds between 
adjacent plastic deformed chitin particles. The presence of moisture within the porous 
structure of chitin enforces the formation of hydrogen bond bridges which increase the 
internal binding upon compaction. Therefore, the use of a smaller amount of chitin (20%) 
with mannitol within the Cop-CM decreases plastic deformation during compression [22, 
45]. 
5.3.3.5 Loading Capacity 
The loading capacity of Cop-CM excipient was studied by using metronidazole as a 
model for an incompressible material. Compressing metronidazole alone (100% as a 
reference) gives rise to tablets with low mechanical strength and long disintegration time. 
However, the effect of increasing the weight ratios of Cop-CM/metronidazole from 0/500 
to 500/0 (wt/wt) on these properties were investigated. The results indicated that by 
increasing the quantity of the Cop-CM in the matrix, the compactability is significantly 
improved and the disintegration time is decreased as shown Figure 5.9. As a result      
Cop-CM is capable to accommodate poorly compressible APIs with high loading 
capacity without significantly affecting the physical and mechanical properties. 
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Figure 5.9 Relationship between tablet crushing force and disintegration time at different 
Cop-CM: metronidazole ratios using a physical mixture of chitin-mannitol (2:8, w/w) as a 
reference. Data are represented as the mean of n = 10. 
5.3.3.6 Functionality 
The functionality of the Cop-CM as an excipient was investigated by examining different 
processing techniques including DC, RC and WG to prepare tablets. The three 
formulations containing Cop-CM and low strength APIs (Monte and Domp) were 
investigated. The performance and mechanical properties of the prepared tablets were 
examined and the results are summarized in Table 5.4.  
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Table 5.4 Composition and physical properties of Monte and Domp ODTs. 
Materials Composition (% w/w) 
Monte Domp 
API 01.77 03.40 
Cop-CM 94.73 93.10 
Strawberry powder flavor 02.00 02.00 
Aspartame 00.50 00.50 
Sodium stearyl fumarate 01.00 01.00 
Tablet Physical Properties 
Tablet preparation process 
DC RC WG DC RC WG 
Crushing force (N) 70 ± 80 60 ± 70 
Friability (%) 0.25 0.32 0.30 0.18 0.29 0.37 
Disintegration time(sec) 20 30 20 26 20 28 
 
The tablets obtained from all the processing techniques showed high internal binding 
(crushing force: 60-80 N and friability: < 0.4%) and fast disintegration timeVVHF. 
The results indicate that Cop-CM is compressible and preserved its functionality whether 
utilized in DC, RC or WG formulations. Hence, it can be used as a multi-functional base 
(binder, filler and disintegrant) in ODT formulations. 
5.3.3.7 Stability Studies 
The stability of Monte and Domp tablets prepared by RC procedures in the functionality 
section was investigated. Tablets were packed in aluminum/aluminum blisters and 
incubated at 25oC and 40oC/75% relative humidity for different periods of time and then 
tested by HPLC methods. The HPLC method was initially tested for system suitability 
(i.e., peak symmetry, repeatability, and resolution) and for validation parameters (i.e., 
specificity, stability in solution, linearity and limit of quantitation (LOQ)) according to 
USP and ICH guidelines [37, 46]. The HPLC results showed a good separation between 
the APIs and their related impurities. Also the methods were found to be suitable for 
stability studies, i.e., the resolution, tailing factors and injection repeatability are within 
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the acceptable criteria. In addition, analysis of samples obtained from stress-testing 
studies in solutions (0.1N NaOH, 0.1N HCl, and 0.3% H2O2) indicated that the HPLC 
methods are stability indicating. The methods were linear over the range of ±50% of the 
target concentrations with r2 of > 0.99. The LOQ values are within 0.08 ± 0.4 and 0.05 ± 
0.14 (w/w %) for Monte and Domp tablets, respectively. 
As shown in the data in Table 5.5, no significant decrease in the potency of Monte and 
Domp tablets occurred upon storage at 40qC/75% RH for 6 months. Monte is liable to 
oxidation by heat [35] forming Monte S-oxide; however, under shelf-life conditions the 
degradation content of this product is within the limit (2.0%). Domp tablets display 
excellent stability when the fraction of impurities does not exceed 0.1% after 6 months 
incubation at 40oC/75% RH. Both products showed fast disintegration (< 30 sec) and a 
drug release (> 90%) before and after incubation at 40oC/75% RH indicating the absence 
of formulation ageing (Table 5.5). 
Table 5.5 Stability data for Monte and Domp tablets.  
Product Compound/Limit 
Percentage (w/w) 
25oC 40oC/75% RH 
Initial 24 months 3 months 6 months 
Monte 
Monte/90% - 110% 99.4 104.8 102.8 98.2 
Monte S-R[LGH 0.9 1.1 3.4 3.6 
Monte cis-LVRPHU 0.1 0.5 0.1 0.1 
$Q\RWKHU 0.0 0.2 0.1 0.1 
7RWDOLPSXULWLHV 1.0 2.0 3.6 3.8 
Domp 
Domp/95%-105% 100.1 - 100.7 101.4 
$Q\RWKHU 0.06 - 0.04 0.04 
7RWDOLPSXULWLHV 0.2 - 0.1 0.1 
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5.4 Conclusions 
Co-processing of crystalline mannitol with D-chitin by RC offers an excellent multi-
functional base for ODT formulations. The novel excipient displayed fast disintegration 
and wetting properties over a wide range of tablet crushing force values in comparison 
with commercially available ODT bases. Regardless of the preparation method (DC, WG 
or DG), the functionality of the novel excipient was preserved. Moreover, the excipient 
can accommodate a high amount of API without affecting its functionality. Utilization of 
the novel excipient in ODT containing active pharmaceutical ingredients, offers very fast 
disintegration and wetting rates, excellent chemical stability and binding properties. 
Consequently, the use of expensive packaging materials for ODT can be eliminated as the 
tablets are not prone to breakage when used by patients. 
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6. SUMMARY AND FUTURE WORK 
6.1 Summary 
The hypothesis that, despite being highly porous and displaying low compactibilty, guest 
molecules such as metal silicates or mannitol can be accommodated in the chitin pores 
via relatively simple co-processing procedures has been proved by the work reported in 
this thesis. The foregoing was clearly shown by the high compactibility and crushing 
force data obtained for the pharmaceutical tablets prepared by using the chitin-metal 
silicates and chitin-mannitol co-processed excipients. Additionally it is to be noted that 
the tablets maintained their high crushing force and internal binding; the fast 
disintegration and wettability characteristics were also preserved. The functionality, 
compatibility and stability of the co-processed chitin excipients were also investigated 
and evaluated using problematic active pharmaceutical excipients. The results obtained 
showed the multi-functionality and suitability of the prepared excipients in improving the 
physical and chemical properties of the prepared tablets.  
6.1.1 Characterization of Chitin±Metal Silicates as Binding Super-Disintegrants 
The modification of chitin (a plastic material), as a selected hydrophilic polymer, using 
different metal silicates (brittle materials) e.g., aluminium, calcium and magnesium has 
resulted in the production of a non-hygroscopic multifunctional excipient with superior 
super-disintegration and binding properties. The interaction of chitin with metal silicate 
excipients does not involve a chemical interaction, as shown by analysis of IR and XRPD 
data. Disintegration and binding properties for the tablets produced using this excipient 
were also found to be independent of particle size and applied compression force. 
Aluminium obviously cannot be used because of e.g. neuronal toxicity. Calcium 
increases the pH of the resulting chitin-metal silicate excipient to a pH of 10.5 which is 
not suitable for most APIs, as it is highly basic. Therefore magnesium silicate was the 
best candidate amongst the metal silicates for co-processing with chitin. The functionality 
of the chitin-Mg silicate co-processed excipient was assessed by formulating different 
APIs including paracetamol, mefenamic acid and gemfibrozil using direct compression as 
well as wet and dry granulation preparation techniques. Chitin-Mg silicate preserved its 
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functionality, whereby LW¶V binding and superdisintegration properties remained 
unaffected by high concentrations of poorly compressible APIs using different 
preparation methods. The physical properties and drug dissolution profile of the 
ibuprofen/chitin-Mg silicate tablet matrix were found to be unaffected even when 5% 
(w/w) lubrication was performed using a powerful lubricant such as MgSt. Also similar 
drug dissolution was attained for gemfibrozil tablets using 3% (w/w) MgSt when 
compared to a reference (LOPID® tablets). This indicates that lubrication has a minimal 
effect on the chitin-metal silicate tablet matrix. 
6.1.2 Characterization of the Impact of Magnesium Stearate Lubrication on the 
Tabletting Properties of Chitin-Mg Silicate as a Super-Disintegrating Binder 
When Compared to Avicel

 200 
Lubricants are vital excipients in tablet formulation. Magnesium stearate is one of the 
most widely used excipients due to its high melting point, efficiency and economy. 
Magnesium stearate reduces tablet hardness and prolongs drug release due to its 
hydrophobicity. Thorough mixing of an active pharmaceutical ingredient with 
magnesium stearate may result in some sort of interaction and thus the ability of powder 
to form tablets is time dependent. Therefore, investigations were conducted to study the 
effects of lubrication on the functionality and performance of chitin-metal silicates. As a 
model, chitin-Mg silicate was selected from amongst the other metal silicates and 
magnesium stearate was used as a lubricant. Avicel® 200 (commercially available 
microcrystalline cellulose with an average particle size of 180 µm) was used as the direct 
compression reference excipient. Microcrystalline cellulose is similar in chemical 
structure to chitin, where the acetyl group of chitin is replaced with a hydroxyl moiety. 
The co-precipitation of magnesium silicate on chitin and Avicel was clearly beneficial 
in minimizing the deleterious effects of MgSt. The addition of MgSt as a lubrication aid 
did not show a significant variation in disintegration, dissolution, and crushing strength of 
compacts made from chitin-Mg silicate. Such variation was clearly observed when a 
comparison was made with Avicel® 200. This is due to the smooth irregular, folded 
particle shape of chitin which results in a high surface area capable of holding/adsorbing 
a high amount of lubricant in its surface pores. Co-precipitation with magnesium silicate 
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changes Avicel® 200 into a less lubricant sensitive excipient with regard to compaction 
and binding properties, whilst the disintegration time of tablets prepared remains high. 
6.1.3 Preparation and Characterization of a Novel Co-Processed Excipient of 
Chitin and Crystalline Mannitol 
Chitin is well known as a disintegrant and filler in tablet and capsule formulation because 
of its unique properties (chemically inactive, naturally abundant, biodegradable,          
non-toxic material). Į-Chitin is a highly compressible material due to its high surface 
porous structure, but the compaction and binding properties of chitin need to be 
improved. Mannitol, a water soluble sugar alcohol, was used in order to improve the 
binding properties of chitin. It is a non-hygroscopic material commonly known as a 
³potential excipient´ since it is compatible with the majority of pharmaceutical active 
ingredients. Unfortunately, crystalline mannitol is friable with limited flow properties and 
poor solubility when compared to lactose and other sugars. A small amount of mannitol 
(< 30% w/w) was physically co-processed with chitin using different methods. The wet 
granulation processing of chitin and mannitol mixture (80:20) resulted in a                    
non-hygroscopic valuable multi-functional excipient in terms of disintegration and 
compaction properties. The tablets prepared from the Cop-MC displayed a fast 
disintegration time while maintaining their superior binding properties. Different APIs 
were incorporated in tablets consisting of Cop-MC and the lubricant. Results showed the 
high stability of the APIs in a Cop-MC matrix. 
6.1.4 A Novel Oro-Dispersible Tablet Base: Characterization and Performance 
ODT tablets need to exhibit rapid disintegration/dissolving effects; therefore high levels 
of superdisintegrants (up to 10-20 % (w/w)) are usually added to achieve this target. 
Accordingly ODTs are packed in unit dose special type blisters due to their low hardness 
and high friability. Additional excipients including filler, binder, lubricant, sweetener, 
and colouring material can be DGGHGWRLPSURYHWKH³HOHJDQFH´and identification of the 
ODTs. Mannitol is widely used in ODT formulations because of its unique properties 
(non-hygroscopic, sweet, smooth and cool taste feel). Therefore it was advantageous, for 
a material like mannitol to be combined with a highly porous disintegrant/filler such as 
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chitin via a physical co-processing methodology to improve its compaction and 
disintegration properties. Roll compaction was found to be a suitable preparation method, 
where optimal physical properties were obtained for the co-processed excipient.            
Co-processed mixtures of chitin (20 and 30% w/w) with mannitol show excellent binding 
properties, fast disintegration and wetting properties upon tablet compression. Further 
studies were performed on the co-processed mixture of mannitol and chitin at a ratio of 
80:20 (Cop-CM), including functionality, compression profile, hygroscopicity and 
loading capacity. Results indicate that the non-hygroscopic excipient is functional when 
different tablet preparation procedures are used by maintaining the overall excellent 
physical properties of the tablets produced. The disintegration and wetting properties of 
Cop-CM are not significantly affected by increasing the crushing force of the tablets 
which allow the formulator to produce hard ODTs with fast disintegration and wetting 
times. The foregoing will permit the use of blister packaging without the need for 
specialised packaging procedures. 
6.2 Future Work 
Metal silicates, via co-precipitation in the pores and surface of chitin are potentially 
useful single multifunctional excipients. The co-processed excipient acts as both a binder 
and filler while maintaining its superdisintegrating properties and it was successfully used 
in formulating hard tablets with super-disinitegration properties.  
Among the sugar alcohols, crystalline mannitol was used for co-processing with chitin 
because of its inert and unique properties. Two different excipeints were prepared by the 
co-processing of chitin with mannitol. The first excipient (Cop-MC) was developed with 
80% w/w chitin where it can be used successfully used as multifunctional excipient in the 
preparation of immediate tablet dosage form. The second excipient (Cop-CM) was 
designed with 80%w/w mannitol to serve as a multifunctional ODT base.  
The following research is aimed at providing recommendations for further work, based 
on results and observations obtained from co-processing chitin with mannitol and metal 
silicates. It is important to investigate the modification of chitin properties using materials 
other than silicates and mannitol to obtain additional co-processed excipients which can 
can be used in a wide spectrum of pharmaceutical applications and dosage forms in terms 
CHAPTER SIX   
 
N.H.M.Daraghmeh±PhD Thesis 211 
of physical properties, suitability and compatibility. Other sugar alcohols including 
sorbitol, erthritol, xylitol, maltitol and lactitol need to be investigated for their suitability 
in formulating fast disintegrating and chewable tablets.   
 
6.2.1 Determination of Degree of Deacetylation in Chitin 
Most of the methods available for the analysis of degree of deacetylation of chitin are 
complicated and time consuming (e.g, NMR, XRPD, mass spectroscopy, differential 
scanning calorimetry and FTIR). However, the aforementioned instruments are not 
always available. In addition most of the current methods rely upon the degradation of 
chitin and this may lead to incorrect results. Therefore, the non-aqueous potentiometric 
titration of the reactive amine groups of chitin may be possible using saturated calcium 
chloride di-hydrate in methanol as a solvent. In addition the spectrophotometric method 
could have potential using the same solvent system by acquiring 1st derivative spectra.  
